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Abstract 
The leishmaniases are neglected tropical diseases with an urgent need for effective drugs. 
Better understanding of the metabolism of the causative parasites will hopefully lead to 
development of new compounds targeted at critical points of the parasite’s biochemical 
pathways. In my work I focused on the pentose phosphate pathway of Leishmania, 
specifically on transketolase, sugar utilisation, and comparison between insect and 
mammalian infective stages of the parasites. 
The pentose phosphate pathway (PPP) is the major cellular source of NADPH, an agent 
critical for oxidative stress defence. The PPP uses glucose, reduces the NADP+ cofactor 
and produces various sugar phosphates by mutual interconversions. One of the enzymes 
involved in this latter part is transketolase (TKT). A Leishmania mexicana cell line 
deleted in transketolase (Δtkt) was assessed regarding viability, sensitivity to a range of 
drugs, changes in metabolism, and infectivity. The Δtkt cell line had no obvious growth 
defect in the promastigote stage, but it was more sensitive to an oxidative stress inducing 
agent and most of the drugs tested. Most importantly, the Δtkt cells were not infective to 
mice, establishing TKT as a new potential drug target. 
Metabolomic analyses revealed multiple changes as a consequence of TKT deletion. 
Levels of the PPP intermediates upstream of TKT increased substantially, and were 
diverted into additional reactions. The perturbation triggered further changes in 
metabolism, resembling the ‘stringent metabolic response’ of amastigotes. The Δtkt cells 
consumed less glucose and glycolytic intermediates were decreased indicating a decrease 
in flux, and metabolic end products were diminished in production. The decrease in 
glycolysis was possibly caused by inhibition of fructose-1,6-bisphosphate aldolase by 
accumulation of the PPP intermediates 6-phosphogluconate and ribose 5-phosphate. The 
TCA cycle was fuelled by alternative carbon sources, most likely amino acids, instead of 
glucose. It remains unclear why deletion of TKT is lethal for amastigotes, increased 
sensitivity to oxidative stress or drop in mannogen levels may contribute, but no definite 
conclusions can be made. 
III 
 
TKT localisation indicated interesting trends too. The WT enzyme is present in the 
cytosol and glycosomes, whereas a mutant version, truncated by ten amino acids, but 
retaining a C-terminal targeting sequence, localised solely to glycosomes. Surprisingly, 
cells expressing purely cytosolic or glycosomal TKT did not have different phenotypes 
regarding growth, oxidative stress sensitivity or any detected changes in metabolism. 
Hence, control of the subcellular localisation remains unclear as well as its function. 
However, these data are in agreement with the presumed semipermeable nature of the 
glycosome.  
Further, L. mexicana promastigote cultures were grown in media with different 
combinations of labelled glucose and ribose and their incorporation into metabolism was 
followed. Glucose was the preferred carbon source, but when not available, it could be 
fully replaced with ribose. 
I also compared metabolic profiles from splenic amastigotes, axenic amastigotes and 
promastigotes of L. donovani. Metabolomic analysis revealed a substantial drop in amino 
acids and other indications coherent with a stringent metabolic response in amastigotes. 
Despite some notable differences, axenic and splenic amastigotes demonstrated fairly 
similar results both regarding the total metabolic profile and specific metabolites of 
interest. 
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1 Introduction 
Leishmaniasis is a neglected tropical disease affecting millions of people worldwide and 
causing immense harm (Uniting to Combat NTDs, 2014; WHO, 2010). Leishmania 
parasites are transmitted between their mammalian hosts by sandflies, hence they 
encounter completely different conditions in each of their hosts, for which they have 
evolved numerous adaptations. The promastigote stage lives inside the insect’s digestive 
system, whereas the mammalian infecting amastigote stage resides inside phagocytic 
immune cells. After successful hijacking of macrophages, Leishmania spread through the 
body into skin, mucocutaneous tissues, internal organs or even bone marrow, depending 
on the species and host status. The final manifestation of the disease is highly variable 
depending on the specific Leishmania species, immune response of each individual, 
malnutrition, combined infection with other diseases and additional aspects. All of these 
factors plus the poor socio-economic conditions in most of the affected countries hinder 
the efforts to bring leishmaniasis under control. 
1.1 Leishmaniasis 
Leishmania parasites cause a wide range of diseases in terms of clinical manifestation, 
severity and geographical area concerned. Leishmaniasis occurs in 98 countries 
worldwide, where 350 million people live under threat of the disease, and the overall 
prevalence is estimated about 12 million people infected in total, 1.8 million people are 
newly infected and about 40,000 die because of leishmaniasis each year (Alvar et al., 
2012; Palumbo, 2008). Approximately half of these cases are children (Palumbo, 2008; 
WHO, 2010). As with the other neglected tropical diseases, leishmaniasis is associated 
with poor living conditions and insufficient medical help available. Predominantly, 
patients live in developing countries with very poor health care without appropriate 
management and funding available to control the disease. Major risk factors for the 
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infection are poor socioeconomic conditions, malnutrition, population mobility, 
environmental and climate changes, and animal reservoirs (Savoia, 2015). Malnutrition 
is a very strong risk factor for development of the clinical disease after leishmania 
infection (Cerf et al., 1987; Harrison et al., 1986), probably due to failure of lymph node 
barrier (Anstead et al., 2001). Untreated patients seem to be the major infection reservoir 
for anthroponotic leishmaniasis and increase the risk of infection 26-fold within the 
household (Alvar et al., 2006). Poor housing conditions are associated with increased 
exposure to sand flies, lack of bed nets and sanitation. The total disease burden is 
substantially higher for women than men due to prejudices and stigma (Alvar et al., 
2006). Basically, leishmaniasis and poverty create a positive feedback loop, especially 
strong because of high cost of the treatment compared to other infectious diseases (Alvar 
et al., 2006).  
Manifestation of leishmaniasis is highly variable ranging from a mild, self-healing skin 
disease to a lethal visceral form, depending mostly on the parasite species but additional 
factors, including host immune status are involved. Cutaneous leishmaniasis affects 
about 0.7 – 1.2 million people each year and causes skin lesions, often self-healing and 
without any long-term effects, unless the scars become disfiguring, or can be debilitating 
if the lesions are multiple. Areas of occurrence are widely distributed, with approximately 
one third of the cases found in Latin America, one third in western Africa and the rest 
stretching from the Middle East to Central Asia (Alvar et al., 2012). 70% of cutaneous 
leishmaniasis cases are confined to Afghanistan, Algeria, Brazil, Colombia, Ethiopia, 
Iran, North Sudan, Peru, Syria, and Costa Rica (Fig 1.1) (Alvar et al., 2012). The major 
causing agents are L. major, L. tropica, L. infantum and L. aethiopica in the Old World; 
L. mexicana, L. amazonensis, L. braziliensis, L. panamensis, L. peruviana, and L. 
guyanensis in the New World (Pace, 2014; WHO, 2010).  
1. Introduction 
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Figure 1.1. Distribution of cutaneous leishmaniasis. WHO 2013. 
Mucocutaneous leishmaniasis is a relatively rare variant of the disease, when the 
parasites reside in mucocutaneous tissues of oral-nasal and pharyngeal cavities and can 
cause awful damage, disfiguring lesions or permanent deterioration of the face. 35,000 
mucocutaneous leishmaniasis cases are reported each year in Peru, Bolivia and Brazil 
(Pace, 2014). The main species responsible are L. braziliensis and L. guyanensis in the 
New World, and L. donovani, L. major, and L. infantum in the Old World (Desjeux, 
2004). Interestingly, recent findings show that especially severe cases of L. braziliensis 
and L. guyanensis infection are related to an RNA virus residing inside the parasites (Ives 
et al., 2011). The exact mechanisms of the viral effects and relevance to the disease 
outcome have not been elucidated so far. 
About 0.2 - 0.4 million people are infected with visceral leishmaniasis each year, called 
by the original Hindi name kala-azar, the most severe form when the parasites infect 
spleen, liver or bone marrow. Visceral leishmaniasis is caused by L. donovani in the 
Indian subcontinent, parts of Asia and  east Africa, L. tropica in the Middle East, and L. 
infantum in the Mediterranean region, south-west and central Asia, and South America 
(Murray et al., 2005; Pace, 2014) (Fig 1.2). The illness manifests with undulating fever, 
loss of weight, enlargement of the spleen and liver, anaemia before turning into a 
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multisystem disease which becomes lethal if not treated. Whereas hepatic infection is 
usually self-limiting, infection in spleen becomes persistent, reflecting the important role 
played by respective immune responses (reviewed in Engwerda and Kaye, 2000). An 
estimated 90% of visceral leishmaniasis cases are found in rural and suburban areas of 
Bangladesh, India, Sudan, South Sudan, Ethiopia and Brazil (Alvar et al., 2012; Uniting 
to Combat NTDs, 2014). Mortality of visceral leishmaniasis is estimated as 10%, but 
seems to be highly variable depending on the region (reviewed in Alvar et al., 2012). 
Figure 1.2. Distribution of visceral leishmaniasis. WHO, 2013. 
Next to these major types of the illness, less common forms can develop if the immune 
system is impaired. Diffuse cutaneous leishmaniasis, for example, develops if the cell-
mediated immune response is defective, and lesions are disseminated with patients 
suffering from relapses. When visceral leishmaniasis is not cured to completion with 
therapy, the so called post kala-azar dermal leishmaniasis (PKDL) syndrome can 
occasionally follow. Significant differences were reported for PKDL development 
between cases from Sudan and India with regard to the proportion of visceral 
leishmaniasis patients affected, the time scale of disease appearance and its severity 
(reviewed in Murray et al., 2005).  
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There are numerous aspects that contribute to the outcome of the disease. First, the 
specific parasite species is crucial, because it determines the type of disease. Despite 
intense efforts, including whole genome sequencing and the latest –omics techniques, to 
compare the species, the specific factors underlying the differences remain unresolved. 
A relatively small number of species-specific genes exist, but considerable variability in 
chromosome copy numbers, thus gene dosage is suspected to play the predominant role 
(reviewed in Cantacessi et al., 2015). Moreover, considering heterogeneity within 
sequence of individual genes and also the potential of interactions between variants 
within a system, clearly a systems wide appreciation of the parasite, and its interaction 
with the host, is needed before true understanding is possible.  
Leishmania parasites infect macrophages and other phagocytic immune cells and the 
individual immune response is crucial in determining the outcome of the infection, for 
example whether the cutaneous disease will be asymptomatic, self-healing or relatively 
severe diffuse type. HIV co-infected patients experience especially severe development 
of the disease, another strong risk factor is malnutrition (Savoia, 2015).  
Desjeux (2004) warned of a disturbing increase in the prevalence of leishmaniasis as a 
consequence of changes to living conditions in affected areas, such as fast urbanization, 
environmental and climatic changes or migration of people. Cases of cutaneous 
leishmaniasis doubled in Brazil from 1998 to 2002 to 40,000 cases, increased four times 
in Kabul, Afghanistan from 1994 to 2002, and numbers of VL patients rose four times in 
north-east Brazil between 1998 and 2002. A major hindrance in bringing the disease 
under control is lack of data and missing knowledge of the actual situation. Ostyn and 
colleagues (2011) reported 100,000 cases of VL in Indian subcontinent due to L. 
donovani infection, but they argue that the real situation may be 5 – 8 times higher. The 
total numbers of infected cases are only estimates, because proper and adequate records 
are missing. Studies aiming to calculate the exact numbers of infected patients draw a 
conclusion that the official numbers may be 4 – 8 times underestimated compared to the 
real situation (reviewed in Alvar et al., 2012). The authors declined to make estimates 
from sub-Saharan Africa, from where no data are available at all. Currently, the numbers 
currently appear to be in decline, for example Murray reported expected toll of 70,000 in 
2005, while Alvar (2012) estimated only 20,000 – 40,000 deaths annually. The latest 
report by the NTD Initiative (2014) is optimistic, especially in south-east Asia, there is 
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an obvious progress towards elimination, since incidence dropped by 60% and number 
of fatality cases by 81% between 2011 and 2013. A big improvement is noted in 
monitoring and supplying updated statistics in the poorest areas, which are the first steps 
necessary for control of the disease.  
Note, however, that circumstances can lead to a rapid change in fortune, as evidenced in 
the increasing incidence in Syria associated with the collapse of health services due to 
the state of war existing there. Movement of people due to war from nonendemic to 
endemic areas can lead to exposure of susceptible population to the parasites and high 
increase of the cases. In southern Sudan between 1984 -1994, it caused an estimated 
100,000 deaths due to VL. In Afghanistan, approximately 300,000 people were affected 
with CL probably after exposure to the parasites in Pakistan (reviewed in Alvar et al., 
2006). In the 2000’s an outbreak of CL took place after the war in Iraq (Du et al., 2016). 
Over the last 20 years, numbers of CL cases in Syria have been increasing from 3,900 
newly reported cases in 1998, to 23,000 cases in 2008, to 53,000 cases in 2012 in 
consequence of socioeconomic changes, rapid urbanization, migration of people into new 
suburbs with inadequate hygiene and sanitation condition, and migration of non-immune 
people into Leishmania endemic areas (Hayani et al., 2015; Salam et al., 2014). The 
numbers continued to increase with the onset of the civil war in March 2011 reaching 
41,000 in the first half of the year 2013, with leishmaniasis emerging even in new areas 
(Du et al., 2016). In addition, WHO estimated that the numbers may be three to five fold 
underestimated (Alvar et al., 2012). It has been reported numerous times in the past that 
war conflicts are accompanied with neglected tropical disease outbreaks, mostly because 
of insufficient health care, migration of people into and from endemic areas, poor living 
conditions, malnutrition and general weakening of the immune system (reviewed in Du 
et al., 2016). Despite recent progress in diagnosis and treatment, in Syria microscopy is 
used for diagnosis and antimonial-based drugs for treatment, whilst AmbiSome or 
miltefosine are not available (Hayani et al., 2015). With migration of refugees from Syria, 
leishmaniasis is emerging in neighbouring countries (Alawieh et al., 2014; Inci et al., 
2015), L. tropica is spreading which is less sensitive to antimonial treatment (Hadighi et 
al., 2006, 2007) and patients from younger groups are the most effected as not being 
immune (Du et al., 2016). Other areas threatened with leishmaniasis increase are Libya, 
Tunisia, or Yemen (Du et al., 2016). 
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1.1.1 Diagnosis, treatment, vaccination 
The statistics available are problematic, partly because the numbers of cases are 
underestimated due to misdiagnosis and lack of reporting of the cases, asymptomatic 
cases and discontinuous distribution of the disease. Due to high numbers of 
asymptomatic cases, proper tests are crucial in controlling the disease, since the 
individuals may possibly serve as reservoirs for further infection. Fortunately,  there are 
new, cheap, easy to use and reliable serological tests available now, including DAT 
(Direct Agglutination Test), various ELISA based tests, a rapid strip test for rK39 
antigen, the latex agglutination urine test, and a DTH (delayed-type hypersensitivity) test 
(Ostyn et al., 2011; Savoia, 2015). Use of these tests has confirmed high numbers of 
positive individuals who never reported clinical disease (Ostyn et al., 2011). However, 
the drawback of serological tests is that high levels of the specific antibodies remain in 
blood years after cure, so the tests cannot distinguish between present and past infection. 
Moreover, the tests are not reliable for HIV-coinfected patients due to 
immunosuppressive effect of the virus (reviewed in Savoia, 2015). The most widely used 
and reliable diagnostic technique remains detection of parasites in infected tissues by 
microscopy. Molecular tests such as PCR give good results regarding sensitivity under 
laboratory conditions but wider use is currently precluded by technical difficulties of 
PCR-based approaches in the affected areas (Savoia, 2015). 
Vaccines have been always considered as having potential to combat leishmaniasis. So 
called, leishmanization - inoculation with virulent parasites, has been used since ancient 
times as a confirmed, reliable prevention. Inoculum is implemented on a selected, hidden 
body part, where a self –healing lesion forms after which the person is protected from 
future infections. The method was mostly abandoned due to safety issues, but is still used 
in high risk areas of Uzbekistan with a mixture of live and killed parasites (reviewed in 
Evans and Kedzierski, 2012). It is believed that 80 – 90% of natural cases are 
asymptomatic, suggesting cell-mediated immunity can combat the parasites (reviewed in 
Evans and Kedzierski, 2012). In most cases, people who overcome a primary cutaneous 
leishmaniasis skin lesion are protected from future infections, unless complications occur 
such as in the diffuse form. The prevailing evidence thus indicates that hopes for a 
vaccine as effective tool against leishmaniasis are not without basis. However, despite 
long lasting multiple efforts, no vaccine has been approved for humans until now. The 
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research and development in this area has included recombinant proteins, polyproteins, 
liposomal formulations of antigens and dendritic cell vaccine delivery systems (reviewed 
in Evans and Kedzierski, 2012). The last cutting-edge approach is usage of DNA 
vaccines, which are expected to induce Th1 responses leading to strong cytotoxic T-cell 
immunity (Das et al., 2014). There are two vaccines available for dogs, which contain 
the protein A2 antigen but their efficacy is only about 40% (Savoia, 2015). On the other 
hand, the caveat is that the parasites affect the immune system itself in multiple ways, 
efficiently blocking and inhibiting the normal immune response. This could mean that 
stable vaccines that behave consistently across the population will continue to confound 
efforts at their development (reviewed in Savoia, 2015).  
1.1.2 Drugs 
The first-line treatment against leishmaniasis has been different formulations of 
antimony-containing drugs for decades. Due to emerging resistant parasitic lines, as well 
as their intrinsic toxicity, they are being replaced with new, potentially more efficient 
and safer drugs such as AmbiSome, miltefosine or paromomycin (Fig 1.3). Crucially, 
drug treatment for leishmaniasis must be applied according to the specific species, given 
different species respond differently to drugs, but simple speciation is currently difficult 
in the field (reviewed in de Vries et al., 2015). Combinations of drugs are discussed and 
recommended due to the reduced risk of development of resistance, moreover, they seem 
to provide more effective treatment with fewer side effects (Seifert and Croft, 2006). 
Increasingly, the future of leishmaniasis chemotherapy would appear to be in 
combination chemotherapy (Melaku et al., 2007; Sundar et al., 2011; Trinconi et al., 
2016). 
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Figure 1.3. The drugs used against leishmaniases. 
Several drugs contain pentavalent antimony (sodium stibogluconate, methylglucamine 
antimoniate), which is a prodrug and needs to be converted into the trivalent form inside 
macrophages to exert a toxic effect. Exactly how trivalent antimonials kill cells is not 
known, although depletion of trypanothione, the major antioxidant of trypanosomatids 
accompanies cell death (Croft et al., 2006). These drugs are effective as direct injections 
into skin lesions, even though painful. A strain resistant to antimonials spread in Bihar, 
India, causing the efficacy to drop to 35% (Murray et al., 2005), thus they are being 
replaced with amphotericin B, particularly in the liposomal formulation, AmbiSome 
where possible. Interestingly, it has recently been suggested that high levels of arsenic, a 
heavy metal in the same group as antimony in the periodic table, in ground water in parts 
of India might have led to selection of resistance to antimonial drugs (Perry et al., 2013, 
2015). Other drawbacks of antimony are long duration of the treatment and adverse 
reactions (Murray et al., 2005). 
Amphotericin B acts by binding selectively to ergosterol which is present in Leishmania 
but not in mammalian hosts where cholesterol is the primary membrane sterol (Croft et 
al., 2006). Even though this compound is not very well tolerated by patients, its liposomal 
formulation AmbiSome causes fewer and less severe adverse effects and seems to be 
more effective even in short (5 – 10 days) regimes (Murray et al., 2005), but is more 
costly. In Asia, AmbiSome is increasingly being used as the first line treatment in a single 
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intravenous dose (Uniting to Combat NTDs, 2014). There has been a single clinical 
resistance case reported so far but numerous resistant cell lines were selected in in vitro 
conditions (Al-Salabi and De Koning, 2005; Mbongo et al., 1998; Purkait et al., 2012; 
Srivastava et al., 2011) and attention must be paid to the risk of selection and spread of 
resistance, especially in light of the single-dose policy. 
Miltefosine is the first oral drug available for use against leishmaniasis. It is active; 
effective in 90% cases of childhood visceral leishmaniasis (Palumbo, 2008), has a long 
half-life (~8 days) (Sundar et al., 2002), but the disadvantages are teratogenicity, 
gastrointestinal adverse reactions and relapse in 5-10% of obviously cured patients 
(Murray et al., 2005). Moreover, its availability as an oral drug, but requiring relatively 
long administration regimens, has made compliance of full dosing an issue and resistance 
is relatively easy to select (Croft et al., 2006). Its mode of action is not known. It has 
been proposed that it acts through inhibition of a glycosomal alkyl-specific-acyl CoA 
acetyltransferase, an enzyme involved in ether-lipid remodelling (Lux et al., 2000), 
among other potential mechanisms. In addition it stimulates T-cells and macrophages to 
secrete activating cytokines (Palumbo, 2008).  
Paromomycin can be used in topical formulation against cutaneous leishmaniasis. It is 
expected to be very promising thanks to high-level efficacy, minimal toxicity and low 
cost (Murray et al., 2005). It is an aminoglycoside-aminocyclitol antibiotic, inhibiting 
protein synthesis in bacteria and the mode of action against Leishmania seems to be the 
same, since it was shown to bind to an rRNA model and inhibit translation (Shalev et al., 
2015). There were resistant bacteria cases reported, caused by decreased uptake and some 
other reasons (Croft et al., 2006), and reduced uptake was also shown to associate with 
resistance in laboratory selected Leishmania lines (Jhingran et al., 2009; Maarouf et al., 
1998). 
There are several potential drugs in the pipeline, which is absolutely necessary. 
Fexinidazole is currently in trials against human African trypanosomiases and may be 
effective against leishmaniasis as well (Savoia, 2015). Nifurtimox is in clinical trials 
against visceral leishmaniasis, other interesting effective compounds should be on the 
way (Savoia, 2015). Pentamidine represents another treatment option but it is not widely 
used, so far as treatment outcomes are not really satisfactory (Murray et al., 2005). An 
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appreciation of the biology of the parasites offers a means to determine potential drug 
targets that may then enable the improvement of the drugs available to treat the disease. 
1.2 Leishmania biology 
1.2.1 Life cycle 
Leishmania parasites are transmitted between mammalian hosts by female sand flies of 
the genus Phlebotomus in the Old World and Lutzomyia in the New World. There are 
about 800 known sand fly species in total and 93 of them were reported as vectors for 
Leishmania (WHO, 2010). When feeding on a host, the insect makes a wound and the 
tissue damage attracts macrophages (Fig 1.4). If the individual is infected, the 
macrophages are picked up by a sand fly including the internalized Leishmania (Bates, 
2007). After entering the insect, temperature and pH changes cause transformation of 
amastigote Leishmania into promastigotes which settle first in the midgut and derive 
nutrition from the ingested blood meal. Afterwards, they migrate towards the foregut and 
attach to the gut epithelium which is a crucial step in determining if the parasites complete 
their lifecycle and the insect will serve as a true vector. After a couple of days, the 
parasites start secreting a so-called promastigote secretory gel composed of high 
molecular weight glycoproteins, creating a plug in the digestive tract (Ilg et al., 1996; 
Rogers et al., 2002). Over time, they change their body shape as they progress through 
different subtle life cycle stages, the last being the metacyclic epimastigotes, which are 
infective for a new mammalian host. When biting next time, the fly needs to clear the 
way in its digestive tract, thus the gel plug is egested together with the parasites (reviewed 
in Bates, 2007). 
1. Introduction 
 
27 
 
Figure 1.4. Leishmania life-cycle. Adapted from Kaye and Scott (2011), permission 
to reproduce this image has been granted by Nature Publishing Group. 
Enclosure within sand fly saliva and the promastigote secretory gel supports the parasites 
in further establishment of infection. Significant differences were observed in mouse 
models, if the injection mixture contained extracts of salivary glands, which appear to 
induce immunomodulatory effects (Titus and Ribeiro, 1988). After recognition by the 
immune system, Leishmania are engulfed by phagocytic immune cells. Macrophages are 
preferred as the host cells but it has been reported that neutrophils may absorb the 
parasites first, serving as “Trojan horses”, and when they undergo apoptosis and are 
ingested by macrophages later, Leishmania survive the process and establish infection in 
macrophages (Laskay et al., 2003; Peters et al., 2008). However, results from different 
Leishmania species vary and depend on the type of inbred mice used for each study, thus 
the definitive picture is still unclear (reviewed in Kaye and Scott, 2011). How the 
pathogens survive within the hostile conditions inside the phagocytic vacuole which are 
meant to destroy them has also not been resolved. Some Leishmania species prevent 
fusion of the primary endocytic vesicles with the phagosome vacuole while for others it 
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was suggested that the large volume of their parasitophorous vacuoles allows dilution of 
the detrimental enzymes and reactive chemical species (reviewed in Cecilio et al., 2014). 
Once inside macrophages, Leishmania differentiate into the amastigote stage which has 
smaller rounded cells without a protruding flagellum. The parasites multiply, eventually 
causing the host cell to burst, disseminating the pathogens around body, infecting lymph 
nodes, skin, liver, spleen or bone marrow depending on the Leishmania species (reviewed 
in Kaye and Scott, 2011). 
1.2.2 Specific traits in morphology and molecular biology 
Trypanosomatid parasites are considered to be one of the earliest branching groups of 
eukaryotes (Cavalier-Smith, 2010), which may explain the absence of some aspects 
considered normal in model eukaryotic cells and  by contrast the presence of various 
unique molecular traits.  
Leishmania are unicellular organisms with an elongated body shape in the promastigote 
stage and a circular morphology in the amastigote stage. Promastigotes have a flagellum 
at the anterior end of the cell to enable directed swimming or attachment. In the 
amastigote stage the flagellum is greatly diminished in size, and the arrangement of 
microtubules is altered (reviewed in Gluenz et al., 2010). Close to the flagellar attachment 
zone is the kinetoplast, a body of mitochondrial DNA composed of dozens of maxicircles 
and thousands of minicircles, highly condensed and thus easily stained with DAPI and 
other DNA staining dyes (Stuart, 1983). The prominence of the kinetoplast is responsible 
for the phylogenetic order containing the Leishmania species to have been classified as 
the Kinetoplastida. Only a single mitochondrion is present in each cell, but it is large, 
reticulated and stretches across the whole cell. In addition to the common organelles of 
eukaryotic organisms (e.g. endoplasmic reticulum, Golgi apparatus and lysosomes), 
various other organellar systems exist including acidocalcisomes and glycosomes 
(Coombs et al., 1982; Vercesi et al., 1994). 
Organization of chromosomes and genes and their expression is very specific in 
trypanosomatids. Leishmania have a relatively flexible genome, meaning that whole 
chromosome duplications or fusions are common (Pages et al., 1989). Chromosome 
rearrangements happen relatively frequently during prolonged laboratory cultivation and 
the extent to which such flexibility is evolutionary advantageous, or merely an in vitro 
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artefact deserves attention. Protein coding genes do not have canonical transcription 
factors, but instead are transcribed into long polycistronic units, which need to be 
processed subsequently (Clayton, 2002; Ivens et al., 2005). During the process of trans-
splicing, the large transcript is cleaved into single gene mRNAs and a common 39 
nucleotide splice leader sequence is added to the 5’ end of each transcript and poly-A tail 
at the 3’ end (LeBowitz et al., 1993). Due to the absence of transcription factors, it 
remains unclear how gene expression is regulated. Control of mRNA stability and 
degradation  and regulation of translation (Vasquez et al., 2014) have been described in 
T. brucei (reviewed in Clayton, 2014). A key role for 3’- untranslated region was 
demonstrated in posttranscriptional regulation of Hsp70 gene in L. infantum (Quijada et 
al., 2000), a paraflagellar rod component (Mishra et al., 2003), or a 600-4 gene in L. 
mexicana (Murray et al., 2007). Various proteins are supposed to be binding to these 
regions and influence mRNA stability and degradation, however, the overall process 
seems to be highly complex and only few of these proteins have been functionally 
characterised so far in T. brucei (reviewed in Clayton, 2013, 2014).  
1.3 Metabolism 
Published data has led to a depiction of Leishmania metabolism (McConville et al., 2015; 
Opperdoes and Coombs, 2007; Saunders et al., 2011, 2014). However, it needs to be 
noted that practically all of the work has been done on in vitro grown cultures and the 
conditions inside a fly’s midgut or macrophage are most likely different, but practically 
unknown (McConville et al., 2015; Opperdoes and Coombs, 2007). The promastigote 
stage of Leishmania has been studied in more detail, given the easier cultivation of these 
cells (Opperdoes and Coombs, 2007; Pan et al., 1993; Trager, 1957). Axenic amastigote 
cultures can be obtained, but it remains a matter of dispute how biologically relevant they 
are (Holzer et al., 2006; Pan et al., 1993; Pescher et al., 2011; Pral et al., 2003). Different 
types of cultivated macrophages can be infected with Leishmania, but it is very difficult 
to separate the parasites subsequently and dissecting metabolism of macrophage resident 
Leishmania parasites is very difficult. Here, I will briefly describe the main aspects of 
the promastigote and amastigote central metabolism as it is currently understood.   
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1.3.1 Promastigotes 
Under optimal growth conditions the major carbon source for a promastigote cell is 
glucose, and aspartate to a limited extent. Additional amino acids and fatty acids are 
taken up as well, but not incorporated into the tricarboxylic acid cycle (TCA) 
intermediates (Saunders et al., 2011). Glucose is used in glycolysis, the pentose 
phosphate pathway and for a succinate fermentation pathway and the derived products, 
acetyl-CoA and malate are further channelled into the TCA cycle. The major ultimate 
source of ATP is the respiratory chain, which was validated when inhibition of the 
separate complexes was shown to be lethal to the parasites, as was inhibition of 
mitochondrial aconitase from the TCA cycle (Hellemond and Tielens, 1997; Saunders et 
al., 2011). The alternative oxidase of the respiratory chain, characteristic of T. brucei, is 
not present in Leishmania (Opperdoes and Coombs, 2007). The major metabolic end 
products are CO2, acetate, alanine and succinate (Saunders et al., 2011).  
The standard metabolism can be altered substantially in cells grown under suboptimal 
conditions, for example cells depleted for glucose transporters can use various sources 
(alanine, acetate, aspartate, glycerol) for mannogen biosynthesis, indicating that these 
substrates  can be used as general carbon sources (Rodriguez-Contreras and Landfear, 
2006). Promastigotes scavenge fatty acids from medium but do not incorporate the 
carbons into the TCA cycle intermediates or sugars, even in the absence of glucose. When 
amino acids were depleted, fatty acid utilisation was not increased, rather lipogenesis was 
reduced (Naderer et al., 2006). The parasites have amylase and sucrase enzymes (Blum 
and Opperdoes, 1994), functions of which were suggested in degradation of starch and 
sugar polymers after sand fly plant meal (Opperdoes and Coombs, 2007), or in 
degradation of extracellular matrix glycosaminoglycans in the amastigote stage (Naderer 
et al., 2015). 
Leishmania are auxotrophic for many nutrients, including specific amino acids, vitamins, 
or purines and in other cases uptake and de novo biosynthetic pathways overlap 
(McConville et al., 2015; Opperdoes and Coombs, 2007). Pyrimidines can be obtained 
by either de novo biosynthesis or salvage pathways. Disruption of each of the branches 
is fully compensated by the other, but cells with deletions in both the pathways were 
viable only in the promastigote stage but not infective to mice (Wilson et al., 2012). The 
purine ring cannot be synthesized by the parasite. Its salvage pathway is complex and 
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redundant with various alternative routes, with the majority being confined to 
glycosomes and some enzymes present in the cytosol (reviewed in Boitz et al., 2012). 
Amino acid metabolism of Leishmania was described based on genome analysis, 
excluding the capacity to synthesize aromatic and branched chain amino acids, histidine, 
and lysine (Opperdoes and Coombs, 2007). However, the presence of additional enzymes 
with non-canonical sequences cannot be excluded until tested experimentally, especially 
regarding the high number of hypothetical proteins with unknown function present in the 
genome (Ivens et al., 2005). Degradation pathways for tryptophan and arginine were 
dissected by LC-MS metabolomics revealing substantial differences between three 
different Leishmania species (Westrop et al., 2015). 
Biosynthesis of mannogen (Fig 1.5), a storage sugar polymer, represents a significant 
and important part of sugar metabolism in Leishmania (Ralton et al., 2003). Activated 
mannose can be used for biosynthesis of mannogen or various mannose-conjugated 
glycolipids or proteoglycans. Deletions of different genes from the aminosugar pathway 
(GDP-mannose pyrophosphorylase (GDPMP), dolicholphosphate-mannose synthase 
(DPMS), phosphomannomutase (PMM)) caused no obvious defects in promastigote 
cultures, but the cells were not infective to macrophages or mice (Garami and Ilg, 2001; 
Garami et al., 2001). The defect seems to be due to deficiency in mannogen rather than 
loss of mannose conjugates of the cell surface (Ralton et al., 2003), although 
lipophosphoglycan together with other glycoconjugates is essential for the parasites’ 
survival in the sand fly’s midgut, attachment to the walls and protection from digestive 
enzymes present there (Sacks et al., 2000). In addition to glucose, glucosamine or N-
acetylglucosamine can be used as substrates for mannogen biosynthesis (Naderer et al., 
2010). Through gluconeogenesis it can also be synthesised from glycerol, alanine and 
aspartate, and in amastigotes from lactate too (Rodriguez-Contreras and Hamilton, 2014; 
Rodriguez-Contreras and Landfear, 2006). 
 Mannogen accumulates during promastigote to amastigote transformation, or in 
response to stress, and the intracellular levels are higher in the mammalian infective stage 
(Ralton et al., 2003). If sugars are not available, mannogen is rapidly consumed, and the 
cells become more sensitive to various types of stress in its absence (Ralton et al., 2003). 
Deletion of glucosamine-6-phosphate deaminase (GND) caused decrease in infectivity 
of amastigotes, whereas promastigotes were still able to grow, if glucose but not amino 
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sugars were supplemented. Deletion of glutamine:fructose-6-phosphate 
amidotransferase (GFAT) provoked auxotrophy for amino sugars, loss of surface lipid-
linked oligosaccharides and hypersensitivity to increased temperatures. The mutant 
promastigotes were unable to infect macrophages ex vivo, but established infection in 
mice and once transformed into amastigotes, the growth was comparable to WT cells 
(Naderer et al., 2008). A similar phenotype was observed in N-acetylglucosamine 
acetyltransferase (GNAT) deficient L. major mutant which was auxotrophic for N-
acetylglucosamine and caused skin lesions in mice, but was unable to infect macrophages 
ex vivo (Naderer et al., 2015). This may be explained by a premise that hyaluronan and 
other sugar polymers are available in vivo, cleaved by various hydrolases inside the 
parasitophorous vacuole and used by the parasites (Naderer et al., 2015). It also indicates 
that even though the mannogen biosynthetic pathway seems redundant (Fig 1.5), free N-
acetylglucosamine is not abundant, and in addition the branch via mannose (bottom part 
in Fig 1.5) is not sufficient to compensate for the whole biosynthesis. Why mannogen is 
essential in amastigotes is still not fully resolved. It may possibly be used during 
transformation of promastigotes into amastigotes or under stress conditions when usual 
carbon sources are limited, and after establishing of macrophage infection, the 
intracellular pool of mannogen is replenished. The nutritional status of the 
parasitophorous vacuole remains a matter of speculation (McConville et al., 2015), and  
may be variable i.e. when sugars are available mannogen may be synthesised, then 
consumed if sugars are depleted. 
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Figure 1.5. Scheme of mannogen biosynthesis. GlcNAc – N-acetylglucosamine, 
GlcNAc6P - N-acetylglucosamine 6-phosphate, GlcN – glucosamine, GlcN6P – 
glucosamine 6-phosphate, Glc – glucose, G6P – glucose 6-phosphate, F6P – 
fructose 6-phosphate, Man6P – mannose 6-phosphate, Man1P – mannose 1-
phosphate, UDP-GlcNAc - uridine diphosphate N-acetylglucosamine, GDP-Man – 
guanosine diphosphate mannose, GPI – glycosylphosphatidylinositol, Dol-P-Man – 
dolicholphosphate mannose. Enzymes are depicted in blue: HK – hexokinase, PGI 
– glucose-6-phosphate isomerase, NAGD – N-acetylglucosamine-6-phosphate 
deacetylase, GND – glucosamine-6-phosphate deaminase, GNAT – glucosamine-
6-phosphate acetylase, GFAT – glutamine:Fru6P aminotransferase, PMM – 
phosphomannomutase, GDPMP – GDP-mannose-pyrophosphorylase, DPMS – 
dolicholphosphate-mannose synthase; dashed arrows indicate multiple enzymatic 
steps; based on Naderer, 2010 and Garami, 2001. 
1.3.2 Amastigotes 
The major difference in metabolism of the amastigote stage is that it has been described 
as stringent given its apparent nutrient sparing nature (Saunders, 2014). When compared 
to promastigotes, the cells consume less glucose (30 times) and glutamate, use it more 
efficiently and secrete less end products (Saunders, 2014). They secrete practically no 
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partly oxidised end products, such as succinate, alanine, or malate (McConville et al., 
2015; Saunders et al., 2014). These metabolic changes seem to be tightly linked to the 
specific life stage, since they take place even in rich culture conditions (McConville et 
al., 2015; Saunders et al., 2014). In addition, lesion amastigotes grow extremely slowly 
with a doubling time of approximately 12 days, as was estimated based on DNA, RNA, 
and protein turnover, suggesting that the parasites enter a semi-quiescent state (Kloehn 
et al., 2015). Even axenic amastigotes have DNA turnover about four times lower than 
promastigotes (Saunders et al., 2014). The fact that all cellular processes are very slow 
may enhance persistence of the parasites and negatively impact on drug efficiency. 
It was suggested by Hart and Coombs (1982) that amastigotes use fatty acids as source 
of carbon. This was confirmed in a current study comparing metabolism of the two life 
stages by untargeted GC-MS metabolomics, when medium was supplemented with a 
mixture of 13C labelled fatty acids, and the labelling was detected in the TCA cycle 
intermediates in amastigotes but not in promastigotes (Saunders et al., 2014). The overall 
labelling patterns seemed quite similar between promastigotes and amastigotes when 
labelled glucose or amino acids were used, confirming that glucose is still the main 
carbon source, used for glycolysis, succinate fermentation and the TCA cycle. The TCA 
cycle is essential and sensitivity to an inhibitor (fluoroacetate) of mitochondrial aconitase 
is 100 times higher than in promastigotes (Saunders et al., 2014).  Gluconeogenesis 
becomes essential in amastigotes, since mutants lacking its key enzyme, fructose-1,6-
bisphosphatase, did not multiply inside macrophages. In the promastigote stage the same 
deletion caused a growth defect in medium containing glycerol as the major carbon 
source, whereas glucose supplementation rescued the phenotype (Naderer et al., 2006). 
Levels of mannogen are much higher in amastigotes than promastigotes and it is crucial 
for survival inside macrophages (Ralton, 2003; Naderer, 2010). As an example of the 
differences between in vitro and in vivo conditions a recent experimental observation 
revealed that when amastigotes grow inside macrophages, they consume polymers of 
saccharides and glycoproteins from the extracellular matrix, possibly thanks to activity 
of secreted digestive enzymes (Naderer, 2015).  
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1.3.3 Glycosomes 
Glycosomes are small organelles characteristic for trypanosomatids and originally 
derived from peroxisomes. They are surrounded by a semipermeable membrane 
equipped with specific transmembrane channels and import machinery for proteins 
(Achcar 2013, Gualdron-Lopez, 2012; reviewed in Michels, Bringaud, 2006). Proteins 
are imported into glycosomes based on presence of the peroxisomal targeting sequence 
(PTS). PTS1 type is composed of the last three amino acid residues –SKL, or similar 
(Gould et al., 1989), whereas PTS2 is close to the N-terminus, is bipartite and more 
variable (Swinkels et al., 1991). In addition, several non-canonical targeting sequences 
were detected, and import of protein complexes, where not all components contain 
distinguishable PTS can also occur (Opperdoes and Szikora, 2006). Once a PTS is 
recognized by a PEX receptor, it is connected with a docking complex on the glycosomal 
membrane and transferred across the membrane (reviewed in Gualdrón-López et al., 
2013).  
Part of the glycolytic pathway is located inside glycosomes and such 
compartmentalisation compensates for allosteric regulation which is missing for 
glycolytic enzymes of trypanosomatids (or completely different from the described 
types). Another advantage is that because investment of ATP is required for initialisation 
of glycolysis, thanks to compartmentalisation the flux through the pathway is 
independent of outside conditions, which are variable (Bakker et al., 2000; Haanstra et 
al., 2008).  
 Bigger molecules such as nucleotide cofactors cannot cross the membrane freely, thus 
the balance of NAD(P)/H and ADP/ATP needs to be maintained inside the organelle. 
That is probably the purpose for the presence of the succinate fermentation pathway 
inside these organelles, to ensure recycling of these molecules needed for glycolysis (Fig 
1.6). Various metabolic pathways have dual subcellular localisation, being present both 
in the cytosol and glycosomes, for example the pentose phosphate pathway, purine 
salvage, pyrimidine biosynthesis, β-oxidation of fatty acids or trypanothione pathway 
(reviewed in Michels et al., 2006). The purpose is mostly suspected to be connection with 
glycolysis but it becomes questionable if we consider the semipermeable character of the 
glycosomal membrane. Various sugar kinases have been identified in the Leishmania 
genome, functions of which are not exactly clear but all of them carry a PTS, indicating 
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a possible connection with the PPP or mannogen biosynthesis (Opperdoes and Coombs, 
2007). Glycosomal localisation is essential for some but not all enzymes. For example, 
for the enzymes of the purine salvage pathway tested, glycosomal localisation was not 
necessary (Carter et al., 2008). Cells containing mislocalised glucosamine-6-phosphate 
deaminase of mannogen biosynthetic pathway were viable, but dependent on glucose 
supplementation unless the WT localisation was restored (Naderer et al., 2010). A 
mutated cytosolic version of hexokinase caused swelling and death of cells (Kumar et 
al., 2010). Glycosomes vary during the life cycle, while promastigotes contain around 
20, there are only 10 in amastigotes (Cull et al., 2014), and their enzyme content changes 
probably as well (Mottram and Coombs, 1985a). 
Figure 1.6. Metabolism compartmentalisation in the glycosome. A – The greater 
parts of glycolysis and the succinate fermentation pathway are confined to the 
glycosome, ensuring ADP/ATP and NAD/H balance; adapted from Michels et al. 
(2006). B – Glycosomal pathways contributing to nicotinamide and ATP cofactors 
pools in the glycosome; adapted from Michels et al. (2000). Permission to 
reproduce this image has been granted by Elsevier. 
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1.4 The pentose phosphate pathway  
The pentose phosphate pathway (PPP) is a key component of cellular metabolism, tightly 
connected to glycolysis as a key consumer of glucose. Its primary roles are to generate 
NADPH as a source of reducing power and other products that feed diverse parts of 
metabolism. These include ribose 5-phosphate (R5P) for nucleotide synthesis and 
erythrose 4-phosphate (E4P) for aromatic amino acid and various vitamin biosyntheses 
(Braus, 1991; Lam and Winkler, 1990; Zhao and Winkler, 1994). The PPP has long been 
considered to offer potential drug targets and the recently invigorated quest for inhibitors 
of enzymes of the pathway in cancer means that new possibilities to seek compounds that 
might inhibit the pathway in the parasites are emerging.  
First reports demonstrating the PPP in trypanosomatids emerged in 1960’s. Studies used 
glucose labeled with 14C at either position 1 or position 6 to feed the parasites after which 
the ratios between 14CO2 produced under either condition were interpreted as pointing to 
the respective fluxes via the PPP and glycolysis. Values between 10% and 41% flux into 
the PPP were reported for T. cruzi (Mancilla and Naquira, 1964; Maugeri and Cazzulo, 
2004), and 6% for Leishmania (Mancilla et al., 1965; Maugeri et al., 2003). However, 
since various degree of incomplete oxidation of glucose occur in all trypanosomatids, 
these numbers may be inaccurate estimates. Specific activities of each enzyme of the 
canonical PPP (Fig 1.7) were measured in the four major life stages of T. cruzi (Maugeri 
and Cazzulo, 2004), and in promastigote L. mexicana, L. braziliensis, L. donovani, and 
L. tropica (Martin et al., 1976; Maugeri et al., 2003). In T. brucei, all of the enzyme 
activities were measured in the procyclic stage (PCF) while transketolase and ribulose 5-
phosphate epimerase were absent in the bloodstream form (BSF) (Cronín et al., 1989). A 
kinetic model of the PPP in BSF T. brucei was constructed (Kerkhoven et al., 2013), 
extending the previous model of BSF trypanosome glycolysis (Bakker et al., 1997, 1999; 
Haanstra et al., 2008) and pointing at gaps in our understanding of the system, 
particularly with regard to how the bound phosphate pool within the glycosome is 
maintained if a proportion of the glycolytic glucose 6-phosphate is shunted through the 
oxidative branch of the PPP (Fig 1.8). The PPP of trypanosomatids has been reviewed 
with focus on structures of the enzymes, comparison with mammalian counterparts and 
search for potential inhibitors (Comini et al., 2013). 
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Figure 1.7. The pentose phosphate pathway. Glucose can be metabolized via 
glycolysis or through the pentose phosphate pathway, branching at glucose 6-
phosphate. The glycolytic pathway is shaded in blue and enzymes hexokinase 
(HK), phosphoglucose isomerase (PGI) and pyruvate kinase (PK) are marked. 
Other reactions between fructose 6-phosphate and glyceraldehyde 3-phosphate 
(GA3P) are summarized through the presence of dotted lines. The oxidative branch 
of the pentose phosphate pathway, shaded in green, comprises the enzymes 
glucose-6-phosphate dehydrogenase (G6PDH), 6-phosphogluconolactonase (6-
PGL) and 6-phosphogluconate dehydrogenase (6-PGDH).  The non-oxidative 
branch, shaded in lilac comprises the enzymes ribulose-5-phosphate epimerase 
(RuPE), ribose-5-phosphate isomerase (RPI), transketolase (TKT) and 
transaldolase (TAL). Sedoheptulose-1,7-bis-phosphatase (SBPase) which can 
introduce sedoheptuolse 1,7-bisphosphate to the pathway is also depicted. 
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Figure 1.8. A mathematical model of the PPP in bloodstream form T. brucei. A - 
Scheme of the modeled metabolic pathways. B - A mathematical model of 
glycolysis in T. brucei, based on kinetic measurements of activities of each enzyme, 
had proven successful in describing glucose metabolism in these cells (model A) 
(Bakker et al., 1997, 1999; Haanstra et al., 2008). As kinetic parameters of the 
pentose phosphate pathway enzymes became available it was possible to add 
these to the model (model B). However, the addition of the pentose phosphate 
pathway created a potentially fatal leak of bound phosphate from the metabolite 
pool in the glycosome of these cells. It was necessary, therefore, to evoke possible 
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solutions to this, which are shown as models C and D. Cytosolic PPP is shaded in 
green, glycosomal PPP in blue, ribokinase reaction in crimson, ATP:ADP antiporter 
in purple, trypanothione recycling in yellow, and fructose utilization in orange. 1,3-
BPGA – 1,3-bisphosphoglycerate, 2-PGA – 2-phosphoglycerate, 3-PGA – 3-
phosphoglycerate, 6-PG - 6-phosphogluconate, 6-PGL – 6-phosphogluconolactone, 
ADP – adenosine diphosphate, AMP – adenosine monophosphate, ATP – 
adenosine triphosphate, DHAP – dihydroxyacetone phosphate, Fru-1,6-BP – 
fructose 1,6-bisphosphate, GA-3-P – glyceraldehyde 3-phosphate, Glc-6-P – 
glucose 6-phosphate, Gly-3P – glycerol 3-phosphate, NADP(H) – nicotinamide 
adenine dinucleotide phosphate, T(SH)2 – trypanothione, T(S)2 – trypanothione 
disulfide, Rib-5-P – ribose 5-phosphate, Rul-5-P – ribulose 5-phosphate. The figure 
was adapted from Kerkhoven et al. (2013). 
1.4.1 Biochemical roles of the PPP and its substrates 
The pathway is conventionally divided into two branches (Fig 1.7), the first three 
reactions comprising the oxidative PPP while the following sugar interconversions make 
up the non-oxidative PPP. The oxidative branch uses glucose 6-phosphate (G6P) from 
glycolysis and converts it to 6-phosphoglucono-1,5-lactone using glucose-6-phosphate 
dehydrogenase (G6PDH) (EC 1.1.1.49)  with NADP as a cofactor. The second enzyme, 
6-phosphogluconolactonase (6PGL) (EC 3.1.1.17) produces 6-phosphogluconate (6PG). 
Following 6-phosphogluconate dehydrogenase (6PGDH) (EC 1.1.1.44) produces a CO2 
molecule and ribulose 5-phosphate (Ru5P) while creating another molecule of NADPH.  
Ru5P is further converted through the non-oxidative PPP, either by ribose-5-phosphate 
isomerase (RPI) (EC 5.3.1.6) into ribose 5-phosphate (R5P), a critical cellular metabolite 
used in nucleotide synthesis, or to xylulose 5-phosphate (Xu5P) by ribulose-5-phosphate 
epimerase (EC 5.1.3.1). Both of these products serve as substrates for the following 
enzyme, transketolase (TKT) (EC 2.2.1.1), which transfers a two carbon keto unit from 
a ketose to an aldose, producing, in this case, sedoheptulose 7-phosphate (S7P) and 
glyceraldehyde 3-phosphate (GA3P). These are further used by transaldolase (EC 
2.2.1.2), which transfers a three carbon aldol unit from S7P to GA3P, producing erythrose 
4-phosphate (E4P) and fructose 6-phosphate (F6P). The latter re-enters glycolysis, 
whereas E4P is used in a further TKT reaction with Xu5P, resulting in GA3P and F6P. 
In this canonical scheme all of the final products feed back into glycolysis. However, as 
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Kleijn and colleagues have suggested, this scheme is an over simplification, and the non-
oxidative PPP could be better considered as a sum of half-reactions, where TKT and TAL 
can use a diversity of substrates ranging from 2 or 3 to 8 or more carbons and combine 
any suitable substrate and product pair (Kleijn et al., 2005). This model of a dynamic 
junction-centre driven by substrate availability seems to offer a better description. 
Metabolomic analyses of PCF (Creek et al., 2012a) and BSF T. brucei (Creek et al., 2015) 
revealed larger monosaccharides including S7P, octulose 8-phosphate (O8P) and 
nonulose 9-phosphate (N9P). Their production from the non-oxidative branch was shown 
in experiments where 50% of glucose in the medium had all six carbons labelled (U-13C-
glucose). The distribution of labelled carbons in metabolic products indicates that O8P 
derives primarily from addition of a 3 carbon unit to R5P while N9P derives from 
addition of a 3 carbon unit to G6P, using TAL (Creek et al., 2012a, 2015). In plants O8P 
has been shown to play a role in sugar cycling in the Calvin cycle (Williams and 
MacLeod, 2006), but roles for these larger monosaccharides are not known in 
trypanosomatids; indeed it is possible that they are merely an inevitable consequence of 
the promiscuous shuffling of carbons carried out by the non-oxidative branch.  
Additional enzymes, which were not regarded as part of the classical pathway, but which 
produce PPP intermediates, and thus should be taken in consideration as well, are being 
discovered in various systems. For example, sedoheptulokinase (SHK) in mammalian 
cells (previously known as CARKL) catalyses the phosphorylation of sedoheptulose to 
S7P (Kardon et al., 2008). In trypanosomatids, although sedoheptulose and S7P can be 
detected in cell extracts, genes with clear orthology to SHK are not known. In 
Leishmania, a variety of different pentose kinases have been inferred from sequence 
analysis and these are assumed to broaden the range of carbohydrates available for use 
from plant fluids consumed by the sand fly vectors of the parasites (Opperdoes and 
Coombs, 2007). 
In yeast, a pathway termed riboneogenesis was described recently, including 
sedoheptulose-1,7-bisphosphatase (SBPase) which removes one phosphate group from 
sedoheptulose 1,7-bisphosphate in order to produce S7P. This step allows creation of 
R5P independent of NADP/NADPH balance (Clasquin et al., 2011). An orthologous 
gene is present in trypanosomes, and the enzyme contains a predicted PTS (Igoillo-
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Esteve et al., 2007), and was detected in glycosomes in two independent proteomic 
studies of PCF T. brucei (Colasante et al., 2006; Guther et al., 2014). 
In addition to its role in creating carbohydrates as precursors in various synthetic 
processes and acting as a “carbon exchange centre” to shuffle carbohydrates to 
glycolysis, the pathway plays a key role in recycling of NADP to NADPH, an essential 
reducing agent for reductive biosynthesis and protection against oxidative stress. In 
trypanosomatids, NADPH is the cofactor for trypanothione reductase, the enzyme that 
catalyses reduction of trypanothione, the central thiol reductant in these cells (Fairlamb 
et al., 1985).  
1.4.2 The role of the oxidative PPP in NADPH synthesis 
The proportion of the cellular NADPH contributed by the PPP varies in different cell 
types and other enzymes also contribute to the production of this crucial cellular 
reductant. A technique tracing deuterium from labelled glucose indicated that between 
25% - 50% of cellular NADPH derives from the PPP in different mammalian cell types 
(Fan et al., 2014). The PPP is subject to rapid regulation in response to prevailing 
conditions and cellular needs. For example, oxidative stress activates the pathway as 
NADPH is consumed in providing defense against such stresses. As NADPH levels rise, 
they contribute to inhibition of the two oxidative branch dehydrogenases, again 
dampening flux through the pathway. Activation under oxidative stress was clearly 
observed in T. cruzi and L. mexicana (Maugeri and Cazzulo, 2004; Maugeri et al., 2003).  
The second most important source of NADPH in trypanosomatids is malic enzyme. In 
Leishmania this enzyme is present in the cytosol, using malate to produce pyruvate and 
NADPH. T. brucei and T. cruzi have a second malic enzyme gene encoding a 
mitochondrial isoform. In PCF T. brucei, the mitochondrial enzyme is essential, whereas 
the cytosolic one is dispensable (Allmann et al., 2013). However, simultaneous depletion 
of cytosolic malic enzyme and G6PDH is lethal which demonstrates the joint contribution 
of the PPP and malic enzyme in fulfilling cytosolic NADPH needs (Allmann et al., 2013). 
The authors speculated that malic enzyme may take on the dominant role in NADPH 
production when glucose is scarce in environments inhabited by particular life cycle 
stages. Mitochondrial isocitrate dehydrogenase, an enzyme of the TCA cycle, also 
produces NADPH, but since the cofactor cannot cross membranes, the NADPH pools 
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are independent in the respective compartments. Methylene tetrahydrofolate 
dehydrogenase from the folate metabolic pathway also makes a significant contribution 
to NADPH production in mammalian cells (Fan et al., 2014), but a contribution of this 
pathway to NADPH production has not been ascertained for trypanosomatids (Vickers 
and Beverley, 2011).  
In humans, partial deficiencies in several enzymes of the pathway are known. The role 
of G6PDH partial deficiency, selected originally in West Africa by resistance to malaria 
for example is a widely spread human inborn error of metabolism. Other deficiencies are 
known too, including 6PGDH, TAL and RPI, and some of them cause severe genetic 
disorders (reviewed in Stincone et al., 2014). The lack of reported deficiencies for other 
enzymes indicates that their loss is lethal during development. A number of studies have 
characterized individual enzymes of the pathway, and their cellular roles, in different 
trypanosomatids.  
 
1.4.3 Subcellular localization of the PPP in trypanosomatids 
In most organisms the PPP is present in the cytosol, and this is also the primary location 
in trypanosomatids, although in silico predictions found peroxisomal (i.e. glycosomal) 
targeting sequences (PTS) on many of the PPP enzymes. Subcellular localisation 
experiments have confirmed the presence of many enzymes of the PPP in glycosomes, 
although most of those activities are found in the cytosol too, indicating a dual 
localisation.  
Digitonin fractionation followed by enzyme assay in T. cruzi localized the majority of 
each PPP enzyme to the cytosol, with a minor glycosomal fraction representing 35% for 
G6PDH and TAL, 20% for RPI and TKT, 15% for 6PGDH and 10% for lactonase, 
respectively. Ru5PE was released at very low digitonin concentration (Maugeri and 
Cazzulo, 2004) which might indicate a unique localisation, or represent an example of 
the limitations of the approach. 
Colasante performed a proteomics study of separated glycosomes and detected G6PDH, 
TKT, SBPase and ribokinase in PCF T. brucei but only ribokinase in BSF (Colasante et 
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al., 2006). In another study, 6PGDH, ribokinase and RPI were detected in both stages of 
T. brucei, G6PDH only in BSF and TKT and TAL only in PCF (Vertommen et al., 2008). 
A highly purified glycosomal fraction, from organelles pulled down using epitope 
tagging on the glycosomal membrane protein PEX13 confirmed a glycosomal 
localisation for G6PDH, 6PGL, SBPase and ribokinase with high confidence in PCF T. 
brucei. The other enzymes showed predominant signal in the cytosol, which may mask 
a minor fraction present in glycosomes (Guther et al., 2014). Glycosomes from 
promastigote L. donovani were separated on sucrose gradients and subjected to 
proteomics where 6PGDH and TKT were detected (Jamdhade et al., 2015). 
1.4.4 The enzymes of the PPP in trypanosomatids 
1.4.4.1 Glucose-6-phosphate dehydrogenase (G6PDH) 
G6PDH is of central importance due to its high control coefficient for the PPP (Kacser, 
1995). G6PDH or 6PGDH depletion in T. brucei indicates no obvious phenotype in PCF 
but loss of either enzyme is lethal for BSF (Cordeiro et al., 2009; Kerkhoven et al., 2013). 
A genome scale RNAi screen, however, did not show immediate lethality, although for 
G6PD differentiation from BSF to PCF was prevented (Alsford et al., 2011). 
Intermediates of human steroid metabolism, dehydroepiandrosterone (DHEA), 
epiandrosterone (EA) and derived 16α-bromoepiandrosterone (16BrEA) are known to be 
uncompetitive inhibitors of mammalian and trypanosome G6PDH. DHEA inhibits the T. 
cruzi enzyme and kills both the epimastigote stage parasites and BSF T. brucei in in vitro 
culture (Cordeiro and Thiemann, 2010; Cordeiro et al., 2009). These compounds also 
reduce parasite levels in mice infected with T. cruzi  (Cordeiro and Thiemann, 2010; 
Cordeiro et al., 2009). However, the same molecules do not inhibit the Leishmania 
enzyme, presumably due to alterations in the as yet unknown hormone binding site. In 
an elegant experiment showing that the anti-trypanosomal activity of DHEA related to 
G6PDH inhibition, the leishmanial enzyme was expressed in T. brucei and these cells 
became insensitive to DHEA (Gupta et al., 2011). 
Interestingly, the genes in both trypanosomes have two alternative start codons and the 
longer protein product contains cysteine residues within an N-terminal 37 amino acid 
sequence preceding a second putative start codon. Versions of the T. cruzi enzyme either 
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containing the 37 amino acid N-terminal domain, or not, were expressed in E.coli and 
purified proteins compared. The longer, but not the shorter version, was inhibited by 
various reducing agents (DTT, glutathione, 2-mercpatoethanol), potentially due to their 
binding to a pair of cysteine residues within the domain. NADPH also inhibited the long 
form of the enzyme. The T. brucei and leishmania enzymes lack those cysteines within 
the homologous N-terminal region and are presumed, therefore, to lose this reductive 
regulation (Igoillo-Esteve et al., 2006). The longer variant of the protein is expressed 
predominantly in all four major life stages of T. cruzi, being most abundant in metacyclic 
trypomastigotes and amastigotes, lower in cultured trypomastigotes and negligible in 
epimastigotes, which seems to correlate with oxidative stress levels encountered in the 
parasite’s natural environment (Igoillo-Esteve and Cazzulo, 2006). The enzymatic 
activity correlates with protein levels but not exactly with mRNA levels, indicating post-
transcriptional control (Igoillo-Esteve and Cazzulo, 2006). Moreover, exposure to 
reactive oxygen species triggered increases in G6PDH expression in metacyclic 
trypomastigotes, but had detrimental effects on epimastigotes, suggesting the adaptation 
to be stage specific (Igoillo-Esteve and Cazzulo, 2006). 
G6PDH has a dual subcellular localization, with a higher glycosomal proportion than 
other PPP enzymes. Almost 50% of the activity was measured inside glycosomes by 
Heise and Opperdoes in PCF T. brucei (Heise and Opperdoes, 1999) while Duffieux et 
al.(2000) also reported over 40% of the activity in glycosomes. 
The sensitivity of T. brucei and T. cruzi to DHEA indicates that G6PDH can represent a 
druggable target in these cells. However, the steroid inhibitors are relatively toxic and of 
limited efficacy. Mercaldi et al.(2014) recently performed a screen of 30,000 compounds 
from the Chemridge DIVERSet in an assay designed to seek other uncompetitive 
inhibitors of the enzyme. After several rounds of screening a series of quinazolines were 
selected with activity against T. cruzi, for consideration for further development towards 
new chemical entities. 
In L. donovani, overexpression of G6PDH de-sensitised these cells to reactive oxygen 
species (Ghosh et al., 2015). Mukherjee et al. (2013) also showed that the G6PDH gene 
locus, along with ascorbate peroxidase, was amplified in L. major strains selected for 
resistance to Sb3+ and the associated chromosomal amplification containing these linked 
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genes decreased reactive oxygen species accumulation in cells exposed to Sb3+. Null 
mutants of G6PDH were then generated in L. major and the promastigote forms grew 
more slowly than wild-type (WT) cells and were of three fold increased sensitivity to 
Sb3+. Moreover, reactive oxygen species accumulated more in the knockout cells (1.5 
fold) in comparison to WT when treated with Sb3+ (Mukherjee et al., 2013). 
1.4.4.2 6-phosphogluconolactonase (6PGL) 
6-phosphogluconolactonase accelerates the hydrolysis of 6-phosphogluconolactone to 6-
phosphogluconic acid (6PG). The genome wide RNAi target sequencing (RITseq) in T. 
brucei indicated a small growth defect in PCF but no phenotype in BSF related to 6-PGL 
loss (Alsford et al., 2011). Targeted analyses on the function of the gene have not been 
carried out in any of the trypanosomatids though. Subcellular fractionation of PCF T. 
brucei cell extracts on sucrose gradients indicated that about 15% of the total activity was 
associated with glycosomes (Duffieux et al., 2000). An NMR study on the reaction 
catalyzed by the T. brucei enzyme was very informative. The half-life of the lactone was 
shown to be non-negligible and given its being a highly reactive electrophile a need for 
an enzyme to prevent accumulation of this potentially toxic species was proposed. The 
version of the lactone formed from G6P is the δ-form.  This form may spontaneously 
hydrolyse, or else form a γ-form by intramolecular rearrangement. This latter form is not 
spontaneously hydrolysed, hence the lactonase appears to be required to convert the δ-
form to 6-PG before the γ-form emerges (Miclet et al., 2001). 
Structural studies on lactonase from T. brucei provided an X-ray crystal structure of the 
enzyme at 2.1 Å resolution, showing that it binds zinc, possibly for a structural rather 
than catalytic role. In silico docking studies were used to show how the lactone orientates 
in the active site (Delarue et al., 2007).  Further studies have investigated dynamics of 
the protein associated with catalysis (Calligari et al., 2012). 
1.4.4.3 6-phosphogluconate dehydrogenase (6PGDH) 
The next enzyme in the pathway, 6-phosphogluconate dehydrogenase, enables 
decarboxylation of 6PG into Ru5P with concomitant reduction of NADP. The 6PGDH 
gene was identified first in T. brucei using a functional complementation approach 
expressing a library of trypanosome DNA fragments in E. coli (Barrett and Le Page, 
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1993). It was a failure to find 6PGDH activity in BSF T. brucei (Ryley, 1962) that led to 
the pathway being largely ignored until Cronín et al. (1989) clearly reported activities of 
each enzyme. The use of 6PGDH as an isoenzyme marker in studies into genetics of T. 
brucei went unnoticed (Tait et al., 1985).  
RNAi indicates no defect associated with 6PGDH loss in PCF, while its absence is lethal 
in BSF T. brucei (Kerkhoven et al., 2013). The gene deletion is lethal in yeast and in 
drosophila, however, since loss of G6PD rescues these cells from loss of the 6PGDH, it 
was proposed that it is accumulation of 6PG per se that is lethal, rather than reduced 
production of NADPH through the oxidative branch (Hughes and Lucchesi, 1976; Lobo 
and Miatra, 1982). Nevertheless, that mechanism was disproven for BSF T. brucei 
(Kerkhoven et al., 2013).  
The structure of the trypanosome enzyme was resolved by X-ray crystallography at 2.8 Å 
resolution (Phillips et al., 1998). The T. brucei crystal structure then allowed modelling 
of the T. cruzi and Leishmania proteins too (Esteve and Cazzulo, 2004; González et al., 
2010). Its high level of sequence divergence from the mammalian enzyme indicated that 
selective inhibitors may be possible. Several screens were made (Dardonville et al., 2003; 
Pasti et al., 2003) and particularly interesting was a reaction-based approach to inhibitor 
design (Dardonville et al., 2004; Ruda et al., 2007, 2010a, 2010b). The reaction 
mechanism involves a high energy 1,2-cis-enediol intermediate (Fig 1.9 A). Gilbert and 
colleagues (Dardonville et al., 2004) reasoned that hydroxamate analogues of the enediol 
might have potent activity. This was proven to be the case. Moreover, the inhibitors 
demonstrated substantially enhanced inhibitory activity of the trypanosome enzyme over 
a mammalian version (Dardonville et al., 2004). The most potent inhibitor discovered 
was 4P-D-erythronohydroxamate with Ki = 10 nM with 250-fold selectivity over the 
sheep enzyme (Fig 1.9 B) (Dardonville et al., 2004). In spite of the potent inhibition of 
the enzyme these molecules had no efficacy against trypanosomes, attributable to the 
failure of phosphorylated compounds to cross the parasite membrane. Gilbert’s team then 
added various groups to mask the charged phosphate moiety and among these series 
arylphosphoramide derivatives (Fig 1.9 C), designed for ester cleavage of the prodrug, 
yielded compounds with pronounced trypanocidal activity (Ruda et al., 2007). 
Unfortunately, the presence of esterases in serum probably de-mask the prodrugs in 
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blood, reducing in vivo activity, hence further developments are required to bring 
compounds derived for this rational approach towards clinical development. 
Figure 1.9. Inhibitor design based on the reaction mechanism of 6-PGDH. A - The 
reaction mechanism that converts 6-PG on the far left to Ru5P on the far right, is 
proposed to involve the production of a high energy enediol intermediate (marked). 
B - Hydroxamate analogues of the enediol intermediate were producted and shown 
to be potent inhibitors of the T. brucei enzyme (Dardonville et al., 2003). C - In order 
to produce cell permeant derivatives of the hydroxamate analogues, ester-based 
masking groups were added to neutralize the charge on the phosphate groups. The 
masking groups are cleaved by esterases post cell entry and this endowed the 
inhibitors with trypanocidal activity (Dardonville et al., 2004). 
Activity in the reverse direction, from Ru5P to 6PG could be measured in the enzyme 
from sheep liver and Candida (Silverberg and Dalziel, 1975; Villet and Dalziel, 1969).  
We have observed in Leishmania parasites that accumulation of pentose phosphates can 
cause the reaction to run in reverse, and in T. brucei too, it was possible to find small 
amounts of 6PG with five labelled carbons in cells grown in glucose containing 6 labelled 
carbons, indicating the reverse reaction can operate with fixation of CO2 and 
consumption of NADPH (Creek et al., 2015). 
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 There is no obvious PTS in the T. cruzi enzyme but L. mexicana contains a non-canonical 
internal PTS1 and in T. brucei a possible PTS1 was suggested to exist on an exposed 
loop (Greenblatt et al., 2002). 6PGDH activity was located almost exclusively in the 
cytosol in PCF T. brucei (Heise and Opperdoes, 1999) as well as in T. cruzi (Esteve and 
Cazzulo, 2004), although digitonin permeabilisation experiments with Western blot 
analysis using an antibody to 6PGDH indicated that small amounts might be found in 
glycosomes in BSF T. brucei (Kerkhoven et al., 2013).  
1.4.4.4 Ribose-5-phosphate isomerase (RPI) 
The trypanosomatid version of RPI clusters phylogenetically with the B isoform of 
prokaryotes, while the mammalian version clusters with the A isoform, hence the 
trypanosomatid and mammalian versions are divergent (Greenblatt et al., 2002; Loureiro 
et al., 2015). RITseq experiment indicated a strong growth defect after depletion of RPI 
mRNA in T. brucei (Alsford et al., 2011), although depletion of RPI by a targeted RNAi 
caused only mild growth phenotype in BSF T. brucei in vitro and lower parasitemia with 
delayed onset and slower progression of the disease in mice (Loureiro et al., 2015), hence 
its utility as a target for drugs remains equivocal. RPI is expressed in all four major stages 
of T. cruzi with higher protein levels in metacyclic trypomastigotes and trypomastigotes 
(Stern et al., 2007). In T. brucei,  localisation was shown to be mostly cytosolic but with 
a small fraction in glycosomes in both stages as determined by immunofluorescence 
microscopy and digitonin permeabilisation (Loureiro et al., 2015). Structure of the T. 
cruzi enzyme has been resolved, including binding with substrates and its low potency 
inhibitor, 4-phospho-D-erythonohydroxamic acid (Stern et al., 2011).  
An alternative route to create R5P is via ribokinase activity using free ribose, that can be 
accumulated from blood or else derived from nucleosides through the action of 
nucleoside hydrolases  (Parkin, 1996). Although gene knockout of the T. brucei 
ribokinase was not possible, RNAi indicated that the RNA could be depleted below 
detection limits without an effect on phenotype (Kerkhoven et al., 2013), which was also 
the conclusion in the genome wide study for BSF, although it appeared essential in PCF 
(Alsford et al., 2011). 
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1.4.4.5 Ribulose-5-phosphate epimerase (RuPE) 
Ribulose-5-phosphate epimerase has not been subject to a targeted study in any 
trypanosomatid so far. The T. brucei RITseq experiment indicated that mRNA depletion 
did not cause any growth defect (rather a gain in fitness phenotype was seen in both BSF 
and PCF) (Alsford et al., 2011). In the absence of TKT in BSF T. brucei, its role is not 
immediately obvious since its product Xu5P is technically a dead end, unless other 
enzymes, for example a Xu5P phosphoketolase, as described in bacteria (Petrareanu et 
al., 2014) were operative. Such an enzyme would create GA3P and acetyl phosphate. 
However, genome searches have not yielded any strong candidates based on homology 
to bacterial variants of the enzyme.  
1.4.4.6 Transketolase (TKT) 
In addition to TKT itself, two additional gene paralogues called transketolase-like 
proteins (TKTL1 and TKTL2), are known in humans and, although TKT activity is 
associated with these  proteins, controversy exists as to their true biochemical function 
(Coy et al., 1996; Meshalkina et al., 2013; Schneider et al., 2012). A number of studies 
clearly link over-expression of TKTL1 with cancer (Langbein et al., 2006; Staiger et al., 
2006a) which is fuelling renewed interest in TKT.  
In yeast, the phenotype of TKT mutants is dependent on the carbon source. Growth is 
reduced on fermentable, but not on gluconeogenic substrates, indicating a role for TKT 
in regulating glycolysis (Sundström et al., 1993). Simultaneous G6PDH and TKT 
depletion is lethal in yeast (Schaaff-Gerstenschläger and Zimmermann, 1993). TKT uses 
thiamine pyrophosphate (TPP) as a cofactor and analogues, including oxythiamine 
(which is phosphorylated inside cells) have been proposed as inhibitors of TKT with 
promising preliminary results as inhibitors of cancer cell growth (Rais et al., 1999). 
However, oxythiamine-PP inhibits other enzymes that use TPP as a cofactor, including 
pyruvate dehydrogenase and oxoglutarate dehydrogenase, hence TKT may not be the 
primary target (Chan et al., 2013). Oxythiamine was active against  P. falciparum but the 
presence of thiamine in the medium diminished the effect and toxicity (weight loss) 
associated with oxythiamine administration to infected mouse models diminishes the 
compound’s attractiveness for further consideration as a therapeutic against malaria 
(Chan et al., 2013). 
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BSF T. brucei lack TKT and knock-out of the gene in PCF T. brucei led to no obvious 
growth defect or morphological change, but metabolomic analysis showed significant 
changes in metabolites of glycolysis and the PPP (Stoffel et al., 2011). The enzyme 
contains a PTS1 sequence and localisation was measured to be 70% cytosolic and 30% 
glycosomal in L. mexicana (Veitch et al., 2004) and 10% glycosomal in PCF T. brucei 
(Stoffel et al., 2011). The crystal structure of the Leishmania enzyme was resolved at 2.2 
Å (Veitch et al., 2004). 
1.4.4.7 Transaldolase (TAL) 
A gene annotated as TAL was cloned from T. brucei and the protein expressed then used 
to determine the ability of the enzyme to create O8P using R5P and F6P as acceptor and 
donor substrates respectively (Creek et al., 2015). This indicates TAL as a likely source 
of the higher carbon content carbohydrates referred to above. It is unclear what the 
function of TAL in BSF T. brucei is, in the absence of TKT and RuPE. RITseq 
experiments indicated the gene to be essential to PCF but not BSF T. brucei (Creek et al., 
2015). Out of three independent proteomics experiments (Colasante et al., 2006; Guther 
et al., 2014; Vertommen et al., 2008), only Vertommen et al., (2008) detected the protein 
within PCF T. brucei glycosomes.  
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1.5 Metabolomics 
Metabolomics refers to high-throughput techniques aiming to dissect the composition of 
metabolites and quantifying them within a single experiment. This is a very challenging 
task compared to other –omics (genomics, transcriptomics, proteomics), because 
metabolites are small molecules of diverse biophysical characteristics, thus they cannot 
all be characterised by a single method. However, current techniques can confidently 
determine hundreds of small molecules and the numbers are still increasing (Bouatra et 
al., 2013). The experimental approach undertaken can be untargeted, represented by 
semi-quantitative analyses of the total cellular metabolome, or targeted, aiming at precise 
quantification of a limited group of compounds of interest. 
The two most widely used platforms are nuclear magnetic resonance (NMR) and mass-
spectrometry (MS). While NMR can provide precise absolute quantification and it is 
usually highly reproducible, the number of metabolites detected is relatively low given 
poor sensitivity, and data analysis becomes difficult in complex samples. Prior to MS 
analysis, the samples are separated by gas or liquid chromatography (GC or LC) or 
capillary electrophoresis with numerous variations, enabling a focus on specific target 
groups of compounds. Usage of GC requires derivatization of the samples accompanied 
with more complicated sample preparation and subsequent data analysis, but it achieves 
high quantitative accuracy and reproducibility. LC can be targeted either at hydrophilic 
or lipophilic compounds, which determines the method of choice. HILIC (hydrophilic 
interaction liquid chromatography) columns are commonly used for metabolomics as 
they are suitable for most cellular metabolites, unless lipidomics analysis is desired 
(reviewed in Creek et al., 2012b; Shulaev, 2006). The approach is semi-quantitative but 
absolute quantification can be obtained if labelled standards are included (Kim et al., 
2015). Despite persisting drawbacks (high costs, data analysis and interpretation, 
uncertainty with compound identification), the positives of metabolomics approaches 
prevail and popularity and usage of metabolomics is growing rapidly. Improvement in 
the technology and decrease in cost coincide with these developments. 
1.5.1 Metabolomics applied to trypanosomatid protozoa 
A range of high-throughput –omics techniques enables to study organisms on different 
levels from the genome towards the final phenotype, and they have been applied to 
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trypanosomatid parasites over the last years. A number of trypanosomatid genomes have 
been sequenced, unravelling a huge number of genes for hypothetical proteins, to which 
is extremely difficult to assign a function (Berriman et al., 2005; Ivens et al., 2005). When 
transcriptomics became available, numerous studies were performed on Leishmania 
comparing promastigote and amastigote life stages, but the extent of differences detected 
was surprisingly small and it was generally concluded that because trypanosomatids do 
not have control on transcriptional level, RNAseq data cannot provide much information 
relevant to the biology (Akopyants et al., 2004; Cohen-Freue et al., 2007). Thus, 
proteomics and especially metabolomics may point to profound differences in parasite 
biology that are not evident through gene expression analysis, because metabolomics is 
closest to the final phenotype of the omics technologies. Metabolomics may, therefore, 
enable us to shed light on persistent questions behind the parasite’s biology and point to 
metabolic weak points offering targets for treatment.  
Numerous metabolomics analyses of trypanosomatids have been performed including a 
comprehensive depiction of central metabolism in T. brucei (Creek et al., 2013, 2015) 
including precise quantification of metabolic end-products by LC-MS (Kim et al., 2015) 
while NMR has been extensively used to dissect pathways of glucose and proline 
metabolism of PCF T. brucei (Mazet et al., 2013; Millerioux et al., 2013). A 
comprehensive overview of L. mexicana metabolism was obtained by GC-MS on 
promastigote (Saunders et al., 2011) and amastigote stages (Saunders et al., 2014). In 
addition, changes in metabolism during development were investigated (Silva et al., 
2011), while study on amino acid metabolism revealed substantial changes between three 
different species (Westrop et al., 2015). Further, metabolomics can answer specific 
questions such as drug target deconvolution (Trochine et al., 2014; Vincent et al., 2010, 
2012), interaction with the host (Caradonna et al., 2013) or specific amino acids 
utilisation (Johnston, 2015). Concerning Leishmania, in addition to the publications 
mentioned above, there is for example an interesting work tracing labelled deuterium, 
which provided information on turnover of DNA, RNA, protein and lipids in parasites 
both from a culture and lesions and showed how much slower the growth is in vivo 
(Kloehn et al., 2015).  
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1.6 Scope of this thesis 
My general aim of this thesis was to use metabolomics approach to study Leishmania 
parasites. I compared promastigote and amastigote cells, assessed utilisation of different 
sugars, and performed analysis of transketolase knock-out cells. Untargeted LC-MS 
approach was used first, and based on the data obtained, further targeted analyses were 
performed focused on specific questions. Additional experiments were performed in 
order to complete the studies and bring as much comprehensive results as possible. 
A comparative metabolomics analysis was performed of L. donovani promastigotes, 
axenic amastigotes and splenic amastigotes. To the best of my knowledge this is the first 
metabolomic analysis of amastigotes obtained directly from an animal tissue. The main 
objective of this study was to evaluate differences between the two types of amastigotes, 
since axenic parasites are cultured in conditions very different form their natural 
environment, especially regarding nutrient availability. Hence, I wanted to compare the 
metabolomes of the cells, which should give us indications if cell metabolism is changed 
in consequence of the specific environment. The data should provide clues useful for 
future studies, i. e. if axenic amastigotes are a good model for studies focused on 
metabolism, or testing potential drugs targeted on metabolism. 
Further, I performed a metabolomics analysis of L. mexicana promastigotes grown in 
media containing different labelled sugars, and afterwards I assessed incorporation of 
carbons from these sugars into metabolism. Maugeri et al. (2003) cultured L. mexicana 
promastigotes in medium containing radiolabelled glucose and calculated the flux in the 
PPP from incorporation of the label into nucleic acids. However, this estimation may be 
inaccurate and highly dependent on glucose and ribose concentrations in the medium. In 
the PPP glucose is turned into R5P which is essential for nucleotide biosynthesis. In 
addition ribose can be taken up from medium and directly phosphorylated into R5P by 
ribokinase, thus we hypothesized that presence of ribose would influence the utilisation 
of glucose for nucleotide biosynthesis. In order to assess that, I cultured cells in medium 
containing labelled glucose, ribose and combinations of the two sugars and analysed 
utilisation of carbons from the sugars into metabolism.  
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Previously L. mexicana transketolase knock-out (Δtkt) cell line was obtained in the 
promastigote stage and I performed phenotypic characterisation of the parasites. The aim 
was to assess its sensitivity to various drugs, infectivity and potential utilisation as a drug 
target. I performed an untargeted LC-MS metabolomics analysis of the cell line and since 
the results indicated major changes in the metabolism beyond the PPP, I performed 
further studies to validate these observations. Additional analyses followed with an aim 
to elucidate the mechanism driving these changes and potential regulatory mechanisms 
of metabolism. 
Preliminary studies on TKT sparked a hypothesis that binding of various sugar substrates 
has an influence on conformation of the protein, especially the C-terminus (Wildridge, 
2012). The C-terminus is flexible and bears a PTS1, hence a change in its conformation 
could have an impact on the subcellular localisation. I prepared a series of constructs of 
TKT with alternations to the C-terminus and examined their localisation by 
immunofluorescence microscopy. One of these constructs appeared to be present solely 
in glycosomes, so subsequently I made an additional construct with purely cytosolic TKT 
and compared phenotypes and metabolomes of cells expressing TKT in a single 
compartment.
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2 Materials and Methods 
2.1 Ethics statement 
All animal experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 and the University of Glasgow care and maintenance quidelines. 
All animal protocols and procedures were approved by The Home Office of the UK 
government and the University of Glasgow Ethics Committee (or Institut Pasteur, Paris, 
France). 
2.2 Cell culture and cell growth 
2.2.1 Cell culture 
Leishmania mexicana M379 promastigote cells were cultured in Homem medium 
(Berens et al., 1976; GE Healtcare) at 25°C supplemented with 10% heat–inactivated 
foetal calf serum (FCS; Thermo Fisher Scientific) at density 105 – 2 x 107 cells/ml. For 
transgenic cell lines antibiotics were added as required, for Δtkt cells 25 µg/ml 
nourseothricin (Sigma-Aldrich) and 25 µg/ml hygromycin (Roche), for Δtkt + TKT re-
expressor 25 µg/ml puromycin (Sigma-Aldrich) in addition. For cells expressing GFP-
TKT episomal constructs 25 µg/ml G418 (Sigma-Aldrich) was added. 
L. mexicana amastigote cells were cultured in Schneider’s Drosophila Medium (Sigma-
Aldrich) supplemented with 20% FCS (Thermo Fisher Scientific) and 15 mg/l hemin 
(Sigma-Aldrich), at 32°C, 5% CO2, pH 5.5 (Bates et al., 1992). Cells were maintained at 
density 106 – 3 x 107 cells/ml. 
L. donovani 1S2D promastigotes were cultured in M199 medium supplemented with 
10% FCS, 25 mM Hepes pH 6.9, 4mM NaHCO3, 1 mM glutamine, 1x RPMI-1640 
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vitamin mix, 0.2 µM folic acid, 100 µM adenine, 7.6 mM hemin, 8 µM biopterin, 50 
U/ml penicillin and 50 µg/ml streptomycin. 
L. donovani amastigotes were cultured at 37°C and 5% CO2 in RPMI-1640 supplemented 
with 1 mM glutamine, 1x RPMI-1640 vitamin mix, 0.2 µM folic acid, 100 µM adenine, 
20% FCS, 1x RPMI-1640 amino acid mix, 28 mM MES, 50 U/ml penicillin and 50 µg/ml 
streptomycin. 
Macrophage THP-1 cell line was cultured in RPMI-1640 medium (Sigma-Aldrich) 
supplemented with 10% FCS (Thermo Fisher Scientific) and 2 mM glutamine. Cells were 
maintained at density 105 – 106 cells/ml. 
Cell density was estimated using Neubauer haemocytometer under a light microscope. 
2.2.2 Alamar Blue Assays 
Toxic effects of various compounds were tested using Alamar Blue Assays in various 
alternations (Allmann et al., 2013; Räz et al., 1997). Compounds were diluted serially 
across 96-well culture plates in appropriate medium, alternatively glucose oxidase 
(Sigma-Aldrich) was added in required dilutions to the medium. Cells were added to the 
plates at the final density 5 x 105 cells/ml for promastigotes and 106 cells/ml for 
amastigotes. Cells were cultured in the plates for 72 hours and subsequently 0.48 mM 
resazurin was added to all wells. After additional 48 hours of incubation, absorbance in 
plates was measured with fluorescence spectrometer FLUOstar OPTIMA (BMG 
Labtech) at excitation wavelength 544 nm and emission wavelength 590 nm. Data were 
analysed with GraphPad Prism software to obtain EC50 values. Technical duplicates were 
collected for each reading and biological triplicates for most experiments, if not stated 
otherwise. 
2.2.3 Macrophage infections 
THP-1 macrophages were activated with 20 ng/ml phorbol 12-myristate 13-acetate 
(Sigma-Aldrich) for 3 days, afterwards the cells were washed with RPMI-1640 medium 
twice, transferred into 16-well tissue culture slides (Lab-tek), 100 µl/well at density 2 x 
105 cells/ml and incubated at 37°C, 5% CO2 overnight. L. mexicana promastigotes in the 
stationary phase were used for infections, at a ratio of 5 or 10 parasites per macrophage. 
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Leishmania cells were washed with PBS and resuspended in RPMI-1640 medium to the 
appropriate density, finally adding 100 µl of parasites per well. Slides were incubated at 
32°C, 5% for 6 hours and subsequently extracellular parasites were washed by slowly 
adding 200 µl PBS to each well and decanting, repeating this step three times. Cells were 
incubated at 32°C, 5% for 24 hours or as required. Finally, cells were fixed by adding 
70% methanol for 1 min and subsequently washed with water. 2.5 µM DAPI (4’,6-
diamino-2-phenylindole) was used for staining of nuclei, visualised with fluorescent 
microscope Axioplan2 (Zeiss) and Volocity software, and the macrophage infection was 
counted. 
2.2.4 Animal infections 
For mouse infection assessment, BALB/c mice and L. mexicana promastigotes in 
stationary phase were used. 2 x 106 cells in total volume of 40 µl PBS were inoculated 
into the right food pad, and the size of ensuing lesions were measured at least once a 
week. When the food pad lesions reached above 4 mm in size, the animals were culled. 
2.3 Molecular biology 
2.3.1 DNA isolation 
For genomic DNA isolation 10 ml of Leishmania culture in logarithmic growth phase 
was used, equivalent to approximately 108 cells in total. A NucleoSpin Tissue kit 
(Macherey-Nagel) was used following the manufacturer’s standard protocol. Final DNA 
concentration was measured using Nanodrop1000 Spectrophotometer (Thermo Fisher 
Scientific). 
2.3.2 GFP-TKT constructs 
In order to express TKT with an N-terminal GFP tag, the pNUS-GFPnH plasmid was 
used (http://www.ibgc.u-bordeaux2.fr/pNUS/greenvectors.html ; based on Tetaud et al., 
2002). Primers used for the amplification are listed in Tab 2.1. 
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gene label sequence 
restriction 
site 
WT TKT MB0766 TAAGATCTATGGCCTCCATTGAGAAGGTGG BglII 
WT TKT MB0767 TACTCGAGTTACATCTTGCTGAATGAAGA XhoI 
cyto TKT MB0812 
TACTCGAGGAATGAAGAGTTCTTGAGCGGCG
CC 
XhoI 
Table 2.1. List of primers used for PCR. All primers were purchased from Sigma-
Aldrich. 
2.3.3 High-fidelity PCR  
For error-prone PCR, 50 µl of PCR reaction mixture contained 0.4 mM dNTPs, 1 µl of 
each primer, 2 µl of genomic DNA, 0.5 µl of Phusion HF DNA Polymerase (Biolabs), 
1x Phusion DNA Polymerase buffer (Biolabs). The cycling program used consisted of 
the following: heated lid at 112°C, denaturation at 98°C for 1 min, then 35 cycles of 
denaturation at 98°C for 15 sec, annealing at 59°C for 30 sec, elongation at 72°C for 2 
min, and final elongation at 72°C for 10 min, using a Thermal Cycler (G-Storm). The 
PCR products were purified using Nucleospin Gel and PCR Clean-up kit (Macherey-
Nagel), following the manufacturer’s protocol. In order to amplify TKT without the 
PTS1, a combination of primers MB0766 and MB0812 was used. 
2.3.4 Ligation and restriction digest 
Prior to ligation into the pGEM-T Easy vector, single adenosine overhangs were added 
to the PCR products by incubating a mixture of 20 µl PCR product, 0.5 µl GO Taq DNA 
Polymerase (Promega), 0.1 mM dATPs and 1x GO Taq Buffer, at 72°C for 30 min.  
For ligation into pGEM-T Easy vector (Promega), 100 ng of vector and 200 ng of insert 
was incubated with 1 µl of T4 DNA Ligase (Promega) in 1x ligase buffer (Promega) for 
1 hour at room temperature (RT). 
For a typical restriction digest reaction, 1 µl of each enzyme, appropriate buffer and 50 
µl of plasmid DNA was used in total volume of 60 µl. Ligation reactions contained the 
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following: 1 µl of T4 DNA ligase (Promega), 1x ligase buffer (Promega), DNA in a ratio 
2:1 of the insert and plasmid, in total volume of 10 µl. 
2.3.5 Transfection into Escherichia coli 
In order to transfect a construct into E.coli cells, 50 µl of competent cells were used, 
mixed with 2 µl of ligation reaction, incubated at 42°C for 45 sec, subsequently on ice 
for 2 min, and supplemented with 600 µl of SOC medium. After 1 h incubation at 37°C 
shaking, bacteria were spread on agar plates with appropriate antibiotics and incubated 
overnight at 37°C. Subsequently, the obtained colonies were screened by PCR. Bacteria 
containing positive plasmids were cultured in 5 ml of LB medium at 37°C shaking 
overnight and the plasmids were isolated using NucleoSpin Plasmid kit (Macherey-
Nagel) following the manufacturer’s protocol, and the integrated genes verified by 
sequencing at MWG, UK. 
2.3.6 Screen PCR 
In order to screen bacteria for insert integration, 25 µl of PCR reaction mixture contained 
GoTaq DNA Polymerase (Promega), 0.4 mM of dNTPs, 1 µl of each primer, template 
DNA, and 1x GoTaq DNA polymerase buffer (Promega). The following cycling program 
was used: heated lid at 112°C, denaturation at 98°C for 2 min; 25 cycles of denaturation 
at 95°C for 30 sec, annealing at 59°C for 45 sec, elongation at 72°C for 2 min, and final 
elongation at 72°C for 5 min, using Thermal Cycler (G-Storm).  
2.3.7 GFP-TKT with mutated C-termini 
In order to prepare mutated constructs of TKT with altered C-termini, dsDNA constructs 
containing the respective sequences were purchased from GenScript, USA. These DNA 
fragments were cloned into pNUS-GFPnH vector containing WT TKT gene using TKT 
internal restriction site for FspAI (Biolabs) and XhoI (Biolabs) restriction site of the 
vector. 
2.3.8 Transfection of Leishmania with episomal constructs 
In order to transfect Leishmania with an episomal vector, about 10 µg of DNA is 
required. Constructs verified by sequencing were grown as mini-preps, plasmid DNA 
purified with NucleoSpin Plasmid kit (Macherey-Nagel) and precipitated with ethanol in 
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a volume ratio 10:1:3 containing DNA, 3 M sodium acetate and 100% ethanol. The 
mixture was incubated at -20°C for 15 min, centrifuged at 14,000 g, 4°C for 30 min, the 
obtained pellet rinsed with 70% ethanol, and following centrifugation at 14,000 g, 4°C 
for 15 min, the pellet was dried and resuspended in sterile water. 5 x 107 Leishmania cells 
were centrifuged at 1,300 g for 10 min, resuspended in 100 µl of Human T Cell 
Nucleofector Solution (Lonza) in transfection cuvettes. The plasmid DNA was added, 
and cuvette placed into Nucleofector Amaxa (Lonza) using program U-033. The cuvette 
was immediately placed on ice and cells subsequently transferred into 10 ml of fresh 
Homem medium. Following overnight incubation at 25°C, the required antibiotic was 
supplemented at 50 µg/ml and cells cultured at 25°C until selected cells emerged.   
2.4 Metabolomics 
2.4.1 Sample preparation 
Preparation of metabolomic samples was adapted from method described by Creek et al. 
(2011). For all metabolomic experiments 4 biological replicates were prepared for each 
condition. Cell cultures were started 2 – 3 days prior to sample preparation at cell density 
5 x 105 cells/ml, subsequently cells in logarithmic growth phase were harvested. 108 cells 
were collected for each final 200 µl sample. Cells were rapidly cooled in a dry ice/ethanol 
bath to 4°C and kept at 4°C for the rest of the preparation. Cells were centrifuged at 1,250 
g, 4°C for 10 min (spent medium was kept for analysis when required) and washed with 
PBS. The cell pellet was resuspended in extraction solvent (chloroform:methanol:water, 
1:3:1 volume ratio) and extracted by shaking vigorously for 1 h at 4°C. Subsequently, 
samples were centrifuged at 16,000 g, 4°C for 10 min and obtained supernatant collected 
and stored at -80°C under argon atmosphere until the LC-MS analysis. For medium 
analysis 10 µl of medium was mixed with 190 µl of extraction solvent. 
For experiments with labelling, the respective labelled sugars were added to the medium 
from the beginning of cell cultivation. U-13C-glucose, U-13C-ribose, or 1,2-13C-glucose 
(all Cambridge Isotope Laboratories, Inc.) were used and mixed in the media as 
appropriate for each experiment. 
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2.4.2 LC-MS 
The analyses were performed using liquid chromatography coupled to mass spectrometry 
on the platform at Glasgow Polyomics. All samples were separated with high 
performance liquid chromatography (HPLC) on ZIC-pHILIC (polymer based – 
Hydrophilic Interaction Liquid Chromatography Column, Merck) using an ICS-5000 
system (Dionex Corporation) prior to mass detection on an Orbitrap Exactive mass 
spectrometer (Thermo Fisher). The samples were run alongside 248 authentic standards 
at 10 µM each for further data analysis. Analysis was performed in positive and negative 
modes, using 10 µl injection volume and a flow rate of 100 µl/min. For HPLC gradient 
solvent A was 20 mM ammonium carbonate in H2O and solvent B was 100% acetonitrile. 
2.4.3 Data analysis for LC-MS 
The raw data were processed and analyzed using Identification and evaluation of 
metabolomics data from LC-MS (IDEOM, Creek et al., 2012). IDEOM uses MZmatch 
software (Scheltema et al., 2011) in the R environment. For analysis of experiments with 
labelling, mzMatchISO software (Chokkathukalam et al., 2013) was used. Standards 
were processed with ToxID software (Thermo Scientific). For further analyses and data 
visualisation MetaboAnalyst interface was used (Xia et al., 2015). 
2.4.4 Derivatisation of samples for GC-MS 
For GC-MS analysis, the samples were prepared following the same protocol as for LC-
MS, the further derivatisation, analysis and data processing was performed by Dr. Stefan 
Weidt at Glasgow Polyomics.  
A retention index mix was prepared from pure alkanes dissolved in hexane to a final 
concentration of 6 mg/ml. Stock solutions were prepared for each from neat reference 
standards in water. A custom standard mixture of sugars, sugar phosphates, and pentose 
phosphate pathway intermediates was then prepared by mixing the stock solutions 
together and diluting with water. 
30 µl of extracted sample, as well as each of the custom standard mix of sugars, sugar 
phosphates, and pentose phosphate pathway intermediates, were transferred to a 300 µl 
KIMSHIELD™ deactivated glass polyspring insert (National Scientific). Internal 
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standards 13C6-Glucose (2 nmol), D27-Myristic acid (2 nmol) and Scyllo-Inositol (1 nmol) 
were added to each sample. Samples were then dried in a Savant SPD1010 SpeedVac 
concentrator (Thermo Scientific) for 90 min. Inserts were then placed into a 9 mm screw 
cap amber borosilicate glass 1.5 ml vial (Thermo Scientific). 50 µl of 20 mg/ml (w/v) 
methoxyamine HCl in pyridine was added to each dried sample and sealed. The vial and 
insert were vortexed for 10 seconds and incubated at 60°C for 120 min. Following the 
methoximation step, 90 µl of MSTFA + 1% TMCS ( N-Methyl-N-(trimethylsilyl) 
trifluoroacetamide + 1% trimethylchlorosilane) was added, followed by a further 10 
second of vortexing. Silylation was performed by incubation at 80°C for further 120 min. 
Samples were cooled to room temperature. 10 µl of retention index alkane mixture was 
added to each sample. Samples were then ready for injection. 
2.4.5 GC-MS analysis 
1µl of derivatized sample was injected into a Split/Splitless (SSL) injector at 280°C using 
a 1 in 50 split flow using a Trace 1310 gas chromatograph (Thermo Scientific). Helium 
carrier gas at a flow rate of 1.2 ml/min was used for separation on a TraceGOLD TG-
5SILMS 30 m length × 0.25 mm inner diameter × 0.25 µm film thickness column 
(Thermo Scientific). The initial oven temperature was held at 70°C for 4 min, followed 
by an initial gradient of 20°C/min ramp rate. The final temperature was 320°C and held 
for 5 min. Eluting peaks were transferred through an auxiliary transfer temperature of 
250°C into a GC-QExactive mass spectrometer (Thermo Scientific). Electron impact (EI) 
ionisation at 70 eV energy, emission current of 50 µA with an ion source of 230°C. A 
filament delay of 5.3 min is used to prevent excess reagents from being ionised. High 
resolution EI fragment spectra were acquired using 60,000 resolution with a mass range 
of 50-650 m/z. The best internal lock mass from 207.0324, 281.0511 or 355.0699 m/z 
was used to maintain mass accuracy throughout the chromatogram. 
2.5 RNA sequencing 
For the RNAseq experiment 5 x 107 cells were used for each sample in biological 
triplicates. RNA was isolated using RNeasy Mini Kit (Qiagen) following the 
manufacturer’s protocol. The concentration of the obtained RNA was determined using 
a Nanodrop1000 Spectrophotometer (Thermo Fisher Scientific). 
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The sequencing was performed at Glasgow Polyomics on the NextSeq500 platform, 
using library preparation by polyA selection, paired-end samples with 13 million reads 
per sample. 
The analysis was performed using the Galaxy interface (Afgan et al., 2012; Giardine et 
al., 2005), using Bowtie2 software (Langmead and Salzberg, 2012) and Cufflinks 
package (Trapnell et al., 2010). 
2.6 Biochemistry 
2.6.1 Glucose consumption assay 
In order to quantify the consumption of glucose by promastigotes, Homem medium was 
prepared containing just 1mM glucose and supplemented with 10% FCS as usual. L. 
mexicana cells were grown up to logarithmic phase, centrifuged at 1,300 g for 10 min, 
washed with PBS, and resuspended in fresh Homem with 1mM glucose. Subsequently, 
at selected time points (12, 15, 18, 21, and 24 hours), cell density was established and a 
sample of medium collected and stored at -20°C. Subsequently, the concentration of 
glucose in the samples was measured using a Glucose oxidase kit (Sigma-Aldrich). Four 
biological replicates were prepared for each group.  
2.6.2 Enzyme activity assays 
For all enzyme activity assays, cells at logarithmic growth were collected, 2 x 107 cells 
were used to create a final 100 µl of cell extract. Cells were centrifuged at 1,300 g, 16°C 
for 10 min and washed with PBS, and resuspended in 100 µl TE lysis buffer (10 mM 
Tris-HCl pH 8, 1 mM EDTA) with 0.15% Triton and Complete protease inhibitor 
cocktail (Roche). Samples were incubated at room temperature (RT) for 20 min, 
centrifuged at 16,000 g, 16°C for 5 min and supernatant collected. Subsequently, the 
protein concentration was established by Bradford Assay using a Bio-Rad Protein Assay 
reagent (Bio-Rad).  
All the reactions described here are coupled to another enzyme in a way to produce or 
consume NAD(P)H which can be easily detected as change in absorbance at λ = 340 nm 
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by UV-VIS Spectrophotometer (Shimadzu). All the chemicals and enzymes were 
purchased from Sigma-Aldrich, if not stated otherwise. 
2.6.2.1 Transketolase 
In order to measure TKT activity, its reaction is coupled in a way allowing its substrate 
GA3P, to be used by triose phosphate isomerase in order to make DHAP, which is then 
used by glycerol-3-phosphate dehydrogenase in a reaction producing NADH (Brin, 
1974). The reaction mixture was prepared containing 100 mM Tris.HCl pH 8.0, 1.2 mM 
MgCl2, 10 µM TPP, 100 µM NADH, 10 mM R5P, 1 mM Xu5P, 1 U triose phosphate 
isomerase (Sigma-Aldrich) and 1 U glycerol-3-phosphate dehydrogenase (Sigma-
Aldrich) and 100 µl of cell extract in 1 ml of total volume. Consumption of NADH was 
measured by UV-VIS Spectrophotometer (Shimadzu) at λ = 340 nm.  
2.6.2.2 Hexokinase 
Hexokinase produces G6P, thus its activity measurement is coupled with the G6PDH 
reaction producing NADPH. The reaction mixture was prepared containing 300 mM 
Tris-HCl pH 7.5, 25 mM NaCl, 3 mM glucose, 2 mM ATP, 2 mM MgCl2, 1 mM NADP 
and 1U G6PDH in 1 ml total volume. 
2.6.2.3 Glucose-6-phosphate isomerase 
The assay for PGI uses F6P as a substrate which leads to production of G6P, and thus 
can be coupled with G6PDH producing NADPH, which is detected. The reaction mixture 
contained 100 mM triethanolamine (TEA) pH 7.5, 7 mM MgCl2, 1.3 mM F6P, 0.4 mM 
NADP, and 1 U of G6PDH in 1 ml total volume. 
2.6.2.4 Glucose-6-phosphate dehydrogenase and 6-phosphogluconate 
dehydrogenase 
Both G6PDH and 6PGDH reactions produce NADPH which can be easily measured, 
however, since the product of the first reaction is spontaneously converted into the 
substrate of the latter, sum activity of the two enzymes has to be measured, and separately 
activity of 6PGDH, and G6PDH is calculated from the difference. For 6PGDH activity 
measurement, the reaction mixture contained 50 mM TEA pH7.5, 5 mM MgCl2, 2mM 
6PG and 1 mM NADP. For measurement of both enzymes, 1mM G6P was also supplied. 
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In order to measure the 6PGDH reaction in the reverse direction, an assay was used as 
described (Villet and Dalziel, 1969). The mixture contained 130 mM triethanolamine, 2 
mM Ru5P, 68 mM NaHCO3, and 50 µM NADPH. 
2.6.2.5 Fructose-1,6-bisphosphate aldolase 
The assay for FbPase activity determination is coupled with TPI and G3PDH consuming 
NADH. The reaction mixture contained 10 mM TEA pH 7.6, 2 µM EDTA, 10 µM 
F1,6bP, 1 U TPI, 1 U G3PDH and 100 µM NADH in 1 ml total volume. 
2.7 Techniques for determination of subcellular localisation  
2.7.1 Immunofluorescence microscopy 
For preparation of samples for immunofluorescent microscopy, 200 µl of cell culture was 
used for each sample. Cells were centrifuged at 1,300g, 10 min, washed in PBS twice 
and resuspended in 100 µl of PBS. 100 µl of 2% formaldehyde was added (methanol 
free, Thermo Fisher) and samples were incubated for 30 min. Triton X-100 was added to 
0.1% final concentration, incubated for 10 min, and glycine was added to 0.1 M final 
concentration. Following 10 min incubation, samples were centrifuged at 1,300 g, for 10 
min, resuspended in 200 µl of PBS, spread on a microscope slide and left to dry at RT. 
Subsequently, slides were washed in PBS and blocked in TB solution (1x PBS with 0.1% 
Triton X-100, 0.1% BSA) for 1h at RT. The primary antibody was added to the desired 
concentration (1:100 dilution for α-TbTIM polyclonal, kindly provided by Prof. Paul 
Michels, University of Edinburgh (Helfert et al., 2001)) in TB solution and incubated at 
4°C overnight. Cells were washed three times in PBS, and incubated with secondary 
antibody (1:1000, AlexaFluor 594 anti-rabbit, Molecular Probes) for 1 h at RT. Slides 
were washed three times in PBS and let to dry at RT, subsequently mounted with 2.5 µM 
DAPI, and covered with cover slides. Cells were visualised using Axioplan2 (Zeiss) and 
Volocity software. 
2.7.2 Digitonin fractionation 
For digitonin fractionation, cells were collected, washed with PBS and 109 cells 
resuspended per 1 ml of STE buffer. Subsequently, a series of samples was prepared 
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containing 100 µl of cell suspension each and increasing concentrations of digitonin from 
0.04 to 1.6 mg/ml. Samples were incubated at RT for 4 min, centrifuged at 14,000g for 
2 min, and the obtained supernatant collected and used for Western blot analysis.  
2.7.3 Western blot analysis 
For Western blot (WB) analysis, cells were harvested, washed in PBS and samples were 
prepared with SDS loading buffer, using 10 µl per 5 x 106 cells and incubation at 95°C 
for 10 min. Samples were loaded on a NuPage Protein gel (Thermo Fisher) and separated 
at 100 mA, using manufacturer’s 1x NuPage running buffer. Subsequently, proteins were 
transferred onto a nitrocellulose membrane (Hybond ECL, GE Healthcare Life Sciences) 
at 40 V for 2 h in 1x transfer buffer. Membranes were blocked in 5% milk solution in 
PBS-T (1x PBS, 0.05% Tween X-100) for 30 min at RT, and subsequently incubated 
with the required primary antibody at 4°C overnight. α-GFP (Sigma-Aldrich) was used 
in 1:5,000, α-TKT (Veitch et al., 2004) in 1:2,000,and α-GDH (kindly provided by Prof. 
Paul Michels, University of Edinburgh (Kohl et al., 1996)) in 1:1000 dilution, 
respectively. Following three washes in PBS-T for 10 min each, the membrane was 
incubated with the secondary antibody (goat α-rabbit, 1:20,000, Invitrogen) for 1h at RT. 
Following additional three washes in PBS-T, the membrane was mounted with 1 ml of 
ECL Western Blotting Substrate (Thermo Fisher), incubated for 1 min and visualised 
using gel doc. 
2.8 Separation of amastigotes from hamster liver 
Isolation of amastigotes from hamster spleen was performed as described previously by 
Pescher et al. (2011). Isolated spleen was added to a tube with 4.5 ml PBS and 0.5 ml of 
25mg/ml saponin then homogenised using a gentleMACS Dissociator (MACS Miltenyi 
Biotec). After adding 20 ml of PBS, samples were centrifuged at 2,000g, 4°C for 10 min. 
Supernatant was collected and cooled in a dry ice/ethanol bath to 4°C. The samples were 
again centrifuged at 2,000g, 4°C for 10 min and the pellet resuspended in 2 ml of PBS 
and 25 ml of PBS with saponin (1mg/ml) then added. Following 5 min incubation on ice, 
samples were centrifuged at 2,000 g, 4°C for 10 min, the pellet resuspended in 50 ml 
PBS and this step repeated twice. Finally, the pellet was separated on 45-90% Percoll 
gradient by centrifugation at 2,500 g, 15°C for 35 min. The layer containing amastigotes 
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was collected, resuspended in 50 ml of PBS and centrifuged at 2,000 g, 4°C for 10 min, 
and this step then repeated. The cells were counted and used for metabolite extraction as 
described in part 2.3.1.  
2.9 Buffers and solutions 
Homem medium, 1l 
0.2 g MgSO4 . 7 H2O 
0.4 g KCl 
6.8 g NaCl 
0.3 g NaHCO3 
1.58 g Na2HPO4 . 2 H2O 
0.292 g glutamine 
1 mg p-aminobenzoic acid 
0.1 mg D-biotin 
3 g glucose 
5.9575 g HEPES 
0.11 g sodium pyruvate 
0.01 g phenol red Na+ salt 
2 mg inositol 
0.1 mg riboflavin 
1 mg thiamine HCl 
1 mg nicotinamide 
1 mg D-calcium pantothenate 
1 mg folic acid 
1 mg choline chloride 
1 mg pyridoxal HCl 
0.0224 g methionine 
0.0706 g valine 
0.0153 g tryptophan 
0.0797 g leucine 
0.0543 g tyrosine 
0.0787 g isoleucine 
0.0495 g phenylalanine 
0.0629 g histidine HCl 
0.1096 g lysine 
0.0715 g threonine 
0.036 g cystine 
0.1896 g arginine HCl  
0.0089 g alanine 
0.0132 g asparagine 
0.0075 g glycine 
0.0105 g serine 
0.0133 g aspartic acid 
0.0147 g glutamic acid 
0.0115 g proline 
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Schneider’s Drosophila Medium, 1l 
0.25 g glycine 
0.4 g arginine 
0.4 g apspartic acid 
0.06 g cysteine 
0.1 g cystine 
0.8 g glutamic acid  
1.8 g glutamine 
0.4 g histidine 
0.15 g isoleucine 
0.15 g leucine 
1.65 g lysine HCl 
0.8 g methionine 
0.15 g phenylalanine 
1.7 g proline 
0.25 g serine 
0.35 g threonine 
0.1 g tryptophan 
0.5 g tyrosine 
0.3 g valine 
0.5 g β-alanine 
0.6 g CaCl2 
1.807 g MgSO4 
1.6 g KCl 
0.45 g KH2PO4  
0.4 g NaHCO3 
2.1 g NaCl 
0.7 g Na2HPO4 
0.2 g α-ketoglutaric acid 
2 g D-glucose 
0.1 g fumaric acid 
0.1 g malic acid 
0.1 g succinic acid 
2 g trehalose 
2 g yeastolate 
 
 
PBS, 1l 
8.0 g NaCl 
0.2 g KCl 
1.42 g Na2HPO4 
0.24 g KH2HPO4 
 
STE buffer for digitonin fractionation 
250 mM sucrose 
25 mM Tris-HCl pH7.4 
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1mM EDTA 
150 mM NaCl 
1mM DTT 
 
4x SDS Loading Buffer for Western Blot 
4ml 100% glycerol 
2.4 ml 1M Tris pH 6.8 
0.8 g sodium dodecyl sulfate 
3.1 ml H2O 
0.5 ml β-mercaptoethanol 
bromphenol blue 
 
Transfer buffer for WB 
3.03 g Tris 
14.4 g glycine 
200 ml methanol 
800 ml H2O 
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3 Metabolomic comparison of 
promastigote and amastigote 
Leishmania donovani 
3.1 Introduction 
One of the persisting questions in Leishmania biology is that of how transformation of 
promastigotes into amastigotes occurs. It is well established that increased temperature 
and decreased pH trigger the transformation, but the underlying molecular mechanisms 
are unknown (Alcolea et al., 2010a; Debrabant et al., 2004; Pan et al., 1993; Saar et al., 
1998). In addition, the extent to which the two life stages are physiologically distinct 
remains unclear. Numerous investigators have performed various high-throughput 
studies, which collectively are contributing to create a comprehensive explanation. 
Transcriptome analysis by Akopyants and colleagues (2004), detected only about 1% of 
nuclear DNA as being expressed differentially between L. major promastigotes, 
metacyclics, and amastigotes isolated from macrophages. The authors also analysed 
transcription of kinetoplast maxicircles, which encode genes for several subunits of 
complexes of the respiratory chain, and this was found to be increased in amastigote and 
metacyclic stages (Akopyants et al., 2004). Another study found that changes in 
expression of particular respiratory chain subunits (including those encoded in the 
nucleus) were not consistent between separate complexes and stages (Alcolea et al., 
2010b). Microarray analysis of L. mexicana showed only 17 genes to be expressed 
differentially between promastigotes and axenic amastigotes, but 288 (3.5% of all genes 
analysed) when comparing promastigotes with lesion derived amastigotes (Holzer et al., 
2006). Another study compared L. major stages by a cDNA microarray approach and 
identified 430 stage-specific genes, 35% of which were increased in amastigotes, 
includng ribosomal proteins, heat shock proteins and surface antigens (Almeida et al., 
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2004). Thus, the authors concluded that there was high degree of gene expression 
regulation in that stage. DNA microarray assays focused on L. major differentiation from 
promastigotes to metacyclics detected 15% of DNA to change significantly, but the 
magnitude of the changes was low, since only 1% (corresponding to 108 genes) were 
upregulated two times or more, and 0.14% (13 genes) were downregulated (Saxena et 
al., 2003). DNA oligonucleotide genome microarrays representing 8,160 genes were 
used to analyse mRNA expression profiles of L. major promastigotes and lesion derived 
amastigotes. In general, a low degree of differential mRNA expression was detected, 
1.5% in each stage corresponding to approximately 120 genes (Leifso et al., 2007). Genes 
upregulated in amastigotes were associated with metabolism, translation, and a 
substantial number encoded hypothetical proteins. Promastigotes harboured higher levels 
of tubulins, leishmaniolysin, glucose transporters, heat shock proteins, or SHERP (Leifso 
et al., 2007). Microarrays were used to investigate a diverse range of sample types: 
amastigote L. major from mice footpads, L. infantum from spleen and L. braziliensis 
from RAW 246.7 macrophages, but only a small number of the target genes were 
transcribed differentially (Depledge et al., 2009). Very few differences were detected 
when L. major amastigotes grown in two different mice strains were analysed, suggesting 
that transcription does not change in response to the host’s immune system (Depledge et 
al., 2009). Global RNA expression profiling was performed to compare L. infantum 
amastigotes cultivated axenically or inside macrophages, and major differences were 
detected in fatty acid metabolism, intracellular transport, membrane vesicular fusion, and 
proteolysis (Rochette et al., 2009). 12.5% of genes were differentially expressed between 
promastigotes and amastigotes, when fold changes higher than 1.7 were considered, 
whilst the proportions of up- and down-regulated genes were the same (Rochette et al., 
2009). The genes increased in promastigotes were, for example, associated with 
translation, whereas in amastigotes it was amastins, A2 protein, SHERP, fatty acid and 
trypanothione metabolism that increased (Rochette et al., 2009), which corresponds with 
other studies and later metabolomic work on amastigotes by Saunders (2014). Similar 
results were obtained in a study focused on differentiation of promastigotes into 
amastigotes under different conditions, where amastigotes upregulated expression of 
amastin-like and hypothetical proteins or trypanothione reductase and downregulated 
numerous nucleotidases, glucose transporters, two glycolytic enzymes and the heme 
biosynthetic pathway (Alcolea et al., 2010a). 
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A proteomic analysis of L. infantum detected about 6% of proteins to be upregulated in 
promastigotes, whereas 12% were up in amastigotes, but only 220 proteins were detected 
in total (McNicoll et al., 2006). The proteins increased in the amastigote stage were 
classified mostly as heat shock proteins, involved in stress response and protein folding. 
The correlation between mRNA and protein levels was poor, and the fold changes were 
higher at the protein than mRNA levels (McNicoll et al., 2006). Another proteomic 
analysis of L. infantum promastigotes and amastigotes detected 91 proteins in total, 72% 
of which were constitutively expressed, 8% (7 proteins) elevated in amastigotes, and 20% 
(18 proteins) increased in promastigotes, including paraflagellar rod components, 
leishmaniolysin and enolase (Leifso et al., 2007). A 2D gel proteomic study comparing 
promastigote and amastigote L. donovani detected about 2,000 protein spots in total, 31 
of which were specific for promastigotes, 65 increased during differentiation into 
amastigotes and 4 decreased (Bente et al., 2003). The stage specific proteins were 
classified mostly into groups related to stress response, cytoskeleton and cell membrane, 
energy metabolism, cell cycle and proliferation, and amino acid metabolism (Bente et al., 
2003). Another study using the same technique on axenically differentiated L. mexicana 
visualised twice as many protein species in total, 47 of which were stage-specific and an 
additional 100 spots changed in intensity during differentiation (Nugent et al., 2004) . 
Collectively, these studies consistently show a rather low degree of differentially 
expressed genes, approximately only 0.2 – 5% at the mRNA level (reviewed in Cohen-
Freue et al., 2007). In addition, the stage specific genes are unique for each species, for 
example only a few common genes are differentially expressed when comparing L. major 
and L. mexicana (Cohen-Freue et al., 2007). Not a single gene was found to be 
upregulated in common between L. major and L. mexicana amastigotes, whereas 51 
genes were common for promastigotes, including tubulins, calmodulins, and the 
paraflagellar rod proteins (Cohen-Freue et al., 2007). Alcolea and colleagues (2014) 
compared results of their differential expression study with previous data and concluded 
that 95% of upregulated genes were different, but they observed lower upregulation in 
amastigotes, consistent with other studies. The correlation between RNA and protein 
expression is low, the proteomic studies detected around 5 – 12% proteins showing 
differential expression between stages (Cohen-Freue et al., 2007). Most of the genes 
seem to be transcribed constitutively during the whole life cycle, which is expected given 
that transcription is polycistronic in trypanosomatids (Ivens et al., 2005). Even post-
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transcriptional control, represented by mRNA stability and degradation (Clayton, 2014), 
however, appears to play a relatively minor role in distinguishing phenotypic differences 
between different life cycle stages. Translational and post-translational regulation of 
proteins therefore may play major roles in determining phenotypes of the respective 
stages.  
Comparing the outcomes from the various studies needs to be carried out with some 
caution since many aspects of the methods differ. On the other hand, it should be possible 
to draw general conclusions for the major changes determining the respective stages. 
Whereas some of the studies used freshly differentiated amastigotes, others used 
established cultures, and it is unknown how different or similar they are. Further, the 
specific methodology, statistics and its stringency applied plays a crucial role for the final 
outcome and data interpretation. 
The knowledge and understanding of amastigote metabolism progressed substantially 
with the publication of work by Saunders and colleagues (2014), who performed GC-MS 
metabolomics on different life cycle stages of L. mexicana. They focused on the major 
trends of carbon metabolism in amastigotes when compared to promastigotes and coined 
the term the ‘stringent metabolic response’ to describe it. Compared to promastigotes, 
consumption of glucose and amino acids was decreased as well as production of organic 
acids and other metabolic end products. Fatty acid utilisation by β-oxidation was 
increased and these fuelled the TCA cycle, which is repressed in cultured promastigotes 
(Saunders et al., 2014). The cells were much more sensitive to inhibition of aconitase of 
the TCA cycle, suggesting that oxidative phosphorylation plays a more important role in 
amastigotes (Saunders et al., 2014). These data correspond with results from several 
transcriptomic analyses, which reported general downregulation of gene expression in 
amastigotes, and drop in expression of glucose transporters and some other carbon 
metabolism enzymes (Alcolea et al., 2010b, 2014; Holzer et al., 2006; Leifso et al., 2007). 
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3.2 Aims 
 Prepare metabolomics samples from L. donovani promastigotes, axenic 
amastigotes, and splenic amastigotes 
 Analyse obtained LC-MS metabolomics data with focus on comparison of the 
two types of amastigotes 
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3.3 Results 
Although numerous transcriptomic studies have been performed, focusing on differences 
between the individual Leishmania life stages, they do not provide satisfactory and 
intuitive explanations for the diversity of phenotypes that distinguish life cycle stages 
(reviewed in Cohen-Freue et al., 2007). More information was obtained by proteomics, 
but metabolomics may offer a superior approach for this question. Of all the omics 
techniques it is the one closest to the final phenotype, and there is a good example 
represented by the metabolomic work by Saunders and colleagues (2014), which 
provided lot of new and concise information. 
Thanks to collaboration with Gerald Spath and Pascale Pescher from the Institut Pasteur 
in Paris, we were able to prepare metabolomic samples from L. donovani amastigotes 
isolated from spleen of infected hamsters. In addition, we prepared samples from 
axenically cultured amastigotes and promastigotes and analysed them by LC-MS 
metabolomics. In this chapter, I present metabolomics data comparing these three sample 
groups. Since these cells differ significantly in their size (Pescher et al., 2011), protein 
content was measured and the metabolomic data were normalised per unit of intracellular 
protein.  
A general overview of the data shows that the three sample groups are separated and 
based on principal component analysis (PCA) that the two amastigote groups are closer 
to each other than either is to promastigotes (Fig 3.1). The PCA plot shows that one of 
the splenic amastigote samples is separated from the other three, which are positioned 
close to all the axenic amastigote samples (Fig 3.1A). Promastigotes are further apart but 
they are barely distinguished from axenic amastigotes based on principal component 1, 
represented by the x axis.  
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Figure 3.1. Overview of the LC-MS metabolomic data comparing L. donovani axenic 
amastigotes, splenic amastigotes and promastigotes. A – PCA plot, colour ellipses 
indicate 95% confidential interval; B – A heat map based on all the metabolites 
identified, the bar on the right indicates fold change; Pm – promastigotes, Ax Am – 
axenic amastigotes, Sp Am – splenic amastigotes. Graphs were made using 
MetaboAnalyst. 
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The most plausible explanation for the splenic amastigote outlier sample is contamination 
with host cells. However, no obvious contaminants (i.e. mammalian specific metabolites) 
were found in the metabolite list, although a group of metabolites was found exclusively 
in splenic amastigotes, but they were not elevated in the outlier sample. For example 
several fatty acids are substantially increased in that sample.  
Figure 3.2. PCA plot and corresponding loading plot. A – PCA plot without Sp Am2 
outlier; B - Loading plot for the PCA plot shown in A. Graphs were made using 
MetaboAnalyst.  
I obtained an additional PCA plot, this time excluding the single splenic amastigote 
outlier sample (Fig 3.2A). Positions of the samples are only slightly changed relative to 
the previous PCA plot (Fig 3.1A), but the 95% confidence regions of amastigotes are 
contained and do not overlap. The loading plot for this PCA plot is shown in Fig 3.2B 
and the metabolites mostly determining separation of principal components (PC) 1 and 2 
are listed in Appendix A5. Metabolites appearing among the top 20 important for 
separation of both PC 1 and PC 2 are hexadecanoic acid, octadecanoic acid, glucose, 
MES (probably a contaminant from the medium), octadec-9-enoic acid, glycerol 3-
phosphate, and choline. Other fatty acids and amino acids are represented substantially 
too. 
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Visualisation of the total metabolomic profile on a heat map confirms that one of the 
splenic amastigote samples is substantially different from others (Fig 3.1B). Each of the 
groups is clearly separated, but a substantial group of metabolites similar between any 
two groups is distinguishable (in the left part of the heat map for promastigotes and 
axenic amastigotes, in the middle for both amastigote groups, and in the right part for 
promastigotes and splenic amastigotes). Prior to sample extraction, promastigotes were 
cultured in M199 medium with 10% FCS and additional supplements, axenic amastigotes 
in RPMI-1640 medium with 20% FCS and added amino acids and vitamins, and splenic 
amastigotes were purified directly from the spleen into PBS. Hence, the overall profile 
shows that the metabolomics reflects truly intracellular metabolism, with the 
environment or medium used for cultivation playing a minor role. 
I focused further on comparison between axenic and splenic amastigote cells. Metabolites 
changing the most between axenic and splenic amastigotes are listed in Tab 3.1, 
(regardless of the change relative to promastigotes). On the other hand, metabolites 
indicating the same trend in both amastigote groups are listed in Tab 3.2. Compounds 
identified as glycogen and cellopentaose are sugar polymers and probably represent 
mannogen in Leishmania. Altogether, it is difficult to draw clear conclusions from this 
data, the metabolites represented do not indicate any specific pathway being clearly 
similar, or diverse between the two types of amastigotes. 
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formula putative identification relative abundance 
  PM Ax AM Sp AM 
C5H8O4 2-Acetolactate 1.00 2.35 165.45 
C10H19N3O5 Lys-Asp 0.00 0.00 6.75 
C5H9NO5 L-erythro-4-Hydroxyglutamate 0.00 0.00 3.01 
C6H10O7 D-Glucuronate 1.00 2.34 96.62 
C5H8O6 2-Dehydro-D-xylonate 0.00 0.00 55.26 
C6H13O8P L-Fucose 1-phosphate 0.00 0.00 7.28 
C5H11NO Betaine aldehyde 0.00 0.38 38.29 
C25H44NO7P 
[PE (20:4)] 1-(5Z,8Z,11Z,14Z-
eicosatetraenoyl)-sn-glycero-3-
phosphoethanolamine 
1.00 0.80 130.72 
C5H6O4 2,5-Dioxopentanoate 1.00 0.22 10.19 
C6H6O6 L-Dehydroascorbate 0.00 0.00 54.29 
C20H25N7O6 5-Methyltetrahydrofolate 0.00 3.35 0.00 
C6H8O4 2,3-Dimethylmaleate 1.00 22.25 4.16 
C4H4O2 3-Butynoate 0.00 1.65 101.74 
C2H7NO3S Taurine 1.00 1.33 288.08 
C15H24O 2-trans,6-trans-Farnesal 1.00 3.85 0.52 
C5H8O5 (R)-2-Hydroxyglutarate 1.00 1.25 28.11 
C4H9NO4 4-Hydroxy-L-threonine 0.00 0.00 10.13 
C4H7NO 2-Pyrrolidinone 1.00 20.04 0.96 
C5H6O5 Methyloxaloacetate 0.00 0.00 17.73 
C20H18O9 
1-Hydroxy-2-(beta-D-glucosyloxy)-9,10-
anthraquinone 
1.00 0.71 42.80 
Table 3.1. Metabolites showing the biggest changes detected between the two 
amastigote groups. The identifications are only putative based on mass, 
metabolites highlighted in bold were confirmed with standards. 
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formula putative identification relative abundance 
  PM Ax AM Sp AM 
C18H13NO4 Stealthin C 0.00 119.92 31.60 
C24H42O21 Glycogen 1.00 34.74 20.70 
C30H52O26 Cellopentaose 0.00 28.63 10.26 
C43H81O13P 
[PI (16:0/18:1)] 1-hexadecanoyl-2-(9Z-
octadecenoyl)-sn-glycero-3-phospho-(1'-myo-
inositol) 
0.00 27.87 16.14 
C2H6O4S 2-Hydroxyethanesulfonate 1.00 19.69 21.61 
C17H29N5O6 Asn-Leu-Gly-Pro 1.00 9.33 4.85 
C24H46O2 [FA (24:0)] 15Z-tetracosenoic acid 1.00 8.65 30.08 
C4H8O3 4-Hydroxybutanoic acid 1.00 6.36 5.69 
C10H18N4O6 N-(L-Arginino)succinate 1.00 5.45 13.56 
C5H4N4O3 Urate 0.00 5.37 3.35 
C6H11NO2 L-Pipecolate 1.00 0.00 0.00 
C5H11NO4 4-amino-4-deoxy-L-arabinose 1.00 0.00 0.02 
C28H40N10O5S Arg-Met-Trp-His 1.00 0.00 0.00 
C7H15NO3 L-Carnitine 1.00 0.00 0.00 
C21H32O4 
11beta,21-Dihydroxy-5beta-pregnane-3,20-
dione 
1.00 0.00 0.00 
C6H13NO3 N-hydroxyisoleucine 1.00 0.00 0.00 
C6H13NO2 L-Isoleucine 1.00 0.00 0.00 
C8H12N2O2 Pyridoxamine 1.00 0.00 0.00 
C14H20N6O4S2 Ovothiol A disulfide 1.00 0.00 0.00 
C9H17NO8 Neuraminic acid 1.00 0.00 0.00 
Table 3.2. Metabolites showing similar changes in axenic and splenic amastigotes 
relative to promastigotes. The identifications are only putative based on mass, 
metabolites highlighted in bold were confirmed with standards. 
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3.3.1 Amino acids 
Probably the most striking change in the whole dataset is a general drop in amino acid 
levels in amastigotes. Basically all of the amino acids decreased substantially in both 
amastigote types as can be viewed in the total comparison (Fig 3.3). 
Figure 3.3. Relative levels of all the amino acids detected by LC-MS. PM – 
promastigotes, Ax_AM – axenic amastigotes, Sp_AM – splenic amastigotes. 
In almost all cases, amino acid levels are decreased to the same extent in both axenic and 
splenic amastigotes when compared to promastigotes. One group of amino acids is 
decreased around ten fold in both types of amastigotes compared to promastigotes, 
including glutamine, proline, leucine, and lysine. About a four-fold decrease was 
observed for threonine, phenylalanine, arginine, and aspartate. In both amastigote groups, 
tryptophan reaches levels half those of promastigotes. Glutamate is decreased six fold in 
axenic amastigotes, but in splenic amastigotes returned to the same level as in 
promastigotes. Serine is decreased two fold in axenic, and five fold in splenic 
amastigotes, respectively. Two amino acids, histidine and methionine, are three fold 
increased in both types of amastigotes (Fig 3.4).  
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Figure 3.4. Relative changes in all amino acids detected by LC-MS. PM – 
promastigotes, Ax_AM – axenic amastigotes, Sp_AM – splenic amastigotes, error 
bars represent standard deviation, n = 4.  
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3.3.2 Carbon metabolism  
Central carbon metabolism is especially important, because it involves glycolysis and the 
TCA cycle, the canonical major energy sources. From glycolysis, we detected glucose, 
G6P, PEP and pyruvate. Glucose and G6P are increased in both amastigote samples, 
while PEP is decreased, which may be interpreted as decreased flux through glycolysis, 
since the inputs at the top of the pathway are accumulated while the output at the bottom 
of the pathway is decreased (Fig 3.5). Pyruvate is 25 fold elevated in axenic amastigotes 
and two fold decreased in splenic amastigotes compared to promastigotes, which is very 
difficult to explain and interpret, and we cannot exclude some kind of artefact, however, 
the low amount of pyruvate present in the medium, comes only from FCS.  
Figure 3.5. Relative changes in metabolites from glycolysis detected by LC-MS. PM 
– promastigotes, Ax_AM – axenic amastigotes, Sp_AM – splenic amastigotes, error 
bars represent standard deviation, n = 4. 
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Not many metabolites from the PPP were detected in this dataset. Ribose decreased to 
the detection limit in both amastigote samples, but R5P was not detected. S7P was 
detected and reaches the same levels in promastigotes and splenic amastigotes, but is two 
fold increased in axenic amastigotes (Fig 3.6). Three metabolites, possibly related to 
mannogen, were detected, corresponding to trimeric, tetrameric and pentameric hexose 
polymers, all of which are highly increased in both types of amastigotes (axenic even 
more than in splenic) (Fig 3.6). 
Figure 3.6. Relative changes in metabolites from the PPP and substitutes for 
mannogen detected by LC-MS. PM – promastigotes, Ax_AM – axenic amastigotes, 
Sp_AM – splenic amastigotes, error bars represent standard deviation, n = 4. 
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Both malate and succinate are decreased three fold in splenic amastigotes, which 
corresponds with the stringent metabolism phenotype, these organic acids being secreted 
as metabolic end products when metabolism is more profligate. In axenic amastigotes, 
malate was decreased two fold while succinate reached the same levels as in 
promastigotes (Fig 3.7). Two metabolites of the TCA cycle were detected, citrate and 
cis-aconitate. Both of them showed the same trend, i.e. a minor increase in axenic 
amastigotes and more than three-fold increased levels in splenic amastigotes (Fig 3.7).   
Figure 3.7 Relative changes in succinate, malate and metabolites from the TCA 
cycle detected by LC-MS. PM – promastigotes, Ax_AM – axenic amastigotes, 
Sp_AM – splenic amastigotes, error bars represent standard deviation, n = 4. 
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It was suggested that fatty acid degradation may play an important role in amastigote 
metabolism (Hart and Coombs, 1982; Saunders et al., 2014). Even though the 
metabolomic method used here is not optimal for fatty acid and other lipid identification 
(which resolve better using reverse phase chromatography), we can still obtain a general 
overview. Acetyl-CoA, the major intermediate of fatty acid degradation, which can be 
channelled into the TCA cycle, is slightly increased in axenic and decreased two fold in 
splenic amastigotes compared to promastigotes (Fig. 5.7).  
The general overview of lipid metabolism, however, does not show any substantial 
change in these metabolites in amastigotes (Fig 3.8). A heat map constructed from 
metabolites classified as part of lipid metabolism does not indicate any striking increase 
in amastigotes (Fig 3.8 A). The sample from splenic amastigotes which stood as an outlier 
in considering the total metabolome also stands apart in the lipid analysis, indicating that 
lipids make a primary contribution to this discriminatory effect.  
A volcano plot offers a different perspective on the data, considering metabolites in 
promastigote as equal to one and indicating relative changes in the two types of 
amastigote samples, and p-values associated with these changes (Fig 3.8 B). A substantial 
group of metabolites whose fold change is increased in splenic amastigotes fail to reach 
statistical significance (p>0.1). Whereas metabolites from axenic amastigotes seem to be 
distributed evenly on both sides of the plot from one, splenic samples are more abundant 
in the right half of the graph, indicating accumulation. These are mostly glycerolipids 
and derivatives of choline. However, most of these data points are associated with high 
p-values and may be possibly caused by the one odd sample with high levels of lipids, 
which causes increase with high variance and thus is not significant (after removing the 
outlier sample, the change is smaller but still not significant).  
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Figure 3.8. Overview of lipid metabolism. A- heat map based on metabolites 
classified as part of lipid metabolism, the bar on the right indicates fold change; B – 
volcano plot showing changes in amastigote samples relative to promastigotes. Pm 
– promastigotes, AxAm – axenic amastigotes, SpAm – splenic amastigotes. The 
heat map was created with MetaboAnalyst, using Euclidean distance measure and 
Ward clustering algorithm. 
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3.4 Discussion 
The aim of this study was to gain insight into the status of different types of amastigotes 
(axenic versus spleen-derived) using metabolomic analysis. There has been debate as to 
whether axenic amastigotes are really representative of splenic amastigotes or whether, 
instead, they are more akin to promastigotes, only altered in morphology (Holzer et al., 
2006; Pan et al., 1993; Pescher et al., 2011; Pral et al., 2003). As mentioned earlier, 
hindrances in working with axenic amastigotes include the risk of introducing artefacts 
during cell cultivation, their relatively large size, their production of promastigote stress 
factors and decreased virulence (Pescher et al., 2011). On the other hand, it is difficult to 
purify amastigotes from macrophages and maintain them pure and intact. The group of 
Gerald Spath established a protocol for purification of amastigotes from mammalian 
tissue with use of a mild detergent, saponin and gradient centrifugation (Pescher et al., 
2011 and Methods 2.7). Hence, we used this protocol to prepare cells for metabolomic 
analysis. We cannot guarantee absolute purity of the obtained samples, and it was not 
possible to perform controls for contamination with mammalian tissue simultaneously 
(for example by Western blot analysis). Moreover, amastigotes take up small molecules 
present in their environment, and distinguishing these from components naturally present 
inside the parasites is impossible. In spite of these caveats, a general overview of the final 
data can be used as a quality control and seems robust (i.e. the splenic amastigote samples 
are not completely different and levels of individual metabolites are similar). In addition, 
the samples were not profoundly influenced by the culture medium, since splenic 
amastigotes were not kept in any medium and still cluster close to axenic amastigotes. 
To the best of my knowledge, direct metabolomic analysis of lesion derived amastigotes 
has not been performed to date, as Saunders (2014) cultivated the amastigotes in culture 
previous to the analysis. 
The general analysis of the whole metabolomic dataset shows that the sample replicates 
group together well (except from one sample) and the respective groups clearly separate 
from each other, which is a good quality control of the analysis. Two different statistical 
methods give slightly different outputs. In the PCA plot the two different types of 
amastigotes are placed closer to each other with promastigotes further separated (Fig 
3.1), whereas the heat map shows the three groups distinctly separated. A PCA is based 
on differences and the final outcome may be driven by a few species which change 
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dramatically. In contrast, a heat map provides visualisation of all the metabolites 
detected, hence both similar and different species are represented. Since it is difficult to 
make any conclusions based on these analyses only, especially if they give different 
results, I focused further on metabolites of central metabolism which we can match with 
standards, i. e. central carbon metabolism, amino acids. 
The most prominent change in the dataset is observed for amino acids. With the exception 
of histidine and methionine, all of the amino acids were decreased in both types of 
amastigotes. Amastigotes probably consume amino acids to a much lesser extent than 
promastigotes, irrespective of their availability, since the medium for axenic culture is 
more rich (Methods 2.2.1). This corresponds with the observation that amastigotes have 
reduced capacity to scavenge glutamate and feed it into the TCA cycle (Saunders et al., 
2014). Some of the amino acids show similar patterns and can be grouped together, but 
these groups do not reflect chemical properties and thus do not seem to be associated 
with specific transporters. mRNA for one putative amino acid transporter was found to 
be 2 fold decreased in promastigotes compared to amastigotes (Leifso et al., 2007). Two 
amino acid permeases were found among the genes whose RNA abundance was most 
decreased in amastigote L. major (Rochette et al., 2008), and one amino acid permease 
was downregulated in amastigote L. infantum (Alcolea et al., 2010b). On DNA 
microarrays, two different amino acid permeases were found to be upregulated and two 
others to be downregulated after transformation of promastigotes into amastigotes, 
leading to speculation that different transporters are used in each stage (Alcolea et al., 
2010a). However, the substrate specificity of these permeases is unclear. There is no 
obvious explanation for the increase in histidine and methionine. Amino acid transporters 
of Leishmania are not well defined functionally and it is not known if, for example, they 
possess a broad spectrum transporter, common for histidine and methionine. A permease 
which can import both of these amino acids was found in yeast (Isnard et al., 1996) and 
for example, the eflornithine transporter TbAAT6 of T. brucei was proven to have low 
substrate specificity (Mathieu et al., 2014). 
It is difficult to make any conclusions about the PPP, but since S7P is a metabolite 
specific for this pathway, it suggests that the flux is comparable in amastigotes and 
promastigotes. Considering that most of the metabolic pathways are decreased in 
amastigotes, we could say then that the PPP may be increased relative to other pathways, 
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which would be expected due to increased demand for NADPH in response to high 
oxidative stress inside macrophages. On the other hand, the GC-MS analysis of L. 
mexicana with labelled glucose did not identify relatively high levels of PPP 
intermediates (Saunders et al., 2014). 
An interesting observation is the increased levels of cis-aconitate and citrate in 
amastigotes, suggesting increased flux through the TCA cycle. When labelled glucose 
was used for GC-MS metabolomics in promastigotes, metabolites from the TCA cycle 
were labelled less than from glycolysis, whereas in amastigotes the labelling was more 
similar in both pathways (Saunders et al., 2014). At the same time, amastigotes were 
shown to be more sensitive to inhibition of aconitase in the TCA cycle (Saunders et al., 
2014). Different labelling patterns in TCA cycle metabolites were observed between 
promastigotes and amastigotes, and the data were interpreted to indicate that the full cycle 
operates in promastigotes, whereas an anabolic mode of operation dominates in the 
amastigote stage, providing intermediates for subsequent synthesis. The increase in the 
TCA cycle intermediates observed here agrees with an increase in TCA cycle flux in 
amastigotes over promastigotes.  
Evidence is also accumulating that suggests increased fatty acid β-oxidation in 
Leishmania amastigotes when compared to promastigotes. Hart and Coombs (1982) 
observed that amastigotes consumed free fatty acids up to 10-fold faster than 
promastigotes. Activities of enzymes of fatty acid β-oxidation were shown to be higher 
in amastigotes than promastigotes, in contrast to glycolytic enzymes (Coombs et al., 
1982). Oxidation of fatty acids was measured in promastigote cultures over time from 
rapidly growing to late stationary phase cultures, and later cultures consumed fatty acids 
faster, which may suggest a trend towards amastigotes (Blum, 1990). In proteomic 
analysis, enzymes of fatty acid catabolism were detected to be more abundant in 
amastigotes, specifically those of unsaturated fatty acid degradation (Paape et al., 2008). 
Utilisation of carbons from fatty acids in the TCA cycle was clearly proven in axenic 
amastigotes using GC-MS based metabolomics and, even though the signal was lower, 
it was still clear in lesion derived amastigotes (Saunders et al., 2014). Activity of both 
salvage and de novo biosynthesis of fatty acids was detected in lesion amastigotes, but 
the turnover was much slower than in other stages (Kloehn et al., 2015). Increased levels 
of some metabolites associated with lipid metabolism in amastigotes were detected in 
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this dataset, which may indicate increased lipid metabolism in total, but no clear 
conclusions can be made, the method used (LC-MS with ZIC pHILIC column) not being 
optimal for lipid analysis, because hydrophobic compounds elute prior to resolution in 
chromatography.  
The so-called stringent metabolic response is the main characteristic of amastigote 
metabolism according to Saunders and colleagues (2014). From this data, a consistent 
decrease in amino acids, significantly decreased levels of succinate and malate, important 
metabolic end products, and a potential decrease in the glycolytic flux are traits clearly 
coherent with that hypothesis. 
A few genes are consistently detected in the comparative transcriptomic and proteomic 
studies mentioned earlier. For example, heat shock proteins, stress response proteins, 
amastins and high number of hypothetical proteins are consistently overexpressed in 
amastigotes. However, these are not directly connected with metabolism and cannot be 
related to metabolomics data. On the other hand, downregulation of glucose transporters 
and some enzymes of carbon metabolism in amastigotes, as well as general 
downregulation of expression (Alcolea et al., 2010b) seems to be consistent with the 
stringent metabolic response. Most of the proteins specific for promastigotes, such as 
tubulins, calmodulins or components of the paraflagellar rod cannot be directly related 
to metabolism. 
In general, my data show splenic amastigotes, axenic amastigotes and promastigotes as 
three distinct groups. They are consistent with the work by Saunders and colleagues 
(2014), and support the stringent metabolism hypothesis suggested for amastigotes. We 
provide an interesting novel observation of consistent and significant decrease in amino 
acid levels in amastigotes, regardless of their growth environment.  
There are some indications (PCA, amino acids, mannogen) that at the metabolic level 
axenic amastigotes are more closely related to splenic amastigotes than they are to 
promastigotes, on the other hand, the total metabolome overview contradicts that and no 
profound conclusions can be made at this point. These results contribute to the so far 
scarce knowledge of amastigotes and give indications which may be considered in future 
studies using axenic amastigotes as a model. It would be desirable, but technically 
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challenging, to perform similar metabolomics analyses of metacyclic cells or 
promastigotes from sand flies in the future. 
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4 Utilisation of glucose and 
ribose by wild-type Leishmania 
mexicana 
4.1 Introduction 
As with most eukaryotic organisms, glucose is the major carbon source for 
trypanosomatids and the extent of its utilisation in metabolism was confirmed by 
metabolomics. When either bloodstream or procyclic form T. brucei cells were grown in 
the presence of U-13C-glucose, a significant proportion of labelling was detected in 
glycolysis and the succinate fermentation pathway and the label was subsequently 
detected in remote metabolic branches (Creek et al., 2012, 2015). Similarly, promastigote 
L. mexicana incorporated carbons from glucose for example into nucleotides (Saunders 
et al., 2014). However, in some conditions, for example different anatomical locations 
within arthropod vectors, and in some in vitro conditions less glucose is available and 
additional substrates, including amino acids and other sugars can be present in abundance 
(Van Grinsven et al., 2009; Opperdoes and Coombs, 2007). Tsetse flies, for example, use 
proline as their primary energy source (Bursell et al., 1973) and procyclic African 
trypanosomes use this as their main source of energy, although they prefer glucose if 
available (Lamour et al., 2005). In the case of Leishmania, the sandfly host feeds 
primarily on plants and accumulates a variety of sugars. In Leishmania it is clear that 
glucose can be replaced by other substrates, since WT Leishmania can grow in absence 
of glucose (Burchmore et al., 2003), but it is unclear which sources can be used instead 
and what changes in metabolism are triggered. 
The Leishmania genome encodes three separate genes for different glucose transporters. 
Concomitant deletion of all of them leads to a growth defect (Burchmore et al., 2003). 
The spontaneous expression of an alternative glucose transporter (LmGT4) from an 
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extrachromosomal element can relieve that growth defect (Feng et al., 2009). All three 
transporters can import glucose, fructose, mannose and galactose (Rodriguez-Contreras 
et al., 2007) but there seems to be some differential preference for other substrates among 
the transporters, for example glucose transporter 2 is more efficient for import of ribose 
(Naula et al., 2010). Expression of sugar and other nutrient transporters reflects substrate 
availability, as they are upregulated under substrate starvation conditions and depleted 
when substrate is in excess, offering means to achieve stable uptake of given substrates 
(Rodriguez-Contreras et al., 2015; Seyfang and Landfear, 1999). Utilisation of sugars by 
the PPP was previously assessed indirectly in L. mexicana, and it was calculated that 
57% of radiolabelled ribose and 11% of glucose is incorporated into nucleic acids 
(Maugeri et al., 2003). The route for glucose incorporation is presumed to be through its 
conversion to R5P via the PPP. However, this value cannot be used as an estimate of the 
total PPP flux, because a substantial proportion of the PPP intermediates is channelled 
back into glycolysis.  
In order to describe utilisation of glucose and ribose more clearly, I performed the 
following metabolomic experiment with differential labelling. WT L. mexicana 
promastigotes were grown in four different types of media where the primary sugar 
content varied: 1) 16 mM glucose, 50% of which was U-13C-glucose, 2) 16 mM ribose, 
50% of which was U-13C-ribose, 3) 8 mM glucose, 50% of which was U-13C-glucose and 
8 mM ribose (unlabelled), 4) 8 mM ribose, 50% of which was U-13C-ribose and 8 mM 
glucose (unlabelled) (Fig 4.1). Subsequently, the labelling patterns of PPP intermediates 
and other metabolites were analysed. 
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Figure 4.1. Scheme of sugar composition in media used in the four sample groups. 
13C-Glu = U-13C-glucose , Glu = glucose, 13C-Rib = U-13C-ribose, Rib = ribose.  
 
4.1.1 Aims 
 Grow WT promastigote L. mexicana in medium containing 16 mM glucose, 16 
mM ribose, or 8 mM glucose and 8 mM ribose. Subsequently prepare the same 
media containing 50% of the sugars U-13C labelled. 
 Prepare metabolomics samples  
 Analyse the data with focus on differential utilisation of carbons depending in the 
type of medium  
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4.2 Results  
Labelling in the separate metabolites was analysed, assessing the proportion of the 
specific number of carbons labelled in each group. That reflects the origin of the 
respective metabolites in relation to the labelled sugar source and points to differences 
that arise in response to the specific medium composition. Changes in the total abundance 
of respective metabolites were not assessed, unless interesting and significant. The 
natural abundance of 13C is approximately 1% and this was not subtracted when 
considering the results, hence a background incorporation of 13C into metabolites 
irrespective of the labelled source occurs. The intensity of this background depends on 
size of each metabolite, for example for metabolites composed of 5 carbons 5% of the 
metabolite will contain one labelled carbon (i.e. 5 x 1%).  
The labelling pattern of glucose offers a proof of principle, since 40% of glucose is fully 
labelled in the cells where 50% of labelled glucose was supplemented in the media, this 
part decreased to 34% if ribose was supplied in addition (Fig 4.2, Tab 4.1). The labelling 
pattern looks completely different in hexose phosphates, however, where the labelling is 
largely similar in the first three sample groups, but minimal in cells which were grown 
in labelled ribose in the presence of glucose (Fig 4.2). This result indicates that if only 
ribose is available, it is converted to hexose phosphates to the same extent as glucose. 
However, when glucose is available too, glucose is preferred and ribose utilisation is 
massively diminished. The relatively high activity of TKT and TAL is clear since these 
enzymes shuffle the carbons creating a rich mixture of products containing different 
numbers of labelled carbon atoms, responsible for the colourful patterns depicted in Fig 
4.2. The respective carbon content profile created when labelled ribose is used is similar 
to that when glucose is used, but shifted with respect to the number of labelled carbons, 
reflecting the carbon content of the sugar provided. The peaks detected for R5P were of 
lower intensity and quality, but we can still see a substantial proportion of fully labelled 
R5P, if the cells were grown in ribose solely, whereas the labelling is much lower in the 
other groups where glucose was present too (Fig 4.2).  
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Figure 4.2. Labelling patterns of glucose, hexose phosphates (sum of G6P and 
F6P), ribose and R5P in the four respective groups described in Fig 4.1. The 
coloured boxes underneath indicates how colours correspond to number of carbons 
labelled, UL - unlabelled. 
 
Table 4.1. Quantification of fully labelled part of glucose and ribose. 
 50% Glu 50% Rib 25% Glu 25% Rib 
U-13C-glucose 40% 0 34% 0 
U-13C-ribose 70% 48% 12% 46% 
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Almost identical labelling patterns were obtained for pyruvate, succinate and malate (Fig 
4.3). All of these metabolites have almost the same extent of labelling in the first three 
sample groups and only minimal labelling in the last group, grown in both sugars with 
labelled ribose, again indicative of ribose utilisation being suppressed if glucose is 
available. Pyruvate and succinate are slightly higher in the first group (Tab 4.2), supplied 
solely with glucose, and this difference is caused mostly by increase in the three carbon 
part. That indicates that more pyruvate is made directly from glucose through glycolysis, 
and it is turned into succinate in the succinate fermentation pathway (Saunders et al., 
2011).  
Figure 4.3. Labelling patterns of pyruvate, succinate and malate. The coloured 
boxes underneath indicates how colours correspond to number of carbons labelled, 
UL - unlabelled. 
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pyruvate 50% Glu 50% Rib 25% Glu 25% Rib 
0 C labelled 40 % 62 % 44 % 82 % 
1 C labelled 14 % 13 % 15 % 13 % 
2 C labelled 12 % 9 % 11 % 2 % 
3 C labelled 35 % 15 % 30 % 3 % 
total abundance 1 0.75 0.76 0.56 
Table 4.2. Quantification of labelling in pyruvate. Total abundance is given in values 
relative to WT. 
From the TCA cycle metabolites, citrate, cis-aconitate and oxoglutarate were detected. 
The results of labelling look similar to the previous group of metabolites, since there is 
substantial and very similar labelling in the first three sample groups and almost nothing 
labelled in the last group (Fig 4.4). 
Figure 4.4. Labelling patterns of citrate, cis-aconitate, and oxoglutarate. Coloured 
boxes underneath indicates how colours correspond to number of carbons labelled, 
UL - unlabelled. 
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From the metabolites typical for the PPP, only S7P was detected with a peak shape 
allowing confidence in relative quantification across groups. The labelling pattern of S7P 
is intriguing. In the first group almost all of the metabolite is labelled from one, all the 
way to seven carbons, indicating that it comes exclusively from glucose and from no 
other source (Fig 4.5). Its total levels are the highest in the second group, grown in the 
presence of 16 mM ribose. The biggest parts are two and five carbons labelled, 
corresponding to its synthesis by TKT from 5 + 2 carbons. The total abundance is much 
lower in the third group and in contrast to the first group, labelling of six and seven 
carbons disappeared, which may be due to depletion of the signal below the detection 
limit. However, it suggests that S7P is synthesised from both the labelled glucose and 
unlabelled ribose. The total abundance is relatively high in the last group, but the 
labelling is very low, which contradicts results of the two previous groups. The 
proportions of all the respective parts are shown in Tab 4.3. E4P could not be detected, 
but O8P provided a substantial signal in the second group with high proportion of 5 
carbons labelled, indicating synthesis from 5 + 3 carbons. 
Figure 4.5. Labelling patterns of S7P and O8P. Coloured boxes underneath 
indicates how colours correspond to number of carbons labelled, UL - unlabelled. 
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S7P 50% Glu 50% Rib 25% Glu 25% Rib 
0 C labelled 10 % 16 % 21 % 83 % 
1 C labelled 12 % 14 % 18 % 14 % 
2 C labelled 18 % 19 % 22 % 2 % 
3 C labelled 21 % 10 % 22 % 0 
4 C labelled 18 % 9 % 11 % 0 
5 C labelled 11 % 16 % 6 % 0 
6 C labelled 6 % 7 % 0 0 
7 C labelled 3 % 7 % 0 0 
total abundance 1 1.53 0.55 0.83 
Table 4.3. Quantification of labelling in S7P. Total abundance is given in values 
relative to WT. 
Metabolites in Fig 4.6 are listed as examples of nucleotide derived metabolites which 
incorporate R5P (additional examples are in Appendix A4). In some of the sample 
groups, a five carbon labelled part is of major significance. This part almost certainly 
represents the R5P part of the nucleotides originating directly from either of the sugars 
supplied. For example in the second group the 5 carbon labelled part represents 29% of 
adenosine monophosphate (AMP), 29% of adenosine triphosphate (ATP) and 26% of 
nicotinamide adenine dinucleotide (NAD+) (Fig 4.6, Tab 4.4). In all of these compounds, 
the total labelling is the lowest in the fourth group (labelled ribose in the presence of 
unlabelled glucose) as was seen previously. However, a substantial proportion with 5 
carbons labelled when labelled ribose is available indicates that if both sugars are 
available, ribose is still used directly for R5P synthesis. A substantial part (8.6%) of 
NAD+ containing 10 labelled carbons reflects the presence of two ribose phosphate 
moieties within this dinucleotide. In uridine triphosphate (UTP), six and seven labelled 
carbon species are present.  
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Figure 4.6. Labelling patterns of AMP, ATP, UTP and NAD. Coloured boxes 
underneath indicate how colours correspond to number of carbons labelled, UL - 
unlabelled. 
AMP 50% Glu 50% Rib 25% Glu 25% Rib 
0 C labelled 26 % 44 % 47 % 71 % 
1 C labelled 13 % 11 % 13 % 12 % 
2 C labelled 17 % 6 % 12 % 4 % 
3 C labelled 17 % 5 % 12 % 2 % 
4 C labelled 9 % 5 % 6 % 1 % 
5 C labelled 17 % 29 % 9 % 10 % 
6 C labelled 0 1 % 0 0 
total abundance 1 0.63 0.68 0.7 
Table 4.4. Quantification of labelling in AMP. Total abundance is given in values 
relative to WT. 
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As examples of amino acids, alanine, aspartate, glutamate and glutamine, were analysed 
(Fig 4.7). The trends observed in some of the previous metabolites are evident here as 
well. The total abundance and distribution of labelling is almost identical in the first three 
groups in aspartate and glutamate (Fig 4.7). The data are similar for the other two amino 
acids, but the total abundance is decreased to 75% for glutamine in the second group and 
decreased to 56% for alanine. The peak shapes for alanine are good, so the almost two 
fold depletion in the ribose group is not ambiguous. As with the previous observations, 
there is almost no labelling in the last group. In general, it is surprising that such relatively 
large quantities of amino acids are made from sugar substrates, when all amino acids are 
present in sufficient amounts in medium. The rest of amino acids detected are shown in 
Appendix A3, but only a minor labelling was detected in serine and asparagine and 
almost none in any of the others. 
Figure 4.7. Labelling patterns of alanine, aspartate, glutamate and glutamine. 
Coloured boxes underneath indicates how colours correspond to number of 
carbons labelled, UL - unlabelled.  
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4.3 Discussion 
The results presented in this chapter reveal a number of general trends. Firstly, the extent 
and pattern of labelling in the first three groups (i.e. mixed labelled and unlabelled 
glucose alone, mixed labelled and unlabelled ribose alone, or labelled glucose with 
unlabelled ribose) is substantial and similar, while the fourth group (labelled ribose with 
unlabelled glucose) leads to minimal incorporation of label into most metabolites. This 
suggests that glucose is the preferred carbon source for synthesis of these representatives 
of various metabolic pathways. If glucose is not available, ribose can completely 
substitute for it, but if both sugars are supplied, glucose is preferred. Cells in the third 
and fourth group were grown in effectively the same medium, varying only in whether it 
was glucose or ribose provided in the labelled form, yet when both sugars are available, 
label enters many metabolites from glucose, but barely any from ribose.  
The first group (glucose alone) produced more labelled pyruvate and succinate than other 
groups. These metabolites come from glucose’s being metabolised to 
phosphoenolpyruvate and further converted to pyruvate or succinate via the succinate 
shunt, which is secreted as an end product (Saunders et al., 2011). This indicates a 
profligate use of glucose, i.e. consumption in excessive quantities with large quantities 
of carbon and potential energy wasted through secretion of these partially oxidised 
products. The same explanation holds for alanine, since the total amount of labelled 
alanine in the second group (ribose as a carbon source without glucose) is two fold lower 
than in the first group (glucose only). Alanine can be made from pyruvate by 
transamination (Saunders et al., 2011), and secreted as an end product, as was shown in 
section 3.3.3. This implies that alanine can be made from ribose, but to produce only half 
of the amount made in first group is sufficient. 
The data provide clear evidence for substantial activity in the PPP, especially the non-
oxidative branch. First, there is striking difference between results for glucose and hexose 
phosphates with respect to labelling, which can be explained by activity of the non-
oxidative PPP converting ribose to hexose phosphates. A substantial amount of S7P was 
detected and almost all of it was labelled to some extent, indicating it originates solely 
from the sugars. The large proportion of the total S7P that contains two or five labelled 
carbons is a proof of its synthesis by TKT (product of SBPase would contain more of 3 
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+ 4 label (Clasquin et al., 2011)). Interestingly, if ribose is present in medium as the only 
sugar, the total levels of S7P increase by one third, although no specific role is known 
for its further utilisation in trypanosomatid metabolism. Ribose is phosphorylated to R5P 
which can be converted in the non-oxidative PPP to GA3P or F6P, a possible entry points 
for glycolysis. S7P may simply be a by-product of reaction 5 + 5 → 3 + 7, the 7 carbon 
sugar then being further used in the non-oxidative branch to create other intermediates. 
Ribose as the main carbon source may trigger activation of TKT, which corresponds with 
increase in O8P in the same sample group. However, such a potential mechanism has not 
been reported to date in other organisms. Alternatively, supplementation with ribose may 
increase the flux through the PPP based on concentration gradients, without affecting the 
TKT enzyme itself.  
Clear regulation of metabolism, however, is apparent depending on which sugars are 
available. For example, the labelling in the last two groups indicates that if both glucose 
and ribose are available, ribose is not utilised for S7P synthesis, which is quite surprising. 
On the other hand, labelling in nucleotides clearly shows that ribose is consumed, 
phosphorylated and incorporated into nucleotides. This is very intriguing. It suggests that 
if both sugars are available, ribose is taken up, phosphorylated and used as R5P directly 
where needed but not fed into the PPP. The PPP is instead somehow separated and 
independently fed by glucose.  
We can only speculate what could make such a barrier. Subcellular localisation could be 
considered, even though both the PPP and nucleotide synthesis are present both in the 
cytosol and in glycosomes (Boitz et al., 2012). Localisation of ribokinase has not been 
investigated in Leishmania, but it has a predicted PTS2 (Opperdoes and Szikora, 2006) 
indicating a glycosomal localisation. In addition R5P should pass through the semi-
permeable glycosomal membrane (Achcar et al., 2013). The observed results could be 
caused by decreased activity of ribokinase and concomitant preferential utilisation of 
R5P for nucleotide synthesis prior to the non-oxidative PPP. Partial inhibition of L. 
mexicana ribokinase by glucose was reported (Ogbunude et al., 2007), but still the theory 
has gaps. For example, ribokinase would need to be in a physical complex with 
phosphoribosyltransferase to enable direct channelling of R5P. However, in Leishmania 
there are multiple phosphoribosyl transferases specific for the different nucleobases. 
However, if, in principle, ribokinase was partly inhibited and phosphoribosyltransferase 
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activity was significantly higher than TKT, then this incorporation of R5P into 
nucleotides but not into the PPP intermediates is feasible. 
There is substantial labelling in the nucleotides observed and it has to be interpreted with 
caution, since these are relatively large metabolites (10 to 21 carbons) and we cannot be 
sure which of the carbons are labelled. However, the high proportion of a five carbon 
labelled part indicates incorporation of labelled R5P, which is supported by the fact that 
this proportion is increased in samples supplied with ribose. The ten carbon labelled part 
in NAD+ likely represents two molecules of R5P in the dinucleotide. There is a difference 
between ATP and UTP, when a clearly distinguishable part of six and seven carbon 
labelled product is detected in the latter. In the case of UTP this represents the sum of 
five carbons from R5P plus one or two carbons from the base, since pyrimidine synthesis 
from glucose through oxaloacetate was shown previously in T. brucei (Creek et al., 2015) 
whereas purines are salvaged (Boitz et al., 2012). 
Regarding amino acids, the high proportion of several amino acids derived from sugars 
is a surprise given the abundance of all of the standard amino acids in medium. 
Incorporation of label from glucose into alanine, aspartate and glutamate was shown 
before, while most of the amino acids detected were not labelled (Saunders et al., 2011) 
which is consistent with the results presented here.  
Altogether, these data provide new information about the utilisation of glucose and ribose 
in L. mexicana promastigotes. Clearly, glucose is the preferred source but ribose can fully 
substitute for it. If both substrates are available, glucose is preferred but ribose is still 
used for R5P synthesis and for metabolites where it is directly incorporated, such as 
nucleotides. The most interesting observation is the potential increase in non-oxidative 
PPP flux if cells are grown on ribose as the major carbon source. Upregulation of the PPP 
in trypanosomatids was previously observed in response to increased oxidative stress 
when the mechanism was proposed to be dependent on NADP/NADPH balance 
(Maugeri and Cazzulo, 2004; Maugeri et al., 2003). Here, however, my results indicate 
a novel mechanism controlling flux through the non-oxidative branch. It would be of 
interest to see whether ribose triggers increase in flux in the PPP alone, or whether it 
induces activation of transketolase and transaldolase. 
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5 Transketolase 
 
5.1 Introduction 
 
Transketolase has been studied from many angles, including its structure and function, 
connection with cancer, or biotechnological application, for example as a biocatalyst for 
asymmetric synthesis (Lindqvist et al., 1992; Nilsson et al., 1997; Ranoux and Hanefeld, 
2013; Staiger et al., 2006b). Here, I will focus on the most important aspects and those 
relevant to its exploitation as a potential drug target in Leishmania. 
Transketolase is an enzyme that transfers two carbon keto units from a ketose to an 
aldose, using a wide range of substrates, mostly sugar phosphates from three to seven 
carbons in size. The enzyme is a homodimer, using as cofactors thiamine pyrophosphate 
(TPP) and Mg2+, which can be substituted by other bivalent metal ions, such as Ca2+, 
Mn2+, Co2+,Ni2+ (Heinrich et al., 1972). Each subunit consists of three domains, an N-
terminal pyrophosphate binding domain, a central pyridinium binding domain and a C-
terminal domain without any known specific binding function attributed so far (Lindqvist 
et al., 1992). The crystal structure was resolved for the yeast enzyme first, showing that 
TPP binds at interface between the two subunits and that there are two catalytic sites at 
interface of the two subunits (Lindqvist et al., 1992). Later, a crystal structure of 
Leishmania TKT was resolved at 2.2 Å resolution (Veitch et al., 2004). Nilsson and 
colleagues Nilsson et al., (1997) obtained a structure of the yeast enzyme with bound 
TPP, Ca2+ and E4P showing that the structure in complex is very similar to the 
holoenzyme. They identified conserved amino acid residues which are responsible for 
the cofactor and substrate binding, which enabled them to prepare various amino acid 
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substitution mutants. The enzyme with Asp477 replaced by Ala conveyed only 1.7% of 
WT enzymatic activity (Nilsson et al., 1997). The substrate was shown to bind in a 
narrow cleft between the two subunits which can accommodate only a single substrate 
molecule at a time, and not both the donor and acceptor simultaneously (Nilsson et al., 
1997). That is consistent with the kinetic ping-pong mechanism of TKT action (Horecker 
et al., 1963). Kinetic measurements stimulated formulation of an alternative hypothesis, 
when the non-oxidative PPP is presented as a sum of half-reactions, where donor 
substrate reacts with the enzyme first, and subsequently any suitable molecule can serve 
as an acceptor (Kleijn et al., 2005). The range of possible donor and acceptor substrates 
is relatively large. While the canonical donor ketoses are X5P, F6P, S7P and erythrulose 
and acceptor aldoses are R5P, E4P, GA3P and glycoaldehyde (Clark et al., 1971; Datta 
and Racker, 1961), in a modified pH-based TKT assay, lithium hydroxypyruvate 
combined with a wide range of aldehydes can be used instead (Yi et al., 2012).  
Essentiality of TKT and its role in metabolism was studied in classical model organisms 
including yeast and E. coli. TKT deletion mutants in yeast showed no defect in rich 
growth medium and interestingly, also grew well on gluconeogenic carbon sources 
(glycerol, pyruvate, lactate, ethanol). However, growth was compromised on fermentable 
carbon sources (glucose, fructose, mannose, galactose, raffinose) (Sundström et al., 
1993). Similarly, after TKT overexpression, yeast cells suffered a growth defect only on 
fermentable carbon sources, which suggests a regulatory mechanism between glycolysis 
and the non-oxidative PPP (Sundström et al., 1993). Further, the TKT knock-out (KO) 
yeast did not grow without aromatic amino acids (tryptophan, tyrosine, phenylalanine) 
which was explained by the fact that E4P, a product of TKT, is a necessary precursor for 
their synthesis (Sundström et al., 1993). Cases of TKT deficiency in humans are not 
known, because mutations are probably lethal at the embryonic stage (reviewed in 
Stincone et al., 2014). Single TKT KO mice suffered from weight reduction and fewer 
animals were obtained in the progeny than expected, suggesting that half of the TKT 
single KO embryos died (Xu et al., 2002). No double KO animals were obtained in their 
progeny which further confirms essentiality of the gene for mammals (Xu et al., 2002). 
Similar conclusions were drawn when TKT RNAi was induced in mammalian oocytes, 
since meiosis arrested at metaphase I stage, and rearrangements of meiotic spindle and 
chromosomes were observed (Kim et al., 2012). Interestingly, mRNA levels of 
ribokinase and phosphoribosyl pyrophosphate synthetase decreased after TKT RNAi, but 
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expression of the other PPP enzymes was unchanged (Kim et al., 2012). The phenotype 
was partly rescued by supplementation with R5P, which again suggests some kind of 
feedback control but is very difficult to pinpoint precisely how this occurs (Kim et al., 
2012). 
In addition to TKT, the human genome encodes TKT-like1 (TKTL1) and TKT-like2 
(TKTL2) genes (Coy et al., 1996). Contradictory results were obtained for TKTL1 
enzymatic activity (Coy et al., 1996; Meshalkina et al., 2013; Schneider et al., 2012), but 
it received increased attention recently, since it is specifically overexpressed in tumour 
cells. The mRNA levels were elevated only in 10% cases but the protein level was 
increased in 40% of cancer tissues tested (Staiger et al., 2006b). The relevance for tumour 
growth was examined and it was confirmed that supplementation with thiamine 
supported further growth (Boros et al., 1997; Comín-Anduix et al., 2001). On the 
contrary, when oxythiamine, an analogue of TPP was applied as a TKT inhibitor, cell 
cycle arrest occurred and cells stopped growing (Rais et al., 1999). TKTL1 expression 
was studied specifically in gastric cancer and was shown to correlate with invasive colon 
and urothelial tumours’ size and poor patient outcome, thus TKTL1 was suggested as a 
potential biomarker for cancer (Diaz-Moralli et al., 2011; Langbein et al., 2006; Staiger 
et al., 2006b). A high-throughput screen of 64,320 compounds for new TKT inhibitors 
was performed, testing selective enzyme inhibition and inhibition of cell proliferation, 
resulting in two compounds being selected as promising hits with good pharmacokinetic 
properties (Du et al., 2004). However, no further reports on their follow up have emerged 
to date. 
TKT was also investigated as a potential drug target, in the malaria parasite Plasmodium 
falciaprum, where the enzyme appears to be hexameric (Joshi et al., 2008). Its role is also 
uncertain given the lack of transaldolase in Plasmodium sp. (Bozdech and Ginsburg, 
2005). The purified enzyme was inhibited by p-hydroxyphenylpyruvate at low 
concentrations in noncompetitive manner with F6P and competitive with 
hydroxypyruvate, which differs from a previous report from yeast where the inhibition 
was competitive to both donors (Joshi et al., 2008; Solovjeva and Kochetov, 1999). 
The metabolomics analysis presented in Chapter 3 indicates that the non-oxidative PPP 
is active in amastigote L. donovani, as the levels of the metabolites are comparable to 
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promastigotes. The analysis with labelled glucose and ribose in Chapter 4 confirmed a 
substantial flux in the PPP in promastigote L. mexicana, which may be potentially 
increased in response to substrate availability, or increased oxidative stress as reported 
previously (Maugeri et al., 2003). In this chapter I focus on TKT in L. mexicana, I studied 
various aspects of the enzyme and scrutinized its utilisation as a potential drug target. 
TKT was also studied in other trypanosomatids e.g. T. brucei and L. mexicana. As 
mentioned earlier, TKT is not expressed in bloodstream T. brucei at all (Cronín et al., 
1989; Stoffel et al., 2011). Double KO in procyclic stage was generated and the obtained 
cell line showed no growth defect or any morphological deformation (Stoffel et al., 
2011). When examined by LC-MS metabolomics, significant changes in glycolysis and 
PPP intermediates were detected, indicating that metabolism was altered but without 
effect on cell growth in rich media. TKT in trypanosomatids contains a well defined 
peroxisomal targeting signal (PTS) enabling import into glycosomes and about 10% of 
the protein is located inside glycosomes in procyclic T. brucei (Stoffel et al., 2011), 
whereas it is 30% in promastigote L. mexicana (Veitch et al., 2004), and 20% in 
epimastigote T. cruzi (Maugeri and Cazzulo, 2004). Two independent high-throughput 
proteomic studies found TKT in glycosomes of only procyclic but not bloodstream T. 
brucei (Colasante et al., 2006; Vertommen et al., 2008). Another study of glycosomal 
proteome using tagged PEX13.1 enrichment followed by SILAC proteomics detected 
signal for TKT in procyclic T. brucei albeit at a level failing to reach statistic significance 
(Guther et al., 2014).  
A cell line was created with both alleles of TKT replaced by antibiotic cassettes (Δtkt) in 
promastigote L. mexicana (Wildridge, 2012). The cells did not demonstrate any growth 
phenotype nor any morphological deformation compared to WT. The Δtkt cell line was 
more sensitive to pentamidine but not to methylene blue, a compound used to evaluate 
oxidative stress response. Δtkt cells consumed the same amount of glucose as WT when 
assessed over 4 days of cultivation, but produced probably less metabolic end products 
(Wildridge, 2012). Whereas medium of WT cultures is acidified after few days of 
cultivation and changes its colour (due to presence of phenol red), medium of Δtkt cells 
changed very little, suggesting much lower production of acidic metabolic end products, 
but no further analysis was performed. Targeted metabolomic analysis was performed in 
collaboration with the Metabolomics Platform in Toulouse showing significant changes 
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in intermediates of glycolysis and the PPP, corresponding to expected consequences of 
the deletion (Wildridge, 2012). I continued with deeper and wider characterisation of the 
Δtkt cell line, especially because infectivity and effects on the amastigote stage were not 
tested and methodology in metabolomics progressed extensively at Polyomics Glasgow, 
allowing further and untargeted analyses. 
5.2 Aims 
 Test sensitivity of Δtkt cell line to oxidative stress, antileishmanial drugs 
 Test infectivity of Δtkt to macrophages and mice 
 Scrutinize changes in metabolism of Δtkt (untargeted LC-MS, LC-MS with U-
13C-glucose, GC-MS, central glycolytic flux) 
 Measure PPP flux in WT promastigote L. mexicana 
 Prepare GFP-TKT  constructs with alternations to the C-terminus and assess their 
subcellular localisation 
 Assess functions of TKT in the cytosol and in glycosomes. Prepare cell lines 
expressing TKT solely in the cytosol or glycosomes and compare their growth, 
sensitivity to oxidative stress, metabolomes. 
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5.3 TKT is an essential enzyme and a possible drug target in Leishmania 
5.3.1 TKT knock-out and complemented cell lines 
First, I compared growth of WT, Δtkt and Δtkt + TKT re-expressor cell lines under 
standard conditions in Homem medium. No significant difference in growth is observed 
between these cells (Fig 5.1A). 
Figure 5.1. Growth curves of TKT cell lines. n = 3, error bars represent standard 
deviation. A – Growth of WT, Δtkt, and Δtkt + TKT cell lines. B – Growth of WT, 
Δtkt, WT + GFP-TKT, and Δtkt + GFP-TKT cell lines. 
 
5. Transketolase 
 
115 
 
 
Following from this, I used a plasmid from the pNUS series (http://www.ibgc.u-
bordeaux2.fr/pNUS/index.html (Tetaud et al., 2002)) for episomal overexpression in 
Leishmania, and prepared a construct expressing TKT fused with a green fluorescent 
protein (GFP) to its N-terminus. The successful transfection with the plasmid was 
verified by fluorescence microscopy, the obtained cell lines were called WT + GFP-TKT 
and Δtkt + GFP-TKT, respectively (Fig 5.2).  
Figure 5.2. Validation of cell lines expressing GFP-TKT. A - WT + GFP-TKT cell 
line. Antibody against triosephosphate isomerase (TIM) was used as a glycosomal 
marker. B – Δtkt + GFP-TKT cell line. 
Enzyme activity of TKT was measured in all of these cell lines, especially because the 
fusion with GFP may affect dimerisation and proper function of the enzyme. The enzyme 
assay using Xu5P and R5P as substrates was used as described by Bergmeyer (Brin, 
1974), where coupling with TPI and GA3PDH leads to consumption of NADH, which 
can be easily measured as change in absorbance at λ=340 nm. An enzyme activity 
comparable to a previous report was detected in WT cell line (Maugeri et al., 2003), no 
TKT enzyme activity was detectable in Δtkt, whereas the activity (twice that of WT) was 
rescued in Δtkt+TKT, probably due to higher expression of the gene from that locus (Tab 
5.1). Enzyme activity was even higher in cells expressing GFP-TKT, but over-expression 
is expected from the construct and it definitely confirmed that the enzyme function is not 
compromised by the GFP tag (Tab 5.1). TKT activity in axenic amastigotes was four 
times lower than in promastigotes (31 versus 113 mU, respectively). 
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 activity (nmol/min/107 cells))  
WT 2.9 7.22 
Δtkt -0.19 0.1 
Δtkt+TKT 6.16 11.08 
WT + GFP-TKT 14.16 14.16 
Δtkt + GFP-TKT 24.56 29.86 
Table 5.1 TKT activity measured in cell extracts of various cell lines. Two biological 
replicates are shown. 
5.3.2 Viability and oxidative stress sensitivity 
In accordance with previous observations, Δtkt promastigote cells grow in rich Homem 
medium under optimal conditions as fast as WT cells. However, the deletion of the gene 
may become more apparent under non-optimal conditions, for example under various 
types of stress. 
Sensitivity to oxidative stress was tested using methylene blue, which is commonly used 
for experiments with bloodstream T. brucei (Boda et al., 2005). However, in addition to 
NADPH depletion (Kelner and Alexander, 1985), it probably interferes with the 
respiratory chain in not completely defined manner and was reported even to support 
growth under specific conditions (Rojas et al., 2012; Schirmer et al., 2003). No 
significant difference was detected in sensitivity to methylene blue (WT EC50 = 2.36± 
0.422 µM; Δtkt EC50 = 1.88±0.155 µM; p=0.137), which corresponds with the previous 
observation (Wildridge, 2012). A more direct test for oxidative stress involves an Alamar 
Blue Assay with glucose oxidase, an enzyme which consumes glucose and constitutively 
produces H2O2, a reactive oxygen species which is very unstable itself (adapted from 
Allmann et al., (2013)). When using this assay, Δtkt cell line was twice as sensitive as 
WT, while Δtkt+TKT partly reverted to WT levels (Fig 5.3; Tab 5.2). 
5. Transketolase 
 
117 
 
 
Figure 5.3. Alamar Blue Assays to test sensitivity to oxidative stress.Whereas 
methylene blue (A) did not show any difference, Δtkt cells were two times more 
sensitive to glucose oxidase than WT (B). Fluorescence indicated on y axis 
correlates with viability of cells. 
 EC50 [mU/ml] p-value 
WT 2.32 ± 0.33  
Δtkt 1.18 ± 0.27 0.01 
Δtkt + TKT 1.53 ± 0.14 0.02 
Table 5.2. Alamar Blue Assay results for GOX sensitivity, n=3. 
The clinically relevant stage of Leishmania is the amastigote, thus it was of interest to 
test the effects of TKT depletion in the amastigote stage. Δtkt cells transformed into 
amastigotes under increased temperature and low pH, when assessed by microscopy, but 
the cells never started dividing and growing. Even after repeated attempts, I never 
obtained a growing culture of Δtkt amastigote cells. Such an observation is interesting in 
indicating a possibly essential role for TKT to amastigote cells. Even though WT cells 
transformed into amastigotes and continued to grow, Δtkt + TKT cell line had the same 
phenotype as Δtkt, thus no conclusions can be made. Moreover, it can be disputed that 
axenic cultures are artificial and not representative, thus I proceeded to infection assays. 
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5.3.3 Macrophage infections 
Following from the previous observations, I wanted to assess infectivity of Δtkt cells 
towards macrophages. THP1 cells were activated with PMA, incubated with stationary 
phase parasites and infection was estimated at different time points as percentage of 
macrophages infected with amastigotes.  
Δtkt cells seem to be around half as infective towards macrophages as WT, although 
variability is high and the results are not always statistically significant (depending on 
individual experiment). Two representative examples are shown in Fig 5.4, but additional 
experiments across different conditions yield less conclusive outputs. Infectivity of Δtkt 
+ TKT cell line seems to be rescued but with overall high variability. Altogether, the 
results are ambiguous and inconclusive. 
Figure 5.4. Infectivity towards macrophages calculated as proportion of 
macrophages infected with Leishmania, error bars represent standard deviations. A 
– 24 hours of cultivation, MOI = 5, n = 4, p = 0.018. B – 4 days of cultivation, MOI = 
10, n = 4, p = 0.091 
5.3.4 Mice infections 
The experimental setting closest to real leishmaniasis is infection of mice models and 
examination of skin lesion development. It is known that ability of Leishmania to infect 
decreases after prolonged in vitro cultivation (Pescher et al., 2011), hence first I infected 
BALB/c mice with my Leishmania strains, culled the animals after 3 months, obtained 
the popliteal lymph nodes from which parasites were recovered. Afterwards, I used these 
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parasites for an in vivo infectivity study. 2 x 106 cells (WT, Δtkt, and Δtkt + TKT cells) 
were injected into foot pads of four BALB/c mice each. Subsequently, size of the foot 
pads was measured weekly, reflecting swelling and development of skin lesions. Mice 
infected with WT Leishmania developed 4 mm lesions in 13 (20 for the last) weeks, 
whereas no obvious lesions developed in mice infected with Δtkt parasites even after 23 
weeks and no parasites were recovered from the lymph nodes. Most importantly, re-
expression of TKT in Δtkt + TKT rescued the infectivity and the skin lesions reached 4 
mm in 15 (21 for the last) weeks (Fig 5.5). This experiment confirms that infectivity was 
decreased due to absence of TKT and that TKT is essential for infectivity and amastigote 
survival in vivo.  
Figure 5.5. Mice infections. Mice were injected into foot pads with 2 x 106 
Leishmania cells. Size of foot pads was measured weekly, each point represents 
average of 4 mice infected, error bars represent standard deviations. 
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5.3.5 Screening for TKT inhibitors 
5.3.5.1 Common Leishmania drugs  
One of the persisting questions in parasitology is mode of action of the drugs used to kill 
the parasites and treat the diseases. For most drugs used against trypanosomatids, their 
targets inside cells and modes of action are unknown (Croft et al., 2006; Horn and 
Duraisingh, 2014). Based on the previous experiments, TKT is clearly essential in the 
amastigote stage and thus a potential drug target. An arising question, therefore, is 
whether it is targeted by any of the drugs currently in use. To test this possibility, Alamar 
Blue Assays were performed using the common antileishmanial drugs (AmB, 
paromomycin, pentamidine, antimonials, miltefosine). However, no difference in 
sensitivity was detected for antimonials between WT and Δtkt and for AmB, miltefosine, 
paromomycin, and pentamidine, Δtkt was slightly more sensitive (Fig 5.6; Tab 5.3). We 
can conclude that TKT is not targeted by any of the drugs tested and its depletion 
increases sensitivity of the cells towards some of the compounds, probably due to 
increased overall stress. 
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Figure 5.6. Alamar Blue Assays with common antileishmanial drugs and 
oxythiamine. Effects of drugs commonly used against Leishmania were tested 
against promastigote WT, Δtkt, and Δtkt + TKT cell lines. The efficacy was similar or 
stronger on Δtkt than WT. Oxythiamine did not inhibit growth until high 
concentrations were reached; n = 2. 
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 WT Δtkt Δtkt + TKT 
fold change 
Δtkt/WT 
AmB 0.0647 0.02945 0.03619 0.46 
miltefosine 19.75 5.59 6.166 0.28 
pentamidine 1.404 0.5993 0.6966 0.43 
paromomycin 122.9 74.04 54.21 0.60 
Sb+3 98.46 77.77 82.68 0.79 
Table 5.3. EC50 values for Alamar Blue Assays from Fig 5.6. Values are averages of 
two biological replicates, [µM], n = 2. 
5.3.5.2 Oxythiamine 
Another compound associated with TKT is oxythiamine (Fig 5.7). It is an analogue of 
thiamine, a precursor of TPP, a cofactor of TKT, and was suggested and tested with 
promising results as a treatment against cancer, due to PPP inhibition aimed at TKT (Rais 
et al., 1999). On the other hand, when tested on P. falciparum, substantial inhibition was 
obtained only in thiamine-depleted medium and most importantly, the authors explain 
the decrease in growth by inhibition of pyruvate and oxoglutarate dehydrogenases, other 
TPP-dependent enzymes (Chan et al., 2013). Thus, it was of interest to examine the 
effects of oxythiamine on WT and TKT-depleted Leishmania cells. However, no 
difference was observed between the two cell lines and the EC50 values measured are 
relatively high (WT EC50 = 25.82 mM, Δtkt = 44.54 mM, Δtkt + TKT = 43.64 mM) (Fig 
5.6). It would be interesting, in the future, to perform the experiment with medium low 
or free of thiamine. 
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5.3.5.3 Thiamine analogues 
Thanks to collaboration with Dr. Fraser Scott from the University of Strathclyde, we 
obtained a series of thiamine analogues (Lünse et al., 2014, and unpublished) (Fig. 3.7). 
The effect of these compounds was tested on WT amastigote Leishmania by Alamar Blue 
Assay. Any of the compounds tested did not show inhibition of growth within the range 
used and EC50 values could not have been determined (Fig. 3.8), thus no further 
experiments were carried forward.  
Figure 5.7. Structures of thiamine, oxythiamine and compounds tested as thiamine 
analogues 1 – 8. 
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Figure 5.8. Alamar Blue Assays with thiamine analogues. Alamar Blue Assays were 
performed with compound analogues to TPP on WT amastigote L. mexicana, 
starting from 100 mM with serial dilutions. The compounds are labelled 1 – 8, AmB 
was used as a control. 
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5.4 Impacts of TKT deletion on metabolism 
A metabolomic analysis of the Δtkt promastigote L. mexicana cell line was performed 
previously (Wildridge, 2012), but the analysis was targeted and provided quantification 
of relatively low number of metabolites, albeit focusing on those most closely associated 
with the glucose metabolising pathways directly associated with TKT. Since untargeted 
LC-MS metabolomics of trypanosomatids is well established at Glasgow Polyomics, it 
was of interest to analyse Δtkt Leishmania by the untargeted method, allowing 
identification of hundreds of metabolites, both directly related to the pathways associated 
with TKT, but also extending into the wider metabolic network. Moreover, considering 
the intriguing phenotype observed, when promastigotes show no defect but amastigotes 
are not viable, it was of interest to use metabolomics to analyse the changes in 
metabolism. Although focusing on promastigotes which are more amenable to analysis, 
the alterations in one stage can allow extrapolation of knowledge to other stages, pointing 
to why the deletion is lethal for amastigotes. Later, an RNAseq experiment was 
performed, in order to relate changes in metabolism to those in gene expression, and these 
are discussed specifically in chapter 3.4.3, but data pertinent to observations within the 
metabolomics experiments are discussed where appropriate and useful here. 
5.4.1 Changes in glycolysis and the PPP detected by LC-MS 
We performed untargeted LC-MS metabolomics analysis of WT, Δtkt, and Δtkt + TKT 
cells. Identifications of most of the metabolites are putative and relative changes in 
abundance are detected while absolute quantification of metabolites is not feasible with 
the methodology used. It is indicated where standards were available for confirmation of 
the identity, otherwise the identification is predicted based on retention time and mass 
detected.  
The general overview of the LC-MS metabolomics results shows that a substantial 
proportion of the most changing metabolites are saccharides and metabolites directly 
connected with sugar metabolism (Fig 5.9). Visualisation of the overall data reflects that 
the changes observed in Δtkt are reverted back towards WT levels in the re-expressor 
cell line (Fig 5.9). Among the metabolites detected, I searched for those which 
correspond to intermediates of glycolysis and the PPP and the changes detected are listed 
in Tabs 3.4 and 3.5 and Fig 5.10.  
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Figure 5.9. Volcano plots showing changes in Δtkt relative to WT as detected by 
LC-MS metabolomics. In to top plot metabolites directly connected with sugar 
metabolism are highlighted in orange. The bottom plot shows overall changes in 
metabolome in Δtkt and re-expressor Δtkt + TKT relative to WT.  
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In glycolysis, glucose accumulates while all of the subsequent intermediates are depleted. 
Those metabolites highest in the pathway (hexose phosphates) decrease by less than two 
fold, whilst subsequent metabolites are diminished by progressively larger amounts, 
resulting in PEP being seven times decreased in Δtkt compared to WT cells. Pyruvate is 
not changed, but it can be supplied from additional routes or taken up from the medium. 
In Δtkt + TKT, most of the metabolites reverted back to WT levels, confirming rescue of 
the TKT deletion phenotype.  
In the PPP, the changes observed correspond with expectations associated with TKT 
deletion. The metabolites upstream from TKT, 6PG and pentose phosphates are 
accumulated, 5 and about 200-fold, respectively, whereas S7P, a metabolite downstream 
from TKT, is three fold decreased (Fig 5.10). The pentose phosphates are massively 
accumulated and subsequently drive the flux into additional reactions resulting in 
production of metabolites not detected in WT, such as O8P, alcohol derivatives of 
pentoses, or alcohol derivatives of pentose phosphates. 
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glycolysis Δtkt Δtkt + TKT 
p-value (Δtkt/  
WT) 
glucose 2.6 1.13 0.022 
G6P 0.75 0.77 NS 
F1,6bP 0.42 0.53 0.002 
GA3P 0.2 0.25 0.023 
glycerol-3P 0.2 0.59 3 x 10-7 
1(2),3bPG increased ND - 
2PG 0.17 0.65 1 x 10-4 
PEP 0.14 0.67 2 x 10-4 
pyruvate 0.92 1.75 NS 
Table 5.4. Metabolites of glycolysis as detected by LC-MS metabolomics. Changes 
in putative metabolites of glycolysis, numbers indicate relative abundance in Δtkt 
and Δtkt + TKT compared to WT, metabolites highlighted in bold were confirmed 
with standards, p-values indicated are for change between WT and Δtkt. In case of 
bis-phosphoglycerate, no peak was detected in WT but a substantial peak in Δtkt, 
thus it cannot be quantified. ND = not detected, NS = not significant, p>0.05. 
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Table 5.5. Metabolites of the PPP as detected by LC-MS metabolomics. Changes in 
putative metabolites of the PPP, numbers indicate relative abundance in Δtkt and 
Δtkt + TKT compared to WT, metabolites highlighted in bold were confirmed by 
standards, p-values indicated are for change between WT and Δtkt. If no value is 
determined, no peak was detected in WT but a substantial peak in Δtkt, thus it 
cannot be quantified. ND = not detected, NS = not significant, p>0.05. 
  
PPP Δtkt Δtkt + TKT p-value (Δtkt / WT) 
6PG 5.23 0.58 3 x 10-4 
R5P 212.06 0.81 4 x 10-6 
S7P 0.31 0.77 0.003 
O8P 230.02 0.77 8 x 10-5 
N9P 0.26 0.77 6 x 10-4 
ribose 0.7 0.81 NS 
xylulose increased ND - 
ribitol 5P increased ND - 
xylitol 210 0.58 1 x 10-5 
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Figure 5.10. Scheme of glycolysis and the PPP with indicated changes as detected 
by LC-MS metabolomics. Red arrows and numbers indicate accumulation in Δtkt 
relative to WT and blue colour indicates relative decrease. Where no numbers are 
given, the peak shapes were not good enough to be quantified. 
5.4.2 GC-MS metabolomic analysis  
Since LC-MS approach does not enable detection of all sugars and separation of isomers, 
in our case most importantly G6P and F6P or the separate pentose phosphates, we 
proceeded with GC-MS analysis, which provides precise identification of lower numbers 
of metabolites. The metabolites detected and their relative changes in Δtkt are listed in 
Appendix A2. These metabolites are mapped to the scheme of glycolysis and the PPP 
shown in Fig 5.11. The general trends overlap with observations from LC-MS, but there 
are some differences in specific metabolites. Likewise, glucose is accumulated but the 
other intermediates from glycolysis are depleted, with an exception of fructose 1,6-
bisphosphate (F1,6bP), which is here seven times increased compared to WT. Levels of 
G6P and F6P are comparable (0.46 versus 0.5), indicating that there is high rate of 
5. Transketolase 
 
131 
 
 
interconversion between them by PGI. Their labelling profiles are probably also similar 
(shown in Fig 5.14). 
 The PPP intermediates are also increased, Ru5P twice as much as R5P. Pentoses in 
general accumulated substantially: arabinose, ribose and xylulose being nominally 80, 
45 and 890-fold increased, respectively. Alcohols derived from sugars were also 
substantially elevated, confirming the reduction reactions observed in the previous LC-
MS experiment. Dulcitol, an alcohol derived from galactose, is 10-fold higher in Δtkt 
cells compared to WT and xylitol levels enhanced almost three fold (Fig 5.11). Moving 
to the transcriptome data discussed later, there are two outstanding changes in gene 
expression detected in this part of metabolism. The first is a two-fold increase in pentose-
5-phosphate isomerase while the mRNA of xylulose reductase is two-fold decreased. The 
reductase turns xylulose to xylitol while consuming NADPH. Such a change may be 
responsible for high accumulation of xylulose (nominally 890-fold over WT) observed. 
It is tempting to speculate that it could be a feedback reaction due to depletion of 
NADPH. 
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Figure 5.11. Metabolites of glycolysis and the PPP as detected by GC-MS 
metabolomics. All identifications are based on matches with standards. Red arrows 
and numbers indicate accumulation in Δtkt relative to WT, and blue colour indicates 
relative decrease. If no value is determined, the metabolite was detected in WT but 
not in Δtkt, suggesting decrease. 
5.4.3 Central carbon flux 
The drop in all glycolytic intermediates post glucose implies that the whole flux through 
glycolysis may be decreased in the Δtkt cells. To test directly this flux we sought to 
quantify inputs and outputs of the pathway, i.e. consumption of glucose and production 
of metabolic end products. Consumption of glucose was measured as a change of 
concentration in Homem medium containing 1 mM glucose (plus about 0.5 mM present 
within 10% FCS) in a fast growing culture over 24 hours. Whereas WT cells consumed 
3.9 (±0.3) nmol glucose/min/108 cells, only 3.2 (±0.3) nmol/min/108 cells were consumed 
by Δtkt cells (p<0.05; Fig 5.12). The RNAseq experiment (Section 3.4.3) revealed that 
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mRNA levels of all three genes for glucose transporters present in the Leishmania 
genome decreased to 75%, which may contribute to the decrease in glucose consumption 
observed (Appendix B3).  
In order to assess the production of metabolic end products, a metabolomic analysis of 
spent media was performed over 4 days of cultivation. The main metabolites produced 
were succinate, malate and alanine, which increased in WT over four days 12, 7 and 3.5 
fold, respectively (Fig 5.13). In the Δtkt cells, alanine was consumed (30% of the starting 
concentration being used) instead, whereas levels of succinate and malate increased only 
2 and 4 fold, respectively. These experiments point to a significant decrease in the central 
carbon metabolic flux in the Δtkt cell line.  
Figure 5.12. Glucose consumption by WT and Δtkt cells over 24 hours, n = 4. 
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Figure 5.13. Accumulation of main metabolic end products in spent media over 4 
days as determined by LC-MS metabolomics. A – succinate, B – malate, C – 
alanine; n = 4, error bars represent standard deviation. 
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5.4.4 U-13C-glucose metabolomic analysis reveals changes in TCA cycle 
metabolism  
The primary products of glucose, pyruvate from glycolysis and malate from the succinate 
fermentation pathway, enter the TCA cycle. In spite of the substantial decrease in 
abundance of glycolytic intermediates, only mild alternations were observed in 
metabolites of the TCA cycle (Tab 5.6). TCA cycle intermediates, however, arise from 
sources other than glycolysis and without using isotope distribution patterns the 
derivation of intermediates cannot be ascertained. To understand the situation better, a 
further LC-MS metabolomics analysis was performed, using cells grown in medium 
containing labelled U-13C-glucose mixed with unlabelled glucose in a 1:1 ratio.  
Table 5.6. Metabolites of the TCA cycle as detected by LC-MS metabolomics. 
Changes in putative metabolites of the TCA cycle, numbers indicate relative 
abundance in Δtkt and Δtkt + TKT compared to WT, metabolites highlighted in bold 
were confirmed with standards. p-values indicated are for change between WT and 
Δtkt. NS = not significant, p>0.05. 
The profile of hexose 6-phosphates (a sum of G6P and F6P) in WT cells shows labelling 
from zero to all six carbons with all variants in between which originate during carbon 
shuffling in the PPP (Fig 5.14). The labelling pattern is completely different in Δtkt cells, 
where only zero and six carbon labelled molecules were detected, consistent with 
disruption of the PPP. Similarly, the proportion of labelling in PEP and pyruvate in Δtkt 
is substantially reduced when compared to WT.  
TCA cycle Δtkt Δtkt + TKT p-value (Δtkt / WT) 
acetyl-CoA 1.02 0.66 NS 
citrate 1.38 0.56 NS 
2-oxoglutarate 0.51 0.31 NS 
succinate 0.35 1.64 0.001 
malate 0.68 1.27 5 x 10-5 
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Figure 5.14. Labelling of metabolites of glycolysis and the PPP as determined by 
LC-MS metabolomics when 50% of glucose is U-13C-glucose. The labelling profile is 
shown for each metabolite detected. Colour codes for labelling are the same as 
indicated for hexose phosphates, coloured proportions of each bar represent the 
relative abundance. Histograms reflect proportion of specific types of labelling in 
WT in blue and Δtkt in orange.   
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The labelling experiment provided especially interesting results for the TCA cycle 
intermediates. Whereas 50 – 60% of the intermediates are labelled to some extent (one 
to five carbons) in WT, this total sum dropped below 10% in Δtkt (Fig 5.15). This pattern 
is consistent for succinate, oxoglutarate, pyruvate, glutamate and aspartate. The majority 
of each of these metabolites is unlabelled indicating they derive from precursors other 
than glucose. This explains why TCA cycle intermediates do not diminish to the same 
extent as those of the glycolytic pathway in Δtkt cells, as their derivation involves other 
carbon sources.  
Another intriguing observation arising from this experiment is the labelling pattern of 
6PG, where the five carbon labelled species represent 30% of the total in Δtkt cells, a 
surprisingly large proportion (Fig 5.14). A likely explanation is that the accumulation of 
Ru5P in the knockout cells causes a change in equilibrium driving the 6PGDH reaction 
in its “reverse” direction, causing CO2 assimilation and NADPH consumption, instead 
of production. The reverse reaction of 6PGDH has been reported previously in sheep 
liver and Candida utilis (Berdis and Cook, 1993; Villet and Dalziel, 1969), but I did not 
succeed in measuring the enzyme activity in the opposite direction from cell extracts 
(data not shown).  
Figure 5.15. Labelling pattern of selected metabolites from LC-MS metabolomics 
analysis with 50% U-13C-glucose. The grey part represents molecules with no 
carbons labelled, blue one carbon, purple two carbons, green three carbons, brown 
four carbons and orange five carbons labelled. Numbers indicate sum of all types of 
labelling in WT. Natural abundance of 13C is approximately 1%. 
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5.4.5 Amino acid and fatty acid metabolism  
 As described above, the TCA cycle in the Δtkt cell line appears to be fed primarily by a 
carbon source other than glucose. Amino acids and fatty acids are both common carbon 
sources in various cell types. Hence, I analysed the metabolomics data derived from spent 
media specifically to assess depletion of amino acids. Aspartate and glutamate are two 
amino acids previously shown to be incorporated into the TCA cycle intermediates by 
WT cells to limited extent (Saunders et al., 2011). However, neither of these substrates 
was consumed more by Δtkt than WT (rather the opposite appeared to be the case on day 
two (Fig 5.16)). The same is true for other amino acids, all of them either being consumed 
to the same extent by both cell lines or actually less by Δtkt (Fig 5.16, Appendix A6). It 
should be noted, that these numbers indicate the relative amounts of each amino acid 
detected in the media rather than uptake of these amino acids per se. In contrast, in spite 
of no apparent increase in their acquisition from the medium, most of the amino acids 
were significantly accumulated inside Δtkt cells. Intracellular tryptophan and tyrosine 
levels accumulated most, about 7 fold and aspartate rose almost 3 times (Tab 5.7). This 
correlates with data from the RNAseq experiment, where six different genes for amino 
acid transporters were detected to be two fold increased at the RNA level (whereas one 
was 5 fold diminished in abundance) (Appendix B3). One of these genes is orthologous 
to a lysine transporter described in L. infantum (Inbar et al., 2012) and two genes are 
orthologous to an arginine permease AAP3 of L. donovani (Shaked-Mishan et al., 2006). 
All of the amino acids detected reach the same or higher levels in Δtkt as in WT (with an 
exception of arginine – Tab 5.8) indicating that they are not utilised more for the TCA 
cycle incorporation than in WT. In addition, no specific amino acid degradation pathway 
was noted as being upregulated significantly either in the metabolomics or the RNAseq 
analyses. 
The first step in amino acid degradation is transamination producing respective 
ketoacids. Relatively few ketoacids were detected, but several were slightly increased in 
Δtkt, and 4-hydroxyphenylpyruvate, the product of tyrosine was more than 4 times 
higher. Indolepyruvate is detected at higher levels in the spent medium of Δtkt, 
suggesting that ketoacids are made and secreted from the cells rather than used as source 
of carbon (Fig 5.17; Tab 5.7). Amino acid metabolism was speculated to be connected 
with immune system evasion, either by depleting the host of amino acids, or by producing 
5. Transketolase 
 
139 
 
 
ketoacids or other intermediates directly affecting host’s immune response (Westrop et 
al., 2015). 
Altogether, no straightforward conclusions can be made about amino acid metabolism. 
They are accumulated inside the cells, but we cannot determine if it is due to higher 
uptake or lower utilisation. The ambivalence is increased by peptides, since there are 
numerous peptides of undefined composition present in the media, which become 
degraded and contribute to the amino acid pool in the media. 
Even though fatty acids were shown not to be used in the TCA cycle by WT 
promastigotes, they are used by amastigotes and it was shown previously that under non-
optimal conditions Leishmania adapt and change their metabolism (Rodriguez-Contreras 
and Hamilton, 2014). However, not a single metabolite from the list of fatty acids or all 
lipids was consumed more by Δtkt than WT (Fig 5.18). 
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Figure 5.16. LC-MS metabolomics of spent media on days 1 to 4. The most 
consumed amino acids are shown. White – fresh medium, black – WT, grey – Δtkt. 
Error bars represent standard deviation, n=4. 
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Figure 5.17 LC-MS metabolomics of spent media, abundance of tryptophan and its 
ketoacid, indolepyruvate. White – fresh medium, black – WT, grey – Δtkt. Error bars 
represent standard deviation, n=4. 
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Figure 5.18. Heatmap of lipids in the spent medium over four days, as determined 
by LC-MS metabolomics. The first column shows fresh medium and the following 
columns spent medium on days 1 to 4 in WT and Δtkt, respectively. Yellow colour 
indicates no change, blue decrease and red increase. No big differences were 
observed between the two cell lines.
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Table 5.7. Intracellular levels of amino acids and ketoacids as determined by LC-MS metabolomics. Numbers indicate relative abundance in 
Δtkt and Δtkt + TKT compared to WT. ND = not detected, NS = not significant, p>0.05, * substantial quantities in the spent medium
Intracellular amino acids ketoacids 
 Δtkt Δtkt + TKT 
p-value 
(Δtkt/WT) 
 Δtkt Δtkt + TKT 
p-value 
(Δtkt/WT) 
Tryptophan 7.41 0.52 0.001 indole-3-pyruvate ND * ND - 
Tyrosine 6.36 2.68 0.002 4-hydroxyphenylpyruvate 4.58 2.84 0.04 
Leucine 2.41 1.52 2 x 10-5 3-methyl-2-oxopentanoate 1.74 3.19 0.05 
Histidine 2.31 1.53 2 x 10-4 urocanate 1.67 1.22 NS 
Valine 1.98 1.29 4 x 10-5 
3-Methyl-2-oxobutanoic 
acid 
1.2  1.81  NS 
Glutamine 1.5 0.37 NS 2-oxoglutaramate 1.61 0.8 NS 
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.  
Intracellular amino acids 
 Δtkt Δtkt + TKT 
p-value (Δtkt / 
WT) 
Phenylalanine 3.96 2.56 3 x 10-4 
Methionine 3.56 1.34 4 x 10-4 
Serine 3.2 0.91 2 x 10-4 
Aspartate 2.83 0.72 2 x 10-4 
Glycine 2.38 1.6 2 x 10-4 
Asparagine 2.09 0.72 0.002 
Threonine 1.42 1.45 0.04 
Lysine 1.28 1.62 NS 
Glutamate 0.93 0.53 NS 
Proline 0.92 0.62 NS 
Alanine 0.89 1.44 NS 
Arginine 0.49 0.98 0.002 
Table 5.8. Intracellular levels of amino acids as determined by LC-MS 
metabolomics. Corresponding ketoacids were not detected. Numbers indicate 
relative abundance in Δtkt and Δtkt + TKT compared to WT. ND = not detected, NS 
= not significant, p>0.05 
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5.5 Elucidating consequences of TKT deletion 
As discussed in the previous chapter, the metabolomics data indicate that TKT deletion 
caused not only perturbation in the PPP as expected, but also further changes in central 
carbon metabolism, which indicates cross-talk between pathways involved in glucose 
metabolism beyond the simple perturbations associated with loss of the individual 
reactions catalysed by TKT. These extended alterations to metabolism are extremely 
interesting, because they indicate that mechanisms of adaptation of metabolism and 
regulatory mechanisms in the parasites are operative. Hence, I strived to dissect the 
regulatory mechanism, since it may be a novel feedback control of glycolysis in 
Leishmania. 
5.5.1 Determination of the PPP flux in WT L. mexicana 
One explanation for the metabolic flux decrease in glycolysis could be the lack of the 
metabolites returning from the PPP loop which is disrupted. In order to test this 
hypothesis, metabolic flux in the PPP in WT promastigote L. mexicana was measured 
according to method published by Lee et al. (1998). Even though the PPP flux was 
estimated previously in promastigote L. mexicana (Maugeri et al., 2003), the authors 
followed incorporation of labelled glucose into nucleic acids, which may be inaccurate 
due to preferential utilisation of ribose as I showed in Chapter 4. I used a method when 
cells are grown in 100% 1,2-13C-glucose and any glucose used in glycolysis produces 
three carbon intermediates (for example pyruvate) that have two or no carbons labelled. 
Whereas if 1,2-13C-glucose is channelled into the PPP, one labelled carbon is cleaved off 
as a CO2 molecule by the 6PGDH reaction, and subsequent three carbon products have 
one or no carbons labelled. Thus, the proportion of different labelling in three carbon 
intermediates indicates the relative utilisation of glucose in glycolysis or the PPP (scheme 
shown in Fig 5.19). I assessed the labelling distribution in PEP and 3-PG and calculated 
that 14% of glucose enters the PPP, which is a number matching with previous reports 
(Maugeri and Cazzulo, 2004; Maugeri et al., 2003). Considering the overall glucose 
consumption established in chapter 3.3.3, an estimated 0.546 nmol of glucose enters the 
PPP in 108 cells/min. 
However, this calculation indicates that the disruption of the PPP in Δtkt is unlikely to 
account for the substantial decrease in glycolytic flux. Glucose consumption dropped by 
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25% and production of succinate and malate indicates an even bigger decrease. Most 
likely, such big drop is caused by a mechanism beyond a 14% reduction in glucose flux. 
A significant labelling with different numbers of carbons labelled was observed in hexose 
phosphates in WT cells in two different experiments, first using 50% U-13C-glucose and 
second, using 100% 1,2-13C-glucose (Fig 5.20). Presumably, this high proportion of 
different types of labelling comes from the carbon shuffling in the non-oxidative branch 
of the PPP, as can be verified by its disappearance in Δtkt. Both of these labelling patterns 
indicate a flux involving much more than 14% of total glucose. 14% represents the PPP 
net flux, but there may be high reverse flux in the non-oxidative branch, which would 
account for the variable labelling patterns in individual metabolites However, 
considering the nature of the TKT and TAL reactions, they do not operate in the 
unidirectional pathway usually depicted in textbooks, but rather act to exchange carbons 
between sugar phosphates in various combinations and order. 
Figure 5.19.The PPP flux. A - Scheme of experiment design for the PPP flux 
calculation. B - Equation used to calculate the PPP flux, PC – pentose cycle flux, m1 
– intensity of molecules containing one 13C substitution, m2 – intensity of molecules 
containing two 13C substitutions, adapted from Lee et al., (1998). 
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Figure 5.20. Labelling patterns of hexose phosphates, when 50% of U-13C-glucose 
(A) and 100% 1,2-13C-glucose (B) is used. Colour codes are the same. 
5.5.2 Metabolomics of Δtkt supplemented with fructose  
Another potential explanation for the observed decrease in glycolytic flux is inhibition 
of PGI. It is well established that PGI can by inhibited by 6PG in vitro (Milewski et al., 
2006; Tsuboi et al., 1971). High accumulation of 6PG in our study then sparks a 
hypothesis, that the glycolytic flux may be decreased as a consequence of PGI inhibition 
by 6PG. If it was the case, then feeding Δtkt cells on fructose should rescue the 
phenotype, since fructose can be phosphorylated by hexokinase and enter glycolysis 
downstream of PGI. I performed LC-MS metabolomics analysis with WT and Δtkt cells 
grown in the presence of either glucose or fructose. However, the results showed almost 
no difference in the metabolomics profiles of Δtkt cells irrespective of which sugar was 
used (Fig 5.21). Glycolytic intermediates were decreased to the same extent in both cases. 
The only metabolite which was partly rescued was mannogen, the storage polysaccharide 
of Leishmania. We can detect tetra-, penta- and hexamers of glucose, which consistently 
show the same trend and they all probably represent mannogen subunits (Fig 5.21 B). 
The mannogen pathway is shown in Fig 5.25, but it does not offer a clear explanation as 
to why the levels are higher in the presence of fructose. Thus, these results are not 
consistent with inhibition of PGI as the control mechanism of glycolysis in Δtkt. 
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Figure 5.21. WT and Δtkt cells grown solely in the presence of glucose or fructose. 
A – Overview of representative and most changing metabolites. B – Levels of sugar 
polymers, presumably all representing mannogen.  
5.5.3 RNAseq analysis of Δtkt 
To obtain an overall image of the changes happening at the RNA level, I performed 
RNAseq analysis of WT, Δtkt and Δtkt + TKT promastigote cells harvested in mid-log 
growth phase. We wanted to examine if diminished glycolysis correlated with reduced 
mRNA levels and if there were any other changes in mRNA abundance, which would 
explain the downstream effects in metabolism observed.  
Overall, there were about 150 genes which were two fold or more abundant in Δtkt cells, 
of which only 14 genes were overexpressed three times or more, and a similar number of 
genes was downregulated (Fig 5.22). Fig 5.23 shows relative changes in mRNA levels 
of glycolytic and PPP enzymes in Δtkt compared to WT. mRNA of most glycolytic 
enzymes dropped to about 70% of their WT levels, which does not seem to be enough to 
cause such a big perturbation to the metabolism. Since the ways by which glycolysis in 
Leishmania is controlled has not been investigated, no clear conclusions can be drawn, 
but no single enzyme stands out as offering control at the mRNA level. Enzymes of the 
PPP did not show substantial changes either; only ribose 5-phosphate isomerase mRNA 
was present at higher levels (almost two fold increased) while the other enzymes were 
slightly downregulated.  
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One of the biggest changes, a three-fold decrease, was observed for mannose 1-phosphate 
guanysyltransferase. This enzyme was not considered in the core mannogen biosynthesis 
pathway previously (Naderer et al., 2010), but because it produces GDP-mannose from 
mannose and GTP, it may be contributing to the polysaccharide biosynthesis 
substantially (Fig 5.24). Hence, this decrease in mRNA level may be responsible for the 
drop in mannogen in Δtkt. Whether this decrease relates directly to the loss of TKT, 
however, is not certa in, since mannogen levels were not restored when re-expressing 
TKT.  
Figure 5.22. Volcano plot of RNAseq analysis. 
mRNAs encoding three enzymes putatively involved in oxidative stress defence: 
ornithine decarboxylase, putative acetylornithine deactylase, and ascorbate peroxidise 
are increased by more than two fold, which might represent an adaptation to the increased 
oxidative stress related to diminished NADPH production. The RNAseq analysis did not 
offer a clear, simple explanation for the decrease in central metabolic flux in the Δtkt 
mutant, not indicate possible alternative carbon source usage. Control mechanisms in 
Leishmania do not, therefore, have their basis primarily in the levels of mRNA of 
metabolic enzymes, but further downstream, on translation or enzyme activity levels.  
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Figure 5.23. A scheme of glycolysis and the PPP with indicated changes in mRNA 
levels of the respective enzymes, values represent relative amount in Δtkt when 
compared to WT. The coloured arrows indicate changes in metabolites as detected 
by GC-MS metabolomics (from Fig 5.11).  
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Figure 5.24. Scheme of mannogen biosynthesis, blue and red colours indicate 
enzymes and relative mRNA abundance in Δtkt when compared to WT. GlcNAc – 
N-acetylglucosamine, GlcN – glucosamine, Glc – glucose, GlcNAc6P – N-
acetylglucosamine 6-phosphate, GlcN6P – glucosamine 6-phosphate, G6P – 
glucose 6-phosphate, F6P – fructose 6-phosphate, Man6P – mannose 6-
phosphate, UDP-GlcNAc – uridine diphosphate N-acetylglucosamine, GDP-Man – 
guanosine diphosphate mannose, GTP – guanidine triphosphate, HK – hexokinase, 
PGI – glucose-6-phosphate isomerase, NAGD – N-acetylglucosamine-6-phosphate 
deacetylase, GND – glucosamine-6-phosphate deaminase, GNAT – glucosamine-
6-phosphate acetylase, GFAT – glutamine:Fru6P aminotransferase, MPGT – 
mannose-1-phosphate guanylyltransferase; adapted from Naderer et al. (2010). 
5.5.4 Measurement of activities of glycolytic enzymes 
RNA levels merely point to the degree to which a gene is transcribed and its message 
retained at a steady state level. Translational control can mean that the enzyme produced 
is not directly related to the levels of that RNA and further regulation of enzyme activity 
(e.g. by post-translational modification, or allosteric control) can lead to phenotypic 
changes that have no direct correlation to RNA levels. Measuring the specific activity of 
individual enzymes has been used classically to determine contributions of enzymes to 
the metabolic network, thus I measured several enzyme activities to assess if there is any 
difference between WT and Δtkt. 
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Activities of hexokinase, glucose 6-phosphate isomerase, fructose 1,6-bisphosphate 
aldolase, and the two dehydrogenases from the PPP were measured and the values are in 
Tab 5.9. Both glucose 6-phosphate and 6-phosphogluconate dehydrogenases are not 
changed after TKT deletion. The only enzyme, showing significantly changed activity 
was fructose 1,6-bisphosphate aldolase (FbPase) which decreased two fold in Δtkt 
(p=0.0005). This is especially interesting because this correlates with the GC-MS data 
(chapter 3.3.2), where F1,6bP, the substrate of FbPase, was accumulated and DHAP, its 
product was twenty fold decreased. From a broader perspective it also corresponds with 
the LC-MS data, where the largest measured decreases in metabolite levels occurred in 
the lower part of glycolysis. 
 
 
activity (nmol/min/mg protein) 
 WT Δtkt 
hexokinase 296 (±161) 429 (±139) 
glucose-6-phosphate isomerase 338 (± 55) 232 (±28) 
fructose-1,6-bisphosphate aldolase 202 (±15) 95 (±11) 
glucose-6-phosphate dehydrogenase 128 (±15) 107 (±25) 
6-phosphogluconate dehydrogenase 131 (±20) 101 (±23) 
Table 5.9. Activities of selected enzymes of glycolysis and the PPP as measured on 
whole cell extracts. n = 4 – 5, values in brackets represent standard error of mean. 
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5.6 Localisation of TKT in L. mexicana 
It is known that the PPP has dual localisation in all trypanosomatids, as it is present both 
in the cytosol and in glycosomes (Igoillo-Esteve et al., 2007). The same is true for TKT 
in L. mexicana, as was shown by digitonin fractionation and enzyme activity 
measurement (Veitch et al., 2004). Due to instability and flexibility of the C-terminal 
part, its precise structure could not be resolved using X-ray crystallography (Veitch et 
al., 2004). Later, a preliminary experiment suggested that the addition of different 
substrates to TKT influences its ability to bind to PEX5 (Wildridge, 2012). Since this 
interaction depends upon the PTS1 sequence, which is represented by the last three amino 
acid residues (SKM), these data suggest there may be a connection between the flexibility 
of the C-terminus and binding to PEX machinery. Hypothetically, binding of different 
substrates could trigger conformational changes in the enzyme structure, which 
subsequently determine the exposure and availability of the PTS1 sequence for PEX5. 
Subsequently, this would determine if the enzyme is retained in the cytosol, or imported 
into a glycosome. I addressed this hypothesis and the first results led to further 
experiments and studies about consequences of different subcellular localisation of TKT. 
5.6.1 Localisation of TKT with varied C-termini 
Presuming the hypothesis formulated above is correct, then an enzyme variant with an 
artificially extended C-terminus may have its PTS1 always exposed and, therefore, be 
always imported into glycosomes. Based on this premise, I prepared a series of constructs 
using a pNUS family vector for episomal overexpression of proteins in Leishmania, with 
a GFP tag attached to the N-terminus of TKT (Fig 5.25). These constructs had 
alternations in the C-termini, so that TKT was elongated by 10, 20 or 30 amino acids, or 
else truncated by 10 or 20 amino acids. The extension was made by repeating the amino 
acids of the flexible C-terminus preceding the SKM targeting sequence and similarly, the 
deletions were cut by the residues preceding the terminal tripeptide, but retaining the 
SKM sequence itself. All of these constructs were transfected into both WT and Δtkt cell 
lines. Fig 5.26 shows the results of immunofluorescence analysis (IFA) with varied GFP-
TKTs and antibody against triosephosphate isomerase used as a glycosomal marker, and 
Fig 5.27 shows control Western blot analyses. 
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WT GFP-TKT is distributed throughout the leishmanial cell. Different mutant proteins, 
however, are found in the two compartments in variable proportions. The most interesting 
is the variant of TKT shorter by 10 AA, which is present primarily in glycosomes. The 
proteins elongated by 10 and 20 AA also seem to be mostly glycosomal but with a more 
notable proportion remaining in the cytosol. The other constructs: TKT plus 30 AA and 
TKT minus 20 AA show the same localisation as WT TKT. These results confirm that 
C-terminus controls subcellular localisation of TKT but not in the manner hypothesised 
earlier. There is no clear pattern in the results, so it is impossible to dissect how exactly 
the localisation control works. 
Figure 5.25. Scheme of the pNUS-GFPnH plasmid used for GFP-TKT expression. 
TKT was ligated into BglII and XhoI restriction sites (http://www.ibgc.u-
bordeaux2.fr/pNUS/greenvectors.html#map).
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Figure 5.26. Immunofluorescence microscopy of WT cells transfected with all variants of altered GFP-TKT constructs. Cartoons on the 
left represent the variants from the longest at the top to the shortest at the bottom. TIM was used as a glycosomal marker. 
10 µm 
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Figure 5.27. Control WB for the cell lines depicted in Fig 5.26, staining with α-GFP 
antibody. 
5.6.2 Digitonin fractionation 
Another method used to study subcellular localisation of proteins in trypanosomatids is 
digitonin fractionation followed by Western blot analysis or enzyme activity 
measurement. Hence, I used the transfected cell lines for the experiment, incubating cell 
samples with increasing amounts of digitonin and using the lysates for Western blot 
analysis. I used enolase as a marker for the cytosol and glycerol-3-phosphate 
dehydrogenase (GDH) as a marker of glycosomes, which showed that glycosomes were 
disrupted by 0.8 mg/ml digitonin (Fig 5.28 B). When using cells expressing GFP-TKT, 
the α-GFP signal was detected in all fractions, and the signal in the first fraction seemed 
relatively strong compared to the enolase signal. Most probably expression of GFP-TKT 
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was so high, that the protein contaminated all fractions, even those where WT TKT is 
not present. High TKT overexpression was indicated by enzyme activity measurements 
in these cell lines (Tab 5.1).  
Subsequently, I repeated the digitonin fractionation experiment with the Δtkt + glyco 
GFP-TKT cell line. However, TKT was again released even in fractions treated with the 
lowest concentration of detergent used, whereas GDH was released only by 0.8 mg/ml 
digitonin (Fig 5.29). Similarly as in the previous case, that is most likely caused by high 
expression of the GFP-TKT-10AA protein, which contaminated all the fractions. Hence, 
no conclusions can be made from this set of experiments and I was not able to confirm 
the IFA data by digitonin fractionation. 
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Figure 5.28. Western blots of digitonin fractionation of Δtkt + GFP-TKT cell line. 
Numbers at the top indicate concentration of digitonin (mg/ml) in the respective 
fractions. A – α-GFP antibody staining for detection of GFP-TKT, B – α-GDH 
antibody staining as a glycosomal marker, C – α-enolase staining as a cytosolic 
marker; GFP-TKT is 100 kDa in size, GDH 39 kDa and enolase 46 kDa. . 
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Figure 5.29. Western blots of digitonin fractionation of Δtkt + GFP-TKT-10AA cell 
line. Numbers at the top indicate concentration of digitonin (mg/ml) in the respective 
fractions. A – α-GFP antibody staining for detection of GFP-TKT, B – α-GDH 
antibody staining as a glycosomal marker.  
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5.6.3 Phenotypic and metabolomic comparison of cells expressing solely 
cytosolic or solely glycosomal TKT 
The cell line Δtkt + GFP-TKT-10AA (later called Δtkt + glyco GFP-TKT) has TKT 
present solely in glycosomes. To give a comparison between cells in which TKT is found 
primarily in the glycosome with one where it is found only in the cytosol, the Δtkt cells 
were transfected with a GFP-TKT construct from which the PTS1 tripeptide was 
truncated (called Δtkt + cyto GFP-TKT). Subsequently, I performed a series of 
experiments focused on comparison of these two cell lines. I expected that such major 
manipulation with localisation of TKT should cause negative effects on the cells and thus 
indicate what specific functions TKT has in the respective compartments. 
First, I assessed the growth of promastigotes and there was no difference in growth rate 
between cells expressing solely cytosolic or solely glycosomal TKT (Fig 5.30). Next, I 
tested sensitivity to oxidative stress by Alamar Blue Assay with glucose oxidase as 
described earlier, nevertheless both the cell lines were susceptible to the same extent (Fig 
5.31). Finally, I performed LC-MS metabolomic experiment with these two cell lines. 
Surprisingly, there were, once again, only minimal differences between them and 
metabolites of the highest interest, i.e. those from glycolysis and the PPP did not differ 
(Fig 5.32). The only differences were in ribose 1,5-bisphosphate which reaches only half 
the abundance in Δtkt + glyco GFP-TKT than in Δtkt + cyto GFP-TKT, and O8P which 
is decreased in the cell line with the glycosomal TKT compared to the line expressing 
the cytosolic variant. 
Based on this data, I can conclude that subcellular localisation of TKT in the 
promastigote stage plays no demonstrable role and the cells are apparently not affected 
by having the enzyme only in a single compartment.  
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Figure 5.30. Growth curves of Δtkt cells expressing cyto GFP-TKT or glyco GFP-
TKT. 
 
Figure 5.31. Alamar Blue Assay with GOX and Δtkt cells expressing cyto GFP-TKT 
or glyco GFP-TKT, fluorescence detected corresponds with viability of cells. 
 
5. Transketolase 
 
162 
 
 
Figure 5.32. LC-MS metabolomics comparison between Δtkt + cyto GFP-TKT and 
Δtkt + glyco GFP-TKT. A - Selected metabolites of glycolysis and the PPP for 
various TKT cell lines, the numbers represent relative abundance compared to WT. 
B – Heat map of all the metabolites detected, each line represents one biological 
replicate, g = Δtkt + glyco GFP-TKT, c = Δtkt + cyto GFP-TKT, yellow indicates no 
change, red increase and green decrease. 
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5.7 Discussion 
5.7.1 Growth, sensitivity to stress, infectivity 
It is very interesting that the L. mexicana Δtkt cell line has no visible phenotype in the 
promastigote stage but is of reduced viability in the amastigote stage. This underlines the 
diversity of the two life stages, but also it points towards flexibility and adaptability of 
the cells, given how promastigote metabolism is clearly altered to a fairly large degree 
and yet no growth or morphological defect is evident, and even sensitivity to oxidative 
stress and various drugs is only marginally increased. When assessing oxidative stress 
sensitivity, I obtained different results for methylene blue and for glucose oxidase (which 
constitutively produced hydrogen peroxide). Since the mode of action of methylene blue 
is not precisely known, glucose oxidase is more reliable agent, in addition, it creates 
oxidative stress continuously, assuming the enzyme was stable in the growth medium. 
Still, the sensitivity in Δtkt was increased only two times. 
When working with axenic amastigotes, I observed that Δtkt cells differentiated into the 
amastigote form, but did not grow thereafter. However, the Δtkt + TKT cell line did not 
grow as amastigotes either, indicating that a change other than loss of TKT per se might 
have been acquired during cultivation that precludes growth of amastigotes, thus no 
conclusions can be made at this point. I proceeded with macrophage infection assays. It 
was the case that Δtkt cells infected two times fewer macrophages, but the data were 
inconclusive due to high variability. Some of the later infection time points showed 
increased infection rates due to continuing infection with extracellular parasites. 
Moreover, we could not be sure about fitness of the Leishmania cells as they had been 
maintained in culture for long time and it is known that Leishmania lose infectivity in 
vitro (Pescher et al., 2011).  
In contrast to the lack of clarity in macrophage infections, mice infections provided clear 
results as animals injected with Δtkt Leishmania did not develop any leishmaniasis 
related lesions and the parasites could not be recovered from lymph nodes. At the same 
time, Δtkt + TKT cell line caused infection to the same extent as WT, albeit slightly 
delayed, proving that the loss of fitness in vivo was caused by TKT deletion. It seems 
that Δtkt cells are able to infect the host cells but do not survive for long, which is 
encouraging for further drug studies. Importantly, these results suggest that TKT is a 
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potential drug target for leishmaniasis. It would also be of interest to assess 
immunogenicity of this cell line, i.e. to determine whether its interaction with the host as 
a viable agent is sufficient to provoke a robust immune response, including development 
of immunological memory that could render the strain a potential live-attenuated vaccine 
for leishmaniasis. 
I performed further experiments exploring the possibilities of using TKT as a potential 
drug target. In summary, the Δtkt promastigote cells are marginally more sensitive to 
several leishmanicides, probably due to additive effects of different types of stress. If the 
drugs are acting by increasing intracellular oxidative stress, a possible additive effect 
with PPP dysfunction is possible. TKT is, however, not itself targeted by any of the drugs 
currently in use which I tested. I will screen GSK LeishBox (Peña et al., 2015) for 
inhibition of TKT enzyme activity with an aim to search for potential hits for inhibitors.  
5.7.2 Metabolomics 
Using various methods and focusing on different parts of metabolism, we can conclude 
that the Δtkt cell line displays a stringent metabolic response, akin to that described as 
promastigotes transform to amastigotes (Saunders et al., 2014). Significantly less glucose 
is consumed, the flux in the central metabolism is decreased and significantly less 
succinate, malate, and no alanine or proline are produced and secreted to the spent media. 
In addition, carbon source utilisation is changed since the relatively high levels of amino 
acids are used to substitute for glucose, albeit without increasing their total consumption 
as the metabolism is not profligate as found in WT.  
Metabolomics results have to be treated with caution as identification of most of the 
metabolites is only putative, changes in quantity detected are relative and if the peak is 
low or has a poor quality shape, the quantification can be inaccurate. However, the 
amount of data obtained is enormous, standards were used for many important 
metabolites and the same changes in related metabolites support that the trends observed 
are real. Most importantly, very similar results obtained from LC-MS and GC-MS 
analyses increase the credibility of assignments. 
The LC-MS data are complemented and concordant with the GC-MS data, the former 
allowing putative identification of large numbers of metabolite, while the latter enables 
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precise quantification and identification of fewer compounds. In general, the GC-MS 
analysis supports the LC-MS results. Isomers of sugar phosphates cannot be separated 
reliably by LC-MS and they are important in these pathways, but we were able to 
distinguish them by GC-MS. Hence, we confirmed that G6P and F6P levels are similar 
(two fold decreased), whereas increases in different pentose phosphates is specific for 
each compound. For example, glucose was detected in WT by LC-MS, but the peak was 
of low quality and thus the relative change in Δtkt cannot be quantified, whereas the other 
approach showed clear 7 fold increase. The biggest difference in results between the two 
methods is a 5-fold accumulation of F1,6bP measured by GC-MS, whereas a two-fold 
decrease was indicated by LC-MS. However, that is one example of a metabolite, 
identification of which is only predicted and detection is poor by LC-MS, thus GC-MS 
is much more reliable. Bisphosphoglycerate showed an unexpected increase by LC-MS 
but we cannot distinguish 1,3- or 2,3- bisphosphoglycerate and the peak quality is poor. 
Unfortunately, the standard was not available for GC-MS analysis and the question 
remains open. Both analyses, however, concur that metabolites from the bottom part of 
glycolysis are substantially depleted (DHAP 20 fold, 2PG and 3PG dropping below the 
detection limit).  
The GC-MS analysis contributed additional intermediates, which were not detected 
previously, such as E4P, DHAP, or quantification for glucose. Further, by focusing on 
carbohydrates, the profound accumulation of pentoses and compounds related to them 
was confirmed. The magnitude of some of the changes (up to 200 fold) may be startling, 
but abundance of these metabolites in WT is probably very low, thus the accumulation 
after TKT depletion causes high relative change. The fact that it is not a single metabolite, 
but a group of interlinked ones, supports that it is a coherent change. Surprisingly, xylose 
seems to be decreased below detection limit, suggesting that the utilisation and 
metabolism of separate pentoses is not uniform. 
The observation that the direction of the 6PGDH reaction may be reversed after TKT 
deletion is intriguing, which is the most plausible explanation for high proportion of 
5 carbon labelling in 6PG, even though it is only indirect proof. 6PGDH running in the 
opposite direction was reported previously in sheep liver and fungi (Silverberg and 
Dalziel, 1975; Villet and Dalziel, 1969), although I did not succeed when measuring it, 
possibly due to insufficient concentrations of CO2. It would be of interest to establish 
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whether such an alteration also occurs in other instances where pentose phosphates are 
accumulated, as was observed for example in TAL or RPI deficiency in humans (Engelke 
et al., 2010; Huck et al., 2004; Vas et al., 2006). It is of importance because the reaction 
in this direction consumes NADPH instead of producing it, which must significantly 
affect the redox balance inside the cells. 
The Δtkt + TKT re-expressor cell line retains some differences from WT, despite 
expressing active TKT (and in levels exceeding those of WT), but most of the changes 
in metabolism are reverted to WT levels.. 
Changes in mannogen in Δtkt are of interest as the level decreased under normal 
conditions but increased again in presence of fructose. It is not clear why mannogen is 
decreased in Δtkt at the first place, although clearly TKT does play a role in carbohydrate 
metabolism and mannogen is a part of that extended network. From the RNAseq analysis 
it seems to be due to decrease in expression (or faster degradation) of mRNA for 
mannose-1-phosphate guanylyltransferase. We cannot exclude a random mutation, due 
to long term cultivation of the cell line. Of note, re-expression of TKT does not restore 
mannogen levels and mRNA for mannose-1-phosphate guanylyltransferase is also three 
fold decreased, indicating it is indeed possible that this change has occurred 
independently, prior to selecting the Δtkt line. To test this it would be desirable to produce 
a second, independent knock-out line to determine whether the same change to mannogen 
levels occurs or not. However, that observation strengthens the presumed importance of 
mannose-1-phosphate guanylyltransferase in mannogen biosynthesis, or maintenance. 
The central carbon flux is significantly decreased in the Δtkt cell line. Consumption of 
glucose measured here is close to value reported previously (about 3.3 nmol (Saunders 
et al., 2014)). Although Wildridge did not detect any difference between WT and Δtkt 
(Wildridge, 2012), he used medium with 16 mM glucose and fewer, but more spaced out 
time points thus he may have missed the difference I detected. The decrease in secreted 
metabolic end products matches the observation that the media in Δtkt culture becomes 
much less acidic (Wildridge, 2012). Glucose uptake may be downregulated in response 
to accumulation of glucose inside cells or due to decreased levels of glucose transporter 
gene expression as identified through RNAseq. Why glucose accumulates inside the cells 
is another question. A complex regulatory mechanism stimulating the stringent metabolic 
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response, as described in amastigotes (Saunders et al., 2014) may be occurring, albeit 
triggered by different mechanism. It could be possibly a general stress response. 
There does not seem to be clear downregulation of the TCA cycle as observed in the 
other pathways of glucose metabolism. This appears to be due to the fact that multiple 
carbon sources e.g. a mixture of different amino acids fuel the TCA cycle. The changes 
detected in the TCA cycle are not consistent between metabolites nor across different 
experiments, for example there are differences in the overall levels in Fig 5.15 and Tab 
5.5. RNAseq data show similar trends, levels of some of the enzymes are slightly 
decreased, other increased but the changes are small.  
It is difficult to make clear conclusions about changes in amino acid metabolism. mRNA 
levels of most of the amino acid transporter genes are increased, supporting use of amino 
acids to compensate for glucose (expression levels of the glucose transporter genes are 
diminished). On the other hand, amino acids in the spent media are not obviously 
consumed more by Δtkt cells than WT. All amino acids accumulate inside cells, which 
would rather indicate decreased catabolism. A possible explanation for some of these 
changes is that under standard conditions, they are transaminated using pyruvate as 
amino group acceptor to produce alanine. But because of pyruvate depletion in Δtkt, the 
whole process is disrupted and there is an accumulation of aminoacids. None of the data 
indicated increased flux into the TCA cycle, or any amino acid degradation pathway, on 
the other hand, that may be interpreted as more efficient use of resources in contrast to 
profligate WT metabolism. It is possible that amino acids are taken up from medium the 
same way by both cell lines, but used inside the cells differently. If Δtkt does not prefer 
a single amino acid, but uses a mixture of different ones, then the changes in specific 
metabolites or genes may be too subtle to generate significant differences in abundance, 
while the net contribution is sufficient. It may be hypothesised that due to stringent 
metabolic response, carbon sources are utilised more efficiently and no substantial 
replacement is needed. The labelling data of the TCA cycle intermediates, however, 
clearly showed that these metabolites originate from a different source than glucose.  
5.7.3 PPP flux 
The 14% flux of glucose into the PPP calculated here corresponds with previous reports 
in other organisms. It was reported to be 10% in T. cruzi (Maugeri and Cazzulo, 2004), 
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7% in healthy humans (Dusick et al., 2007), 5.7% in human hepatoma cells (Lee, 1998), 
10% in Corynebacterium but increased to 30–60% under stress (Moritz et al., 2002). 
Maugeri (2003) estimated that 11% of radiolabelled glucose is incorporated into DNA in 
promastigote L. mexicana, meaning that it is channelled into the PPP and turned into 
R5P. This method may not be very precise because ribose can also be taken up from 
medium, phosphorylated by ribokinase and incorporated into nucleic acids preferentially. 
Nevertheless, the two values obtained by different techniques are very close. 
Based on the labelling experiments here, it seems that 14% flux measured in the PPP 
represents the net flux via the pathway. Flux via the oxidative branch is possibly the 
same, but a higher flux in the non-oxidative branch, including cycling between the 
intermediates, is not reflected in these measurements. The non-oxidative PPP should be 
considered as allowing free interconversion of carbons between various substrates in no 
particular order rather than a straightforward pathway with a prevailing direction as 
depicted classically (Fig 5.33). The sensitivity of the metabolomics methodology has 
shown that unusual metabolites such as O8P and N9P also appear in the non-oxidative 
branch of the pathway. These large monosaccharides (at least O8P) are associated with 
sugar cycling in the Calvin cycle or biosynthesis of lipopolysaccharides for bacterial cell 
wall (Kneidinger et al., 2002; Williams and MacLeod, 2006), but roles for these 
metabolites are not clear in trypanosomatids. However, it is possible that they are simply 
the inevitable products of the non-oxidative PPP given the promiscuity of the enzymes 
and their ability to remove and add carbon units. 
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Figure 5.33. An alternative scheme of the PPP, reflecting the mode of action of TKT 
and TAL.  
After observing downregulation of central carbon metabolism as a consequence of TKT 
deletion, I tested various hypotheses in order to find the control point. Purified PGI was 
shown to be inhibited by 6PG, although it was never proven inside cells. This work 
disproves this as an explanation for diminished glycolysis through PGI inhibition in L. 
mexicana, since using fructose rather than glucose did not alter the overall metabolic 
network distribution, in spite of the fact that fructose enters the pathway beneath the 
isomerase reaction. Nevertheless due to the compartmentalisation of glucose catabolism 
in trypanosomatids, the hypothesis could still hold for other organisms. Of the 
possibilities tested, inhibition of FbPase activity seems to be the mechanism most likely 
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responsible for the block in glycolysis. This corresponds with the metabolomics data and 
explains the drastic drop in the lower part of glycolysis, and accumulation of metabolites 
upstream. It was reported previously that FbPase is inhibited by R5P and 6PG in various 
organisms (Bais et al., 1985; Lal et al., 2005; Moorhead and Plaxton, 1990) and I 
observed high accumulation of both of these metabolites. The protein sequences are 
similar, and amino acid residues responsible for substrate binding are conserved across 
species, including Leishmania (Fig 5.34). To test this hypothesis, the enzyme from 
Leishmania would need to be purified and the inhibition established, but at the moment 
it seems to be the most likely explanation. 
We cannot exclude that additional regulatory and feedback mechanisms take place 
concomitantly. The stringent metabolic response which was observed could be the 
outcome of coordinated control mechanisms responding to stress, or it could be outcome 
of additive effects of random changes triggered by artificial deletion of the TKT gene.  
 
 
 
 
 
 
Figure 5.34. Alignment of FBPase protein sequences. Representatives of the 
enzymes reported to be inhibited by PPP intermediates and L. mexicana sequences 
are shown. Arrows indicate the conserved amino acid residues crucial for substrate 
binding and activity. The alignment was made using PRALINE tool (Heringa, 2002). 
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5.7.4 Why is the infectivity of amastigotes decreased? 
I did not manage to bring a straightforward answer to the question regarding the causes 
of a detrimental effect of TKT deletion to the amastigote stage. It seems that Δtkt 
amastigotes are able to infect host cells, but they do not survive inside for long term. 
Under natural conditions, amastigotes are exposed to high oxidative stress and their 
defence mechanisms may be disabled by the PPP disruption and decreased NADPH 
production. Promastigote Δtkt were only twice as sensitive to GOX as WT, but the 
situation may be completely different in the amastigote stage. The highest demand for 
NADPH is in trypanothione reductase recycling, but other NADPH consuming pathways 
are found in lipid metabolism, notably ergosterol biosynthesis (De Vas et al., 2011) and 
fatty acid synthesis (Lee et al., 2007), which may be operative and relevant to the 
amastigote stage, and thus decrease in their activity could contribute to Δtkt lethality. 
Further, glutamate dehydrogenase catalyses transamination of oxoglutarate to glutamate 
at concomitant consumption of NADPH, but that step is not expected to be essential 
(Saunders et al., 2011). On the other hand, the PPP is not the only NADPH producing 
pathway, as it is made in addition by malic enzyme (Mottram and Coombs, 1985b), 
isocitrate dehydrogenase in the TCA cycle (Saunders et al., 2014), and possibly in 
tetrahydrofolate metabolic pathway (Vickers and Beverley, 2011). 
Mannogen was reported to be essential for amastigotes (Ralton et al., 2003) and it is 
highly decreased in Δtkt. However, infectivity is restored in the TKT re-expression line, 
in spite of mannogen levels remaining low, pointing to TKT being the determinant of 
infectivity in both of these cell lines. TKT deletion may have caused intracellular stresses 
within the promastigote lines in which they were selected, but adaptive mechanisms 
might have evolved to permit survival in this stage. However, transformation to 
amastigotes within the host system, might then have over-ridden any such bypass 
mechanism after which death ensued.  
5.7.5 Localisation 
The results of experiments focused on localisation of TKT are quite surprising, especially 
the solely glycosomal localisation of the TKT protein truncated by 10 amino acids. 
Although Western blot analysis following digitonin lysis did not confirm the IFA 
observation, the latter technique is more reliable and shows unambiguously the 
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localisation of the protein inside the cells. Considering the differences in localisation that 
vary as the C-terminus varies, it is clear that this part of the protein does play a role in 
cellular targeting, although a better understanding of exactly how this works will require 
further work. The mechanism is not as simple as hypothesised originally, where it was 
considered possible that it was a simple case of extending a flexible tail that enabled 
binding to PEX components of the glycosomal targeting pathway, whilst withdrawing 
the tail would prevent that. Possibly, the flexible C-terminus forms a particular structure 
depending on the amino acid sequence from which it is composed, in which case this 
structure differs between the constructs I made, and it is this that influences availability 
of the PTS1 sequence and the final localisation. A possible way to approach the question 
could by through X-ray crystallography or protein NMR, which can provide detailed 
information about structure. To address this question from a different angle, we are 
collaborating with Ylva Lindqvist’s crystallography group from the Karolinska Institute, 
in order to obtain structure of TKT in complex with different substrates. One of the 
objectives is to examine whether the conformation of the C-terminus differs depending 
on the binding of different substrates. 
When comparing the cells expressing TKT solely in one compartment, I expected to 
detect significant differences at the level of the metabolome, between them. However, no 
substantial changes were found. At the moment, it seems curious that cells have a 
presumably very complex mechanism of localisation control, when no difference to 
metabolism is apparent irrespective of localisation. On the other hand, I did not manage 
to compare these variants in the amastigote stage, and it is possible that a particular 
phenotype becomes obvious only in a specific stage (amastigote, or even other parts of 
the life cycle), or under specific conditions. However, these results confirm the presumed 
semi-permeable nature of the glycosomal membrane (Achcar et al., 2013), because it 
does not matter where the enzyme is present, if the substrates and products can pass 
across the membrane and access the enzyme freely irrespective of its localisation.
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6 General discussion 
My work was focused on Leishmania metabolism, which I studied using various 
metabolomic approaches and the data presented here are connected by two common 
topics: the pentose phosphate pathway and stringent metabolism. Using labelled glucose 
and ribose for a metabolomics study provided us with information on utilisation of these 
sugars in overall cellular metabolism and on the activity of the PPP. Further, I used an L. 
mexicana cell line depleted of transketolase, which answered questions on the essentiality 
of this gene and consequently the non-oxidative branch of the PPP. Interestingly the Δtkt 
cell line shows characteristics of a stringent metabolic response, described previously for 
amastigotes. That is the main topic of the last part of my work, where I compared 
metabolomics data for promastigote and amastigote L. donovani. 
6.1 Metabolomics approach 
A key benefit of untargeted LC-MS metabolomics approaches is that they provide a large 
amount of unbiased data. Nevertheless, certain drawbacks are evident too. The method 
of separation (GC versus LC, column and gradient choice) prior to MS analysis can be 
chosen specifically depending on the group of metabolites of interest, but no method is 
optimal for all metabolites. The predominant method used here (LC-MS with ZIC-
pHILIc) is suitable for amino acids, carboxylic acids, glycolytic intermediates, but not 
for fatty acids and other non-polar molecules, or very small molecules. Metabolites are 
identified based on matches with standards used, of which there are around 200 in our 
case, leaving most of the identifications as only putative. Unless calibration standards are 
used, relative quantification only is possible (Kim et al., 2015). In addition, if the peak 
detected is of poor quality, even the relative quantification is unreliable and this may lead 
to misleading results. The reproducibility was very good in my experience, i. e. the major 
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changes appearing consistently in different datasets. When I used a GC-MS method for 
the same sample analysis, I obtained precise quantification albeit with far fewer 
metabolites with confident identification. However, the sample and data processing is 
much more demanding.  
6.2 Amastigotes 
The metabolomics data on amastigotes presented here are in general consistent with 
stringent metabolism reported for this stage previously (Saunders et al., 2014). A key 
hallmark of the amastigote dataset, and an observation not reported before, is the decrease 
in levels of all amino acids (except for methionine and histidine). Amastigotes produce 
lower quantities of the metabolic end products, succinate and malate, and the data are 
consistent with a decrease in glycolysis too. Levels of sugar polymers are high in 
amastigotes, corresponding to mannogen being essential in the mammalian infective 
stage (Naderer et al., 2006; Ralton et al., 2003). Axenic and splenic amastigotes seem to 
be fairly similar based on the total metabolic profile as well as examination of specific 
metabolites of interest.  
An alternative to describing amastigote metabolism as a ‘stringent metabolic response’ 
would be to describe WT promastigote metabolism as ‘profligate’, since the cells seem 
to consume unnecessary high amounts of substrates and to secrete large quantities of 
incompletely oxidized products such as succinate and alanine. This can be concisely 
concluded from the analysis of metabolic end products, comparison of glucose and ribose 
utilisation as carbon sources, and the comparison between promastigotes and amastigotes 
in this work, and has also been concluded based on previous observations too 
(McConville et al., 2015). It would be of interest to establish how promastigote 
metabolism observed in vitro relates to in vivo conditions in the sand fly which are 
practically unknown. The ‘profligate metabolic response’ could be an artefact induced 
by the very rich in vitro conditions. Amastigotes, however, are also cultured in similar 
rich medium, but their metabolism does not become profligate and they seem fairly 
similar to lesion-derived parasites. Hence there remains much to learn about the triggers 
and mechanisms that cause different Leishmania forms to metabolise in different ways. 
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6.3 Utilisation of glucose and ribose 
The data obtained from metabolomics with labelled glucose and ribose in different 
combinations showed clearly that glucose is the preferred carbon source. The two sugars 
are preferentially carried by different transporters, phosphorylated by specific kinases 
and whereas G6P enter glycolysis directly, R5P transits the PPP first. Ribose can be 
utilised to the same extent and incorporated into the same metabolites, since it is 
channelled through the non-oxidative PPP as can be seen through increases in the 
intermediates and the labelling patterns. Hence feeding cells on ribose alone seems to 
increase flux in the non-oxidative PPP. If both sugars are available, glucose is preferred 
and ribose is used only to a minor extent. Surprisingly, when glucose is abundant, ribose 
was phosphorylated to R5P and incorporated into nucleotides, but not transformed into 
other metabolites. That indicates on an intriguing regulatory mechanism, the details of 
which remain elusive. It may involve subcellular localisation or inhibitory effects of the 
sugars and could be a part of the parasite’s adaptive mechanisms to different 
environments and energetic sources. Possibly, using TKT mutant cell lines expressing 
the enzyme in a single compartment may help to explain the mechanisms involved. In 
addition, detailed functional characterisation of ribokinase in Leishmania may provide 
more insight into its regulation. 
We may speculate whether utilisation of ribose for nucleotide synthesis and fructose for 
mannogen biosynthesis may have a similar regulatory control. Glucose seems to be the 
preferred carbon source, but if unavailable the parasites can replace it with other sugars. 
When different sugars are available, glucose seems to be preferred for central 
metabolism, but ribose for incorporation into nucleotides and fructose is favoured for 
mannogen biosynthesis. Learning more about the regulatory mechanism controlling 
preferential use of different carbon sources for different biochemical pathways will be an 
interesting topic of future investigation. 
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6.4 TKT deletion triggers stringent metabolic response 
It was surprising to see no growth or morphological defect in Δtkt promastigote L. 
mexicana. Looking at a scheme of the PPP, function of TKT does not seem crucial per 
se, but the oxidative branch of the PPP produces NADPH, which is, in addition to other 
functions in metabolism, essential in defence against oxidative stress, specifically for 
recovery of trypanothione reductase, a process itself essential for the parasite (reviewed 
in Leroux and Krauth-Siegel, 2015). Blocking the non-oxidative branch is expected to 
cause accumulation of intermediates upstream and to disrupt flux in the whole pathway. 
Both G6PDH and 6PGDH, the two NADPH producing enzymes, are known to be 
essential in bloodstream form but not procyclic form T. brucei (Cordeiro et al., 2009). 
The depletion of G6PDH in promastigote L. mexicana resulted in a growth defect and 
increased sensitivity to Sb3+ (Mukherjee et al., 2013), but further effects were not 
investigated, and comparison across the two genera may be misleading, even though in 
both cases oxidative stress is expected to be higher in the mammalian infective stage. 
The fact that TKT is essential only in amastigote L. mexicana stage is in agreement with 
this speculation. 
By employing a metabolomics approach I showed that even though Δtkt cells did not 
demonstrate any obvious phenotype, they underwent substantial changes in metabolism. 
That demonstrates that the parasites have high flexibility and adaptability with regard to 
metabolism, which was demonstrated again in other parts of my work, such as when WT 
cells were shown to be able to utilise both glucose and ribose in similar ways, even though 
the entry points into metabolism are different. In addition to the metabolic changes, TKT 
deletion is accompanied by increases in general sensitivity to stress. For example, the 
cells are more sensitive to oxidative stress and almost all of the current anti-leishmanial 
compounds tested, activity of which is partly conveyed by oxidative stress too. However, 
the rise in sensitivity is rather small, definitely smaller than predicted when considering 
that what is presumed to be the major source of NADPH for these cells is disrupted. No 
data is available on relative production and consumption of NADPH by the respective 
pathways in Leishmania, and the data reported for mammalian cells show high variability 
(Fan et al., 2014). Moreover, the labelling data presented here indicate that huge 
accumulation of pentose phosphates leads to reversion of the 6PGDH reaction, resulting 
in consumption of an NADPH molecule instead of production. It is difficult to predict 
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the final outcome of such a situation, since it would involve 6PGDH consuming NADPH 
and producing 6PG, and then G6PDH reaction would be driven by NADPH demand 
against high level of its product, 6PG. The final outcome of the reactions’ activity would 
depend on the more energetically favourable directions, but most likely the canonical 
flux would not be very high. Possibly, accumulation of intermediates may spread 
upstream of the pathway resulting in blockage and total destruction of the flux.  
The Δtkt cells may be compensating for this block by increasing other enzymes involved 
in oxidative stress defence such as ascorbate peroxidase, mRNA of which was 2.3 fold 
increased in Δtkt. In addition two enzymes from polyamine metabolism, ornithine 
decarboxylase and putative acetylornithine deacetylase, were more than two fold 
elevated and they may possibly increase trypanothione biosynthesis. In addition, other 
NADPH producing enzymes are present such as malic enzyme and isocitrate 
dehydrogenase, and dispensability of G6PDH indicates that production of NADPH from 
other pathways than the PPP may be sufficient (Mukherjee et al., 2013). 
I measured 14% of glucose used in WT L. mexicana passes through the PPP, which is 
similar to flux reported for other organisms (10% in T. cruzi (Maugeri and Cazzulo, 
2004), 7% in humans (Dusick et al., 2007)) and corresponds with previous studies on the 
PPP in L. mexicana (Mancilla et al., 1965; Maugeri et al., 2003). It was shown previously 
that the flux increases in response to oxidative stress (Maugeri et al., 2003) and the ribose 
labelling data presented here suggest that the flux also increases when ribose is the major 
carbon source, and the non-oxidative PPP is needed for its conversion to glycolytic 
intermediates. The flux calculation represents the net flux and could possibly measure 
only the oxidative branch, but the two branches seem to be independent in this regard. It 
may be impossible to measure flux in the non-oxidative PPP, because the straightforward 
pathway with a clear direction as depicted in textbooks, doesn’t really exist, instead a 
mosaic of carbon interconversions between various substrates in variable combinations, 
performed by TKT and TAL occurs, as indicated in an alternative scheme I present in 
Fig 5.33. 
Some of the metabolic changes following TKT deletion corresponded with anticipated 
outcomes, but other changes went beyond expectation and impact on distant branches of 
the metabolic network. Even though there are some minor differences between the data 
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from GC-MS and LC-MS, there is good correlation between the two and the same trends 
are seen. Accumulation of metabolites upstream of TKT (6PG, pentose phosphates) were 
expected, even though the extent of the increase was surprising. Accumulation of pentose 
phosphates drives flux into reactions which are otherwise not detected, such as 
conversion into alcohols or O8P, whilst metabolites downstream from TKT (S7P, GA3P) 
were depleted. E4P signal completely disappeared in Δtkt based on GC-MS. Whereas 
O8P levels increased a lot, N9P decreased significantly, because these sugars are most 
likely produced by TAL in 5 + 3 and 6 + 3 carbon reactions, respectively, thus the 
production depends on availability of the substrates. Most importantly, the changes 
observed in the metabolome are consistent with previous analyses of Δtkt L. mexicana 
(Wildridge, 2012) and T. brucei (Stoffel et al., 2011) (Appendix A1). 
Interestingly, the flux in central carbon metabolism is decreased in Δtkt. Consumption of 
glucose is decreased by 25% and glycolytic intermediates dropped up to 20% of their 
WT concentrations. Decrease in glucose uptake is probably caused by depletion of 
mRNA for all three major glucose transporters by 25%. It is tempting to speculate that it 
is a feedback reaction to accumulation of glucose inside cells (by 7.5 fold), even though 
no such mechanism has been reported in trypanosomatids so far. Trypanosomatids have 
polycistronic transcription and mRNA regulation is conveyed by a balance between 
stability and degradation of mRNA, but no details are known about glucose transporters 
(Boucher et al., 2002; Clayton, 2002; Quijada et al., 2000). Hexokinase inhibition is also 
a possible explanation, since glucose is accumulated while G6P decreases. mRNA levels 
for hexokinase are increased by 27% and hexokinase activity was higher in lysates of the 
Δtkt cell line (although not significant due to high variability) (Tab 5.8). Translational or 
allosteric regulation within the cellular system may therefore be responsible for the 
decrease in activity in situ. L. mexicana depleted for all three glucose transporter genes 
was assessed for changes in mRNA levels, and among the most upregulated genes were 
hexokinase and ribokinase (Feng et al., 2011), which indicates that the cells sense a 
shortage of these sugars and attempt to compensate for it by enhancing enzymes that can 
utilise sugars at the gene expression level. The other genes reported as overexpressed in 
that glucose transporter KO study do not overlap with my data on the Δtkt line, except 
for serine hydroxymethyltransferase, mRNA of which was 2.5 fold increased in Δtkt and 
7.7 fold increased in the glucose transporter knock-out, although there is no clear 
connection with sugar metabolism (Feng et al., 2011). 
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Since production of all the major metabolic end products which were detected (succinate, 
pyruvate, alanine) decreased substantially, the phenotype resembles stringent metabolic 
response described in amastigotes (Saunders et al., 2014). However, a big difference 
between the stringent metabolic response reported for amastigotes and the Δtkt line 
relates to amino acids. These are greatly decreased intracellularly in amastigotes 
compared with promastigotes, while they increase within the Δtkt line. TKT itself is a 
good example of amastigote stringent metabolism, because the enzyme activity is four 
fold lower in amastigotes, but it is essential in these cells in contrast to promastigotes. 
There is no obvious reason why deletion of TKT causes a similar induction of a stringent 
response as seen in amastigotes. Stringent metabolism may be part of a general stress 
response for Leishmania, as has been suggested by McConville et al. (McConville et al., 
2015). It would be of interest but challenging to dissect the signalling and feedback 
mechanisms.  
Flux through glycolysis could be disrupted due to inhibition of F1,6bPase by 6PG or 
R5P. Δtkt cells displayed half of the F1,6bPase activity compared to WT and the 
metabolomics data point at disruption in this step (accumulation of F1,6bP, depletion of 
the products), and such inhibition was described previously for mammalian and plant 
enzymes (Bais, 1985; Lal, 2005; Moorhead, 1990). To confirm this hypothesis, the 
Leishmania enzyme needs to be purified and the inhibition tested. Unfortunately, I did 
not have sufficient time to proceed with this work. However, the amino acid residues in 
the enzyme’s active site responsible for substrate binding are conserved in the 
leishmanial one (Fig 5.34). 
Another change in Δtkt metabolism is replacement of glucose by a different carbon 
source. Since the cells switch to stringent metabolism, they should, by definition, use less 
carbon. Whereas in WT about 50% of TCA cycle intermediates come from a source other 
than glucose, 90% of these intermediates are from non-glucose sources in Δtkt, while the 
total amount of these intermediates is the same or lower in absolute numbers. We have 
not been able to ascertain these alternative carbon sources. It was observed in WT L. 
mexicana that next to glucose, aspartate and glutamate are used to minor extent (Saunders 
et al., 2014). Hence, most likely it is the same situation for Δtkt, and possibly a wider 
range of amino acids may be used. In order to clearly answer the question, multiple 
metabolomic analyses would need to be performed with various amino acids carbon-
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labelled to dissect which are fed into the TCA cycle. The Δtkt cells do not consume more 
amino acids, but they use them differently. Since the metabolism is stringent, levels of 
TCA cycle intermediates are decreased, and the same amounts of amino acids make up 
for much higher proportion of carbon in TCA cycle intermediates. Levels of mRNA for 
amino acid transporters are elevated in Δtkt, possibly indicating feedback in response to 
the block in carbon metabolism. Intracellular levels of many amino acids are increased 
(eleven amino acids are elevated 2 fold or more).  
6.5 Why are Δtkt amastigotes not viable? 
Whereas Δtkt cells have no growth defect as promastigotes, they are not viable as 
amastigotes. Experiments with axenic amastigotes indicated this to be the case, but the 
data were not conclusive, since I did not obtain a growing culture of the Δtkt + TKT cell 
line either. Infections of macrophages indicated decreased infectivity, but the parasites 
were still able to infect the host cells. Infections of mice, however, showed that Δtkt cells 
failed to develop leishmaniasis lesions even after 23 weeks. It seems that Δtkt cells can 
infect phagocytic host cells and survive inside short term, but not long enough to establish 
infection.  
The reason for this loss of viability, however, remains unclear. A suspected possible 
reason would be loss of oxidative stress defence. However, Δtkt promastigotes are only 
two times more sensitive to glucose oxidase and Δtkt + TKT cell line reverted to WT 
levels only partly in the same assay (but this re-expressor line caused normal infection in 
mice). On the other hand, it is unknown how promastigote and amastigote defence 
systems compare and in general it seems that promastigotes can handle more disruption 
and higher stress. A second possible explanation would be that inhibition of F1,6bPase 
and subsequent decrease in glycolytic flux is intolerable for amastigotes. If the switch to 
stringent metabolism results in parasites that use only what is needed, then even only 
partial inhibition may have lethal consequences. mRNA for F1,6bPase was detected to 
be around two fold decreased in amastigotes in three independent transcriptomic studies 
(Alcolea et al., 2010a, 2010b; Holzer et al., 2006). Intriguingly, leishmanial F1,6bPase 
was also shown to be present in the cytosol of infected macrophages and suggested to 
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activate tyrosine phosphatase SHP-1 and inhibit expression of mammalian nitric oxid 
synthase (Nandan et al., 2007). 
In addition, I also observed a significant drop in levels of mannogen, a storage sugar 
essential for amastigotes. No direct connection with TKT is obvious, but decreases in 
mRNA for mannose 1-phosphate guanylyltransferase seemed to be responsible for 
mannogen depletion. We do not know if it is due to some kind of feedback in 
consequence of the metabolic changes, or if it is a random additional mutation in the 
original Δtkt cell line. In order to test that, an independent Δtkt cell line would need to 
be made. Nevertheless, mannogen levels are still low in Δtkt + TKT, but the cells caused 
infection, which excludes this as a reason for loss of viability. Finally, it is possible that 
different types of stress contribute together resulting in detrimental effect on Δtkt 
amastigote cells. Altogether, TKT is a potential drug target against Leishmania, and I am 
planning to screen the LeishBox of leishmanicidal agents from GSK (Peña et al., 2015) 
for potential inhibitors of the enzyme’s activity. 
6.6 Localisation of TKT 
Another interesting feature of TKT is its subcellular localisation. Previously it was shown 
that about 30% of the enzyme is confined to glycosomes in promastigote L. mexicana 
with the majority being cytosolic (Veitch et al., 2004). A crystal structure of the protein 
was resolved and it was noted that the C-terminal residues were unstructured with a 
possible explanation that this part of the protein is flexible (Veitch et al., 2004). 
Additional preliminary data indicated that binding of TKT to the PEX machinery varied 
depending on different sugar substrates added to the protein (Wildridge, 2012). These 
pieces of information led to formulation of hypothesis that binding of various substrates 
induces conformational changes in the enzyme including the C-terminal part containing 
PTS1 targeting sequence, having impact on its final intracellular localisation.  
In order to shed more light on these data, I prepared a series of five TKT constructs with 
a C-terminus of varied length prior to the PTS1 sequence. Surprisingly, a version of the 
protein truncated by ten amino acids located solely into glycosomes. Some of the other 
mutants showed an increased proportion localised to the glycosomal part too, whilst 
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localisation of the others was the same as WT TKT. Altogether, no clear conclusions can 
be drawn solely from this data. The total net length of the C-terminal tail is not the 
decisive aspect in driving localisation. Instead it may be the secondary structure of the 
C-terminal part, dependent on its composition and interaction with the rest of the protein 
that is responsible for different localisation. The C-terminus plays a key role in the final 
localisation of the enzyme and the dual localisation in WT may be caused by its flexibility 
and changing availability of the recognition site for the PEX machinery. On the other 
hand, the whole PPP has the same dual localisation (with slightly varied proportions for 
different enzymes) and it is unknown how the dual localisation is controlled for the other 
components. In addition, proteins can be imported into peroxisomes in oligomeric 
complexes (Glover et al., 1994; McNew and Goodman, 1994; Opperdoes and Szikora, 
2006) and such a scenario has not been investigated for the other PPP enzymes.  
Having obtained a cell line expressing TKT with a purely glycosomal location, I prepared 
another mutant, lacking the C-terminal glycosomal targeting sequence which was solely 
cytosolic. Surprisingly there were no differences between these two cell lines. They were 
sensitive to oxidative stress to the same extent and metabolomics analysis showed only 
minimal changes in general, and none in the levels of metabolites of carbohydrate 
metabolism. This seems to confirm the presumed semi-permeable character of 
glycosomal membrane, when substrates and products of the enzyme (up to six carbons) 
can freely pass through the membrane (Achcar et al., 2013), and thus it does not matter 
where TKT is localised. It is intriguing, therefore, that a complicated regulatory 
mechanism of dual localisation takes place, given the final localisation of TKT appears 
irrelevant. On the other hand, the localisation may play a particular role under different 
conditions or in the amastigote, or other stages of the life cycle. It would be of interest to 
test infectivity of these mutated TKT cell lines in animals in future. 
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6.7 Conclusions and future work 
 Metabolomics analysis of in vivo grown L. donovani amastigotes is presented. 
Metabolomes of splenic amastigotes, axenic amastigotes and promastigotes are 
reflected as three separate groups. In general, the data are consistent with stringent 
metabolic response in amastigotes. Both types of amastigotes had very low 
intracellular levels of amino acids compared to promastigotes, independent of their 
environment. 
 Glucose is the preferred carbon source for WT promastigote L. mexicana, but it can be 
replaced by ribose. Ribose is the preferred source only for R5P part of nucleotides. 
Supplementation with ribose increases the flux in the non-oxidative PPP. 
 WT promastigote metabolism under standard culture conditions is profligate. 
 TKT deletion in promastigote L. mexicana causes no obvious phenotype (growth rate, 
oxidative stress and drug sensitivity), but substantial changes in metabolism were 
observed beyond the PPP. 
 TKT deletion causes decreases in central carbon flux, possibly due to inhibition of 
fructose-1,6-bisphosphate aldolase by the accumulated PPP intermediates. 
 The PPP consumes 14% of all glucose in promastigote L. mexicana, but in the non-
oxidative PPP carbons are shuffled in a stochastic way, which cannot be quantified 
easily. 
 Conformation of the C-terminus of TKT determines the final subcellular localisation 
of the protein. If the C-terminus is truncated by 10 AA, TKT is present exclusively in 
glycosomes. 
 Changes in subcellular localisation have no effect on growth rate, oxidative stress 
sensitivity or metabolism. 
 
This thesis has shown that the PPP enzyme TKT is essential to amastigote forms of L. 
mexicana even though its loss has little impact on the promastigote stage. The enzyme 
may therefore be considered as a drug target. Metabolomics analysis has shown that loss 
of TKT causes changes in the levels of substrates of the PPP but also leads to a decrease 
in use of glucose through glycolysis, pointing to novel regulatory cross-talk between 
these pathways. Whether the enzyme is localised solely to the glycosome, solely to the 
cytosol or dually localised to both compartments, neither promastigote parasite viability, 
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nor metabolism was altered. This supports a model where smaller metabolites are free to 
move between the glycosome and cytosol. Comparative analysis of metabolism in 
promastigote and amastigote forms of the parasite reveals metabolism to be stringent in 
the amastigote form and yet profligate in the promastigote form. The TKT knockout cells 
reproduced the stringent response even as promastigotes. Transcriptomic analysis 
indicated that much of the switch to a stringent response during differentiation occurs at 
stages in the gene regulatory flow beyond the level of RNA abundance. 
Considering the progress in development of tools for genetic manipulation, it would be 
possible and desirable to prepare an inducible TKT knock-out cell line in the future. Use 
of DiCre (Duncan et al., 2016) and CRISPR-Cas9 (Sollelis et al., 2015) mediated systems 
was demonstrated in Leishmania already. That would enable to assess the phenotype in 
early time points after induction, which may allow to distinguish between direct and 
subsequent downstream effects. In the current study, I was not able to do any experiments 
with Δtkt axenic amastigotes because they are not viable. An inducible knock-out system 
would possibly overcome this issue, and more studies of these cells may provide useful 
information and indications why Δtkt are not infectious. In addition, expression of 
mannose-1-phosphate guanylyltransferase and levels of mannogen could be assessed in 
the new knock-out cell line, which would answer the question if the changes observed 
here are direct consequences of TKT deletion, or an additional random mutation in our 
original cell line.  
Further, it would be technically challenging but desirable to perform metabolomics 
analysis of metacyclics as another Leishmania stage. Similarly, it would be interesting to 
compare promastigotes obtained from sand flies to in vitro cultured parasites. I did not 
observe any substantial difference between promastigote cells expressing TKT solely in 
the cytosol, or glycosomes. It would be of interest to test this perturbation in the 
amastigote stage, where a stronger phenotype or defect in infectivity may be observed. 
Further, it would be desirable to measure the flux in the PPP in the amastigote stage too. 
The activity of the pathway may differ in each stage, being increased in amastigotes due 
to higher demands for NADPH. The metabolomics data are consistent with stringent 
metabolic response in amastigotes, but the PPP activity may be the same in both stages 
and thus relatively higher to glycolysis in amastigotes. 
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Appendix A Metabolomics 
Appendix A1. Comparison of metabolomics data from this work with previous 
publications (Stoffel et al., 2011; Wildridge, 2012). All values are relative to WT. 
 
Stoffel, 
2011, T. 
brucei 
Wildridge, 2012 this work, LC-MS 
this work 
GC-MS 
cell line TKT KO TKT KO 
re-
expresso
r 
TKT KO RIB TKT TKT KO 
G6P 0.94 0.80 0.28 0.75 0.77 0.46 
F6P 0.63 0.70 0.25 - - 0.5 
6-PG 1.78 1.00 0.12 5.23 0.58 1.21 
Pen5P 7.91 11.43 0.43 212 0.81 58.8 
F1,6bP 1.03 0.60 0.40 0.42 0.53 6.86 
2/3-
phosphoglycerate 
0.57 1.73 0.50 0.17 0.65 - 
glycerol 3P 0.31 0.41 0.36 0.2 0.59 - 
PEP 0.22 0.13 0.47 0.14 0.67 - 
Pen1P 1.16 1.80 0.91 - - - 
M6P 0.58 0.25 0.20 - - - 
fumarate 0.76 0.67 0.53 - - - 
succinate 0.80 0.81 2.43 0.35 1.64 - 
malate 0.25 0.69 0.67 0.68 1.27 - 
ketoglutarate 0.13 1.18 0.68 0.51 0.31 - 
citrate 1.17 1.57 1.15 1.38 0.56 - 
cis-aconitate 0.89 1.00 1.00 1.41 0.78 - 
orotic acid 0.99 1.00 1.00 1.06 0.9 - 
E4P - 23.45 0.72 - - - 
S7P - 0.07 0.18 0.31 0.77 0.12 
G1P - 0.60 0.18 - - - 
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Appendix A2. All metabolites detected in GC-MS analysis. Values indicate relative 
abundance in Δtkt compared to WT. ND = not detected. 
 Δtkt relative abundance 
2-Deoxy-ribose 0.26 
2-Phosphoglycerate ND 
3-Phosphoglycerate ND 
6-Phosphogluconic acid 1.21 
D-Arabinose 80.76 
D-Erythrose ND 
D-Erythrose 4-phosphate ND 
D-Fructose 1,6-bisphosphate 6.86 
D-Fructose 1-phosphate ND 
D-Fructose 6-phosphate 0.50 
D-Glucose 7.47 
D-Glucose 6-phosphate 0.46 
Dihydroxyacetone phosphate 0.05 
D-Lactose 0.05 
D-Mannose 0.34 
D-Ribose 44.97 
D-Ribose 5-phosphate 58.79 
D-Sorbitol 10.39 
D-Threose ND 
Dulcitol 9.99 
D-Xylose ND 
D-Xylulose 890.23 
Fructose 5.81 
Fucose 2.79 
Lactic Acid 0.42 
L-Alanine 0.15 
L-Glutamine 5.36 
L-Rhamnose 1.36 
L-Tryptophan 5.56 
Maltose 1.47 
myo-Inositol 2.77 
myo-Inositol 1-phosphate 0.88 
Octadecanoic acid 0.98 
Palmitic acid 1.13 
Ribulose 5-phosphate 125.15 
scyllo-Inositol 0.93 
Sedoheptulose 7-phosphate 0.12 
Serine 0.19 
Sucrose 0.80 
Xylitol 2.72 
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Appendix A3. Labelling of amino acids depending on the presence of labelled 
glucose or ribose in the medium. 
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Appendix A4. Labelling of nucleotides and coenzyme A depending on the presence 
of labelled glucose or ribose in the medium. 
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Appendix A5. The top 20 metabolites of the loading plot shown in Fig 5.2 for each 
principal component. 
PC1 PC 2 
Hexadecanoic acid Hexadecanoic acid 
Octadecanoic acid Octadecanoic acid 
L-Glutamine D-Glucose 
L-Glutamate MES 
4-Imidazolone-5-propanoate (R)-2-Hydroxyglutarate 
Isobutyronitrile [FA (18:1)] 9Z-octadecenoic acid 
D-Glucose Taurine 
Orthophosphate.1 sn-Glycerol 3-phosphate 
L-Threonine 
[GL (20:0/22:2)] 1-eicosanoyl-2-
(13Z_16Z-docosadienoyl)-sn-glycerol 
Choline Choline 
[FA (18:1)] 9Z-octadecenoic acid D-Glucose 6-phosphate 
MES Ala-Val-Val-Pro 
L-Leucine L-Histidine 
L-Lysine 
[FA trihydroxy(4:0)] 2_3_4-trihydroxy-
butanoic acid 
Pyrimidine.2 Dodecanoic acid 
sn-Glycerol 3-phosphate Hypoxanthine 
HEPES D-Sorbitol 
Theophylline sodium dodecyl sulfate 
L-1-Pyrroline-3-hydroxy-5-carboxylate L-Methionine 
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Appendix A6. Amino acids detected in spent medium metabolomics analysis. White 
– fresh medium, black – WT, grey – Δtkt. Error bars represent standard deviation. 
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Appendix B Transcriptomics 
Appendix B1. Genes detected in the trasncriptomic analysis when comparing WT 
and ΔTKT upregulated with fold change 2<. 
 
gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.30.0880 amino acid permease 3  0.00005 4.092 
LmxM.12.1090 
promastigote surface antigen protein 
PSA  
0.00005 3.670 
LmxM.04.0210 surface antigen-like protein  0.00005 3.369 
LmxM.23.1050 
small hydrophilic endoplasmic 
reticulum-associated protein (sherp)  
0.00005 3.357 
LmxM.04.0130 unspecified product  0.00005 3.312 
LmxM.28.1050 hypothetical protein, conserved  0.00005 3.213 
LmxM.10.0470 GP63, leishmanolysin  0.00005 3.169 
LmxM.16.1660 hypothetical protein, conserved  0.00005 3.164 
LmxM.22.1150 hypothetical protein, conserved  0.00005 3.101 
LmxM.30.0771 hypothetical protein  0.00005 3.089 
LmxM.28.1060 hypothetical protein, conserved  0.00005 3.088 
LmxM.28.1930 unspecified product  0.00005 3.069 
LmxM.30.0760 hypothetical protein, unknown function  0.00005 3.017 
LmxM.23.1061 
small hydrophilic endoplasmic 
reticulum-associated protein (sherp)  
0.00005 3.005 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.25.1700 hypothetical protein, conserved  0.00005 2.999 
LmxM.26.1340 DNA ligase k alpha, putative  0.00005 2.978 
LmxM.30.0900 hypothetical protein, conserved  0.00005 2.967 
LmxM.04.0390 hypothetical protein  0.00005 2.960 
LmxM.28.1930 zinc transporter, putative  0.00005 2.949 
LmxM.05.0900 surface antigen-like protein  0.00005 2.921 
LmxM.04.0040 hypothetical protein  0.00005 2.905 
LmxM.21.1350 hypothetical protein, conserved  0.00005 2.877 
LmxM.34.0460 hypothetical protein, conserved  0.00005 2.826 
LmxM.10.0380 unspecified product  0.00005 2.769 
LmxM.23.1665 hypothetical protein  0.00005 2.767 
LmxM.33.2479 hypothetical protein, conserved  0.00005 2.757 
LmxM.28.1120 hypothetical protein, conserved  0.00005 2.728 
LmxM.28.2740 
activated protein kinase c receptor 
(LACK)  
0.00005 2.721 
LmxM.07.0025 hypothetical protein, conserved  0.00005 2.720 
LmxM.28.2740a unspecified product  0.00005 2.715 
LmxM.28.2750 unspecified product  0.00005 2.703 
LmxM.28.1280 phenylalanine-4-hydroxylase, putative  0.00005 2.662 
LmxM.12.0890 surface antigen protein 2, putative  0.00005 2.657 
LmxM.22.0100 hypothetical protein, conserved  0.00005 2.615 
LmxM.12.0990 surface antigen protein, putative  0.00005 2.596 
LmxM.29.2960 hypothetical protein, conserved  0.00005 2.594 
LmxM.12.0980 
promastigote surface antigen protein 2 
PSA2  
0.00005 2.592 
LmxM.32.1460 hypothetical protein, conserved  0.005 2.587 
LmxM.33.0010 hypothetical protein, conserved  0.00005 2.561 
LmxM.28.0240 
glycerol-3-phosphate dehydrogenase, 
putative  
0.00005 2.561 
LmxM.28.2205 ribosomal protein S29, putative  0.00005 2.558 
LmxM.12.0470 hypothetical protein, unknown function  0.00005 2.548 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.28.1430 DNA polymerase kappa, putative  0.00005 2.546 
LmxM.09.0690 hypothetical protein, conserved  0.01875 2.538 
LmxM.36.3140 hypothetical protein, conserved  0.00005 2.537 
LmxM.12.0891 surface antigen protein 2, putative  0.00005 2.530 
LmxM.32.0990 hypothetical protein, unknown function  0.00005 2.521 
LmxM.34.5200 hypothetical protein, conserved  0.00005 2.515 
LmxM.28.1030 ribosomal protein S20, putative  0.00005 2.488 
LmxM.01.0450 alpha/beta-hydrolase-like protein  0.00005 2.483 
LmxM.04.0625 hypothetical protein  0.00005 2.481 
LmxM.09.0150 
ATG8/AUT7/APG8/PAZ2, putative 
(ATG8C.1)  
0.00005 2.470 
LmxM.28.2370 serine hydroxymethyltransferase  0.00005 2.457 
LmxM.16.0500 hypothetical protein, unknown function  0.00005 2.454 
LmxM.28.1011 ribosomal protein S20, putative  0.00005 2.441 
LmxM.24.0290 hypothetical protein, conserved  0.00005 2.436 
LmxM.27.1080 hypothetical protein, conserved  0.00005 2.434 
LmxM.09.0180 unspecified product  0.00005 2.434 
LmxM.05.1110 hypothetical protein, conserved  0.00005 2.431 
LmxM.31.2660 
amino acid transporter, putative,amino 
acid permease, putative  
0.00005 2.413 
LmxM.23.1267 hypothetical protein, unknown function  0.00005 2.409 
LmxM.04.0310 beta-fructofuranosidase, putative  0.00005 2.401 
LmxM.28.1010 ribosomal protein S20, putative  0.00005 2.372 
LmxM.08.0810 unspecified product  0.00005 2.365 
LmxM.21.1480 hypothetical protein, conserved  0.00005 2.364 
LmxM.28.2950 hypothetical protein, conserved  0.00005 2.364 
LmxM.30.2800 hypothetical protein, unknown function  0.00005 2.361 
LmxM.15.0630 hypothetical protein, unknown function  0.00005 2.360 
LmxM.29.1920 hypothetical protein, unknown function  0.00005 2.359 
LmxM.10.0390 GP63, leishmanolysin  0.00005 2.356 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.12.0870 surface antigen protein 2, putative  0.00005 2.352 
LmxM.36.2730 D-tyrosyl-tRNA deacylase, putative  0.00005 2.342 
LmxM.08_29.0940 hypothetical protein, conserved  0.00005 2.340 
LmxM.07.0400 hypothetical protein, conserved  0.00005 2.336 
LmxM.10.0405 GP63, leishmanolysin  0.00005 2.328 
LmxM.12.0280 ornithine decarboxylase, putative  0.00005 2.321 
LmxM.28.2560 40S ribosomal protein S17, putative  0.00005 2.303 
LmxM.14.1100 unspecified product  0.00005 2.303 
LmxM.33.0070 
ascorbate-dependent peroxidase, 
putative  
0.00005 2.294 
LmxM.24.1280 
amastin-like surface protein-like 
protein  
0.00005 2.286 
LmxM.28.2555 40S ribosomal protein S17, putative  0.00005 2.280 
LmxM.12.0850 surface antigen protein 2, putative  0.00005 2.264 
LmxM.12.0860 surface antigen, putative  0.00005 2.263 
LmxM.31.2640 cystathionine beta-lyase, putative  0.00005 2.260 
LmxM.07.0270 acetylornithine deacetylase-like protein  0.00005 2.242 
LmxM.30.1760 hypothetical protein, unknown function  0.00005 2.241 
LmxM.20.0030 
histone-lysine N-methyltransferase, 
putative  
0.00005 2.233 
LmxM.25.0280 hypothetical protein, conserved  0.00005 2.231 
LmxM.07.0500 60S ribosomal protein L7a, putative  0.00005 2.219 
LmxM.07.0510 60S ribosomal protein L7a, putative  0.00005 2.206 
LmxM.12.0910 
promastigote surface antigen protein 
PSA  
0.00005 2.205 
LmxM.03.0380 unspecified product  0.00005 2.202 
LmxM.11.0660a 
protein associated with differentiation 
4, putative  
0.00005 2.197 
LmxM.28.0540 ribosomal protein S26, putative  0.00005 2.194 
LmxM.34.1020 hypothetical protein, unknown function  0.00005 2.171 
LmxM.10.0370 folate/biopterin transporter, putative  0.00005 2.168 
LmxM.06.1260 pteridine transporter, putative  0.00005 2.160 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.24.1620 hypothetical protein, conserved  0.00005 2.160 
LmxM.15.1040 tryparedoxin peroxidase  0.00005 2.159 
LmxM.30.1170 hypothetical protein, unknown function  0.00005 2.159 
LmxM.34.0380 hypothetical protein, conserved  0.00005 2.151 
LmxM.31.2155 hypothetical protein, conserved  0.00005 2.145 
LmxM.14.1110 kinesin K39, putative  0.00005 2.142 
LmxM.28.2780 heat-shock protein hsp70, putative  0.00005 2.137 
LmxM.20.0700 hypothetical protein, conserved  0.00005 2.128 
LmxM.14.0020 phosphatidylinositol 3-kinase, putative  0.00005 2.126 
LmxM.30.0350 
amino acid transporter aATP11, 
putative  
0.00005 2.124 
LmxM.28.2770 heat-shock protein hsp70, putative  0.00005 2.117 
LmxM.26.2530 
serine/threonine protein phosphatase, 
putative  
0.00005 2.109 
LmxM.07.1160 
transmembrane amino acid 
transporter, putative  
0.00005 2.096 
LmxM.27.1440 hypothetical protein, conserved  0.00005 2.088 
LmxM.36.0730 hypothetical protein, conserved  0.0001 2.085 
LmxM.04.0320 unspecified product  0.00005 2.084 
LmxM.27.2020 D-lactate dehydrogenase-like protein  0.00005 2.083 
LmxM.34.5350 amino acid permease, putative  0.00005 2.073 
LmxM.30.0870 amino acid permease 3  0.00005 2.072 
LmxM.26.0160 
nuclear lim interactor-interacting 
factor-like  
0.00005 2.071 
LmxM.22.1690a unspecified product  0.00005 2.065 
LmxM.07.0890 hypothetical protein, unknown function  0.00005 2.046 
LmxM.28.1300 hypothetical protein, conserved  0.00005 2.046 
LmxM.24.0680 sugar transporter, putative  0.00005 2.046 
LmxM.28.1940 hypothetical protein, conserved  0.00005 2.044 
LmxM.28.0080 hypothetical protein, unknown function  0.00005 2.042 
LmxM.03.0400 unspecified product  0.00005 2.041 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.18.1580 nonspecific nucleoside hydrolase  0.00005 2.031 
LmxM.28.2460 ribosomal protein S29, putative  0.00005 2.031 
LmxM.23.1025 hypothetical protein, conserved  0.00005 2.028 
LmxM.04.0200 surface antigen-like protein  0.00005 2.025 
LmxM.33.3645 unspecified product  0.00005 2.023 
LmxM.28.3000 protein kinase, putative  0.00005 2.017 
LmxM.25.0920 hypothetical protein, conserved  0.00005 2.013 
LmxM.31.0630 hypothetical protein, conserved  0.00005 2.009 
LmxM.28.0130 hypothetical protein, conserved  0.00005 2.006 
LmxM.36.6570 
hypothetical protein, 
conserved,y113g7b.23 protein-like 
protein  
0.00005 2.003 
LmxM.28.0210 histone H2B variant  0.00005 2.001 
LmxM.36.2760 hypothetical protein, conserved  0.00005 2.001 
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Appendix B2. Genes detected in the trasncriptomic analysis when comparing WT 
and ΔTKT downregulated with fold change 2>. 
gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.24.2060 transketolase, putative  0.00105 
-
1716.56 
LmxM.30.0571 
amino acid transporter aATP11, 
putative  
0.00005 -4.90 
LmxM.30.1440b unspecified product  0.00005 -4.74 
LmxM.21.1360 hypothetical protein, conserved  0.00005 -4.33 
LmxM.30.1440 
hypothetical protein, unknown 
function  
0.00005 -4.29 
LmxM.02.0170 unspecified product  0.00005 -3.74 
LmxM.30.1440a unspecified product  0.00005 -3.36 
LmxM.19.1485 hypothetical protein, conserved  0.00005 -3.32 
LmxM.15.0150 
hypothetical protein, unknown 
function  
0.00005 -3.25 
LmxM.30.1442 
hypothetical protein, unknown 
function  
0.00005 -3.25 
LmxM.25.0590 hypothetical protein, conserved  0.00005 -3.14 
LmxM.02.0160 unspecified product  0.00005 -3.11 
LmxM.18.1110 methyltransferase, putative  0.00005 -3.03 
LmxM.08.1222 hypothetical protein, conserved  0.00005 -3.02 
LmxM.36.5780 hypothetical protein, conserved  0.00005 -2.94 
LmxM.27.0230 hypothetical protein, conserved  0.00005 -2.93 
LmxM.17.0770 hypothetical protein, conserved  0.00005 -2.93 
LmxM.22.1230 hypothetical protein, conserved  0.00005 -2.91 
LmxM.30.2620 hypothetical protein, conserved  0.00005 -2.82 
LmxM.03.0690 hypothetical protein, conserved  0.00005 -2.78 
LmxM.23.0110 
mannose-1-phosphate 
guanyltransferase  
0.00005 -2.76 
LmxM.29.0720 hypothetical protein, conserved  0.00005 -2.74 
LmxM.36.6530 hypothetical protein, conserved  0.00005 -2.71 
LmxM.36.5610 hypothetical protein, conserved  0.00005 -2.64 
Appendices 
 
199 
 
 
gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.25.1620 hypothetical protein, conserved  0.00005 -2.63 
LmxM.29.0640 hypothetical protein, conserved  0.00005 -2.63 
LmxM.36.2685 hypothetical protein, conserved  0.00005 -2.59 
LmxM.20.1360 
RNasePH-like protein,exosome 
associated protein 1 (Rrp42 
homologue), putative  
0.00005 -2.55 
LmxM.33.1410 
d-isomer specific 2-hydroxyacid 
dehydrogenase- like protein  
0.00005 -2.51 
LmxM.36.6920 hypothetical protein, conserved  0.00005 -2.47 
LmxM.36.4145 transcription factor S-II-like protein  0.00005 -2.45 
LmxM.36.4460 hypothetical protein, conserved  0.00005 -2.44 
LmxM.25.0140 hypothetical protein, conserved  0.00005 -2.43 
LmxM.36.6350 hypothetical protein, conserved  0.00005 -2.43 
LmxM.31.3610 hypothetical protein, conserved  0.00005 -2.43 
LmxM.26.2710 glutamate 5-kinase, putative  0.02195 -2.43 
LmxM.33.1430 
tyrosine phosphatase isoform, 
putative  
0.00005 -2.42 
LmxM.21.0340 
mitochondrial processing peptidase 
alpha subunit, putative,metallo-
peptidase, Clan ME, Family M16  
0.00005 -2.41 
LmxM.23.1640 hypothetical protein  0.00005 -2.40 
LmxM.24.1840 lysophospholipase, putative  0.00005 -2.38 
LmxM.09.0120 kinesin, putative  0.00005 -2.38 
LmxM.29.0205 hypothetical protein, conserved  0.00005 -2.37 
LmxM.22.1610 hypothetical protein, conserved  0.00005 -2.37 
LmxM.33.3120 
lipophosphoglycan biosynthetic 
protein (lpg2)  
0.00005 -2.36 
LmxM.17.0550 RNA-binding protein, putative  0.00005 -2.36 
LmxM.33.3440 DNA topoisomerase IB, large subunit  0.00005 -2.35 
LmxM.08_29.2450 heat shock protein 20, putative  0.00005 -2.35 
LmxM.30.1140 monoglyceride lipase, putative  0.00005 -2.34 
LmxM.22.1450 cyclophilin, putative  0.00005 -2.34 
LmxM.34.0560 
phosphatidylinositol-4-phosphate 5-
kinase-like, putative  
0.00005 -2.34 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.34.3540 hypothetical protein, conserved  0.00005 -2.34 
LmxM.33.1415 
d-isomer specific 2-hydroxyacid 
dehydrogenase- like protein  
0.00005 -2.33 
LmxM.30.2580 
ubiquinol-cytochrome-c reductase-
like protein  
0.00005 -2.33 
LmxM.22.0090 
methyltransferase, putative,mRNA 
cap methyltransferase-like protein  
0.00005 -2.33 
LmxM.33.1400 
d-isomer specific 2-hydroxyacid 
dehydrogenase- like protein  
0.00005 -2.32 
LmxM.24.2220 hypothetical protein, conserved  0.00005 -2.32 
LmxM.30.1550 hypothetical protein, conserved  0.00005 -2.29 
LmxM.32.1090 guanylate kinase, putative  0.00005 -2.29 
LmxM.29.1130 hypothetical protein, conserved  0.00005 -2.28 
LmxM.34.0720 hypothetical protein, conserved  0.00005 -2.28 
LmxM.27.0180 hypothetical protein, conserved  0.00005 -2.28 
LmxM.04.0370 hypothetical protein, conserved  0.00005 -2.27 
LmxM.36.6760 hypothetical protein, conserved  0.00005 -2.26 
LmxM.18.1490 chaperone protein DNAj, putative  0.00005 -2.25 
LmxM.07.1170 
phosphoglycan beta 1,3 
galactosyltransferase 1  
0.00005 -2.25 
LmxM.24.0600 hypothetical protein, conserved  0.00005 -2.25 
LmxM.23.1060 hydrophilic surface protein  0.00005 -2.25 
LmxM.27.0220 hypothetical protein, conserved  0.00005 -2.24 
LmxM.34.2670 ankyrin repeat protein, putative  0.00005 -2.24 
LmxM.29.1890 hypothetical protein, conserved  0.00005 -2.24 
LmxM.32.2060 hypothetical protein, conserved  0.00005 -2.24 
LmxM.26.2290 hypothetical protein, conserved  0.00005 -2.23 
LmxM.09.1350 hypothetical protein, conserved  0.00005 -2.23 
LmxM.36.1660 
tRNA pseudouridine synthase A, 
putative  
0.00005 -2.23 
LmxM.30.2000 
GP63-like protein, leishmanolysin-like 
protein,metallo-peptidase, Clan 
MA(M), Family M8  
0.00005 -2.23 
LmxM.32.1140 hypothetical protein, conserved  0.00005 -2.23 
LmxM.09.0580 surface antigen-like protein  0.00005 -2.23 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.32.0150 hypothetical protein, conserved  0.00005 -2.22 
LmxM.26.2495 
phosphatidylinositol-4-phosphate 5-
kinase, putative  
0.00005 -2.22 
LmxM.20.0820 hypothetical protein, conserved  0.00005 -2.22 
LmxM.21.1555 hypothetical protein, conserved  0.00005 -2.21 
LmxM.25.0010 beta galactofuranosyl transferase  0.00005 -2.21 
LmxM.32.0520 d-xylulose reductase, putative  0.00005 -2.21 
LmxM.30.3190 
phosphoglycan beta 1,3 
galactosyltransferase 5  
0.00005 -2.20 
LmxM.29.2820 chaperonin HSP60/CNP60, putative  0.00005 -2.20 
LmxM.33.4230 hypothetical protein, conserved  0.00005 -2.20 
LmxM.36.2570 
membrane-bound acid phosphatase 
precursor  
0.00005 -2.20 
LmxM.26.2500 hypothetical protein, conserved  0.00005 -2.19 
LmxM.36.4710 hypothetical protein, conserved  0.0014 -2.18 
LmxM.30.2600 calreticulin, putative  0.00005 -2.17 
LmxM.27.0640 
hypothetical protein, unknown 
function  
0.00005 -2.17 
LmxM.18.1610 hypothetical protein, conserved  0.00005 -2.17 
LmxM.30.1165 hypothetical protein  0.00005 -2.16 
LmxM.08.0940 hypothetical protein, conserved  0.00005 -2.15 
LmxM.33.2240 hypothetical protein, conserved  0.00005 -2.15 
LmxM.11.1030 hypothetical protein, conserved  0.00005 -2.15 
LmxM.03.0680 hypothetical protein  0.00005 -2.15 
LmxM.34.0890 hypothetical protein, conserved  0.00005 -2.15 
LmxM.36.5060 hypothetical protein, conserved  0.0001 -2.14 
LmxM.36.5365 hypothetical protein, conserved  0.00005 -2.14 
LmxM.36.5040 hypothetical protein, conserved  0.00005 -2.13 
LmxM.36.1330 hypothetical protein, conserved  0.00005 -2.13 
LmxM.34.5090 hypothetical protein, conserved  0.00005 -2.12 
LmxM.10.1320 fatty acid desaturase, putative  0.00005 -2.12 
LmxM.08_29.1400 hypothetical protein, conserved  0.00005 -2.11 
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gene Annotation_TriTrypDB p_value 
Fold-
change 
LmxM.30.1885 mannosyltransferase-like protein  0.00005 -2.11 
LmxM.36.5670 RNA helicase, putative  0.00005 -2.11 
LmxM.32.0240 thiol-dependent reductase 1  0.00005 -2.10 
LmxM.34.4300 hypothetical protein, conserved  0.00005 -2.09 
LmxM.23.0030 beta propeller protein, putative  0.00005 -2.08 
LmxM.24.1710 
ubiquitin-conjugating enzyme e2, 
putative  
0.00005 -2.07 
LmxM.27.2210 
dual specificity protein phosphatase, 
putative  
0.00005 -2.07 
LmxM.25.0620 
RNA polymerase I second largest 
subunit, putative  
0.00005 -2.07 
LmxM.29.2750 hypothetical protein, conserved  0.00005 -2.07 
LmxM.27.1690 hypothetical protein, conserved  0.00005 -2.07 
LmxM.31.3710 hypothetical protein, conserved  0.00005 -2.06 
LmxM.34.2860 hypothetical protein, conserved  0.00005 -2.06 
LmxM.20.0020 hypothetical protein, conserved  0.00005 -2.06 
LmxM.29.0730 co-chaperone GrpE, putative  0.00005 -2.06 
LmxM.29.3120 
S-adenosylmethionine decarboxylase 
proenzyme- like, putative  
0.00005 -2.05 
LmxM.26.2305 hypothetical protein, conserved  0.00005 -2.05 
LmxM.36.1770 hypothetical protein, conserved  0.00005 -2.05 
LmxM.33.1440 hypothetical protein, conserved  0.00005 -2.05 
LmxM.32.0270 hypothetical protein, conserved  0.00005 -2.04 
LmxM.24.1850 
hypothetical predicted multi-pass 
transmembrane protein  
0.00005 -2.04 
LmxM.27.0050 DEAD-box helicase-like protein  0.00005 -2.04 
LmxM.23.0700 hypothetical protein, conserved  0.00005 -2.04 
LmxM.19.1190 hypothetical protein, conserved  0.00005 -2.04 
LmxM.26.2580 hypothetical protein, conserved  0.00005 -2.03 
LmxM.32.2080 hypothetical protein, conserved  0.00005 -2.03 
LmxM.22.0010 hypothetical protein, conserved  0.00005 -2.03 
LmxM.33.4590 hypothetical protein, conserved  0.00005 -2.03 
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Fold-
change 
LmxM.34.1990 hypothetical protein, conserved  0.00005 -2.02 
LmxM.33.1450 hypothetical protein, conserved  0.00005 -2.02 
LmxM.21.0725 hypothetical protein, conserved  0.00005 -2.02 
LmxM.34.1030 
hypothetical protein, unknown 
function  
0.00005 -2.01 
LmxM.08_29.1020 hypothetical protein, conserved  0.00005 -2.01 
LmxM.34.1610 hypothetical protein, conserved  0.00005 -2.01 
LmxM.32.2980 hypothetical protein, conserved  0.00005 -2.01 
LmxM.23.1350 acetyltransferase-like protein  0.00005 -2.01 
LmxM.34.0070 prohibitin, putative  0.03265 -2.00 
LmxM.22.0210 hypothetical protein, conserved  0.00005 -2.00 
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Appendix B3. Results of the transcriptomic analysis for genes of interest. Values 
indicate fold change relative to WT. 
gene ID glucose transporters TKT KO RIB-TKT 
LmxM.36.6300 GT1 0.75 1.34 
LmxM.36.6290 GT2 0.75 1 
LmxM.36.6280 GT3 0.77 1.02 
LmxM.24.0680 myo-inositol/proton symporter 2.05 1.7 
 glycolysis 
LmxM.21.0240 hexokinase 1.27 0.88 
LmxM.12.0530 PGI 0.97 1.3 
LmxM.08_29.2510 phosphofructokinase 0.82 0.95 
LmxM.36.1260 aldolase 0.76 0.99 
LmxM.24.0850 TPI 0.84 1.1 
LmxM.29.2980 GA3PDH glycosomal 0.63 0.79 
LmxM.20.0100 PGK glycosomal 0.66 0.92 
LmxM.36.2350 GA3PDH cytosolic 1.33 1.81 
LmxM.20.0110 PGK cytosolic 0.67 0.9 
LmxM.10.0510 G3PDH glycosomal 1.38 1.01 
LmxM.28.0240 G3PDH mitochondrial 2.56 1.19 
LmxM.14.1160 enolase 0.81 0.77 
LmxM.34.0020 PYK 0.65 0.85 
 succinate shunt 
LmxM.27.1805 PEPCK 0.66 0.91 
LmxM.28.2860 malate DH cytosolic 0.8 0.65 
LmxM.19.0710 malate DH glycosomal 0.58 0.64 
LmxM.24.0320 fumarase 1.88 1.59 
 
LmxM.23.0110 mannose-1P guanyltransferase 0.36 0.35 
 AA transporters 
LmxM.30.0350 aATP11 2.12 2.73 
LmxM.07.1160 transmembrane transporter, putative  2.1 1.65 
LmxM.31.2660 amino acid transporter, putative 2.41 2.1 
LmxM.30.0320 amino acid transporter, putative  1.7 2.02 
LmxM.34.5350 amino acid permease, putative  2.07 1.17 
LmxM.30.0880 amino acid permease 3  4.09 4.27 
LmxM.30.0870 amino acid permease 3  2.07 2.22 
LmxM.30.0571 amino acid transporter aATP11, putative  0.20 0.29 
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